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ABSTRACT

The unusual structure of y-glutamyl amino acids makes them resistant to hydrolysis by
peptidases. Instead they are degraded by y-glutamyltransferase (y-GT) and y-glutamyl amino
acid cyclotransferase.

In this study the compounds excreted by patients with the rare disorder, y-GT deficiency,
demonstrated the probable physiological substrates and role of y-GT in the human kidney.
Abnormal

metabolites

excreted

were

reduced

glutathione,

y-glutamylcysteine,

y-glutamylglutamine, y-glutamyl-a-aminobutyrylglycine and cysteine. The last three have not
been previously described in this disorder. Cystine, a proven in vitro substrate of y-GT, was
found in normal amounts. Disulphides and mixed disulphides of the above thiols were present
even in fresh urine but may have been products of thiol-thiol oxidation and thiol-disulphide
exchange in the bladder. Plasma levels of the y-glutamyl compounds and cysteine seemed not
to be increased.

gamma-Giutamylglutamine was positively identified in plasma and cerebrospinal fluid from
hyperammonaemic patients with urea cycle defects and was reabsorbed by the kidney even
when plasma levels of y-glutamylglutamine were >214 f.Lmoi/L.

However in patients with

phenylalanine hydroxylase deficiency, y-glutamylphenylalanine was detected in their urine but
not their plasma.

This contrast in the renal handling of y-glutamyl amino acids may occur

because y-glutamylphenylalanine,

unlike y-glutamylglutamine,

is a poor substrate for

intracellular y-glutamyl amino acid cyclotransferase.

Enzyme studies on serum, urine and fibroblasts from the two Australian patients confirmed that

y-GT activity was deficient and that the y-glutamyl amino acid cyclotransferase activity in their
red cells was normal.

Human lens, a tissue model for the degradation of y-glutamyl compounds, was analysed for
y-glutamyl amino acid cyclotransferase activity. The investigation found that this activity was
located on the periphery of the lens, was higher in a child compared with adults and was lower
in a cataractous (and probably GSH depleted) lens compared with lenses from normal controls
of similar age.
This study has shown for the first time that y-glutamylglutamine, ophthalmic acid and cysteine
are physiological substrates of human renal y-GT.

Hence both the hydrolysis of y-glutamyl

compounds and the transpeptidation of cysteine appear to be important physiological functions
of human y-GT in the renal tubule, allowing for direct synthesis of y-glutamylcysteine and some
role in renal ammonium metabolism.

iii

To MP
Her skill, as an analytical and clinical biochemist, has been the guiding light in my career
and she shared her sense of wonder with me.

iv

TABLE OF CONTENTS

ii
iv
vii
ix
xi
xiii
xiv

ABSTRACT
TABLE OF CONTENTS
TABLES
FIGURES
ABBREVIATIONS
DECLARATION
ACKNOWLEDGMENTS
CHAPTER 1

INTRODUCTION

1.1
1.2

1.3

1.4

1.5

1.6

1. 7

PREAMBLE
y-GLUTAMYL COMPOUNDS IN HUMAN TISSUE
1.2.1
Properties of y-Giutamyl Peptides and y-Giutamyl Amino Acids
1.2.2
y-Giutamyl Compounds in Plasma
y-Giutamyl Compounds in Urine
1.2.3
1.2.4
y-Giutamyl Compounds in Other Human Tissues
ENZYMES RELATED TO Y"GLUTAMYL COMPOUNDS
1.3.1
y-Giutamylcysteine Synthetase
1.3.2
y-Giutamyltransferase
1.3.3
y-Giutamyltransferase Deficiency
1.3.4
y-Giutamyl Amino Acid Cyclotransferase
1.3.5
The "y-Giutamyl Cycle"
RENAL HANDLING OF AMINO ACIDS, PEPTIDES AND y-GLUTAMYL
COMPOUNDS
1.4.1
Renal Absorption of Amino Acids
1.4.2
Renal Handling of y-Giutamyl Compounds
ANALYSIS OF y-GLUTAMYL COMPOUNDS
1.5.1
Identification Procedures
1.5.2
Separations of y-Giutamyl Compounds by Chromatography and HVE
QUANTITATIVE ANALYSIS OF THIOLS AND AMINO ACIDS
1.6.1
Thiol Species in Plasma and Urine
1.6.2
Integrity of Samples
1.6.3
Quantification of Thiols and Amino Acids
SCOPE OF THE CURRENT STUDY

1
2
2
2
3
4
6
7
8
9
13
15
17
18
18
20
21
21
22
23
23
23
25
28

PART I
CHAPTER2

STUDIES IN PATIENTS WITH y-GLUTAMYLTRANSFERASE DEFICIENCY

2.1
2.2

2.3

2.4

2.5

INTRODUCTION
IDENTIFICATION OF ABNORMAL COMPOUNDS EXCRETED
2.2.1
Objectives of the Study
2.2.2
Isolation and Identification of y-Giutamyl Amino Acids and Peptides
2.2.3
Results
2.2.4
Discussion
ANALYSIS OF THE ABNORMAL COMPOUNDS IN URINE
2.3.1
Objectives of the Study
2.3.2
Qualitative and Quantitative Analysis
2.3.3
Results
2.3.4
Discussion
ANALYSIS OF FRESHLY OBTAINED URINE AND PLASMA
2.4.1
Introduction and Objectives of the Study
2.4.2
Methods
2.4.3
Results
2.4.4
Discussion
SUMMARY AND IMPLICATIONS OF FINDINGS

30

31
31
31
32
35
36
38
38
38
42
46

49

49
51
53

59
62

v

CHAPTER3

STUDY IN PATIENTS WITH HEREDITARY DEFECTS OF THE UREA CYCLE
3.1
3.2

3.3

3.4

3.5

CHAPTER4

INTRODUCTION
ISOLATION AND IDENTIFICATION OF y-GLUTAMYLGLUTAMINE FROM
PLASMA
3.2.1
Objectives of the Study
3.2.2
Isolation and Identification of the Abnormal Compound
Results
3.2.3
Discussion
3.2.4
ANALYSIS OF y-GLUTAMYLGLUTAMINE AND AMINO ACIDS IN PLASMA
Objectives of the Study
3.3.1
Quantification of y-Giutamylglutamine and Amino Acids in Plasma
3.3.2
Results
3.3.3
Discussion
3.3.4
ANALYSIS OF y-GLUTAMYLGLUTAMINE AND 5-0XOPROLINE IN URINE
Objectives of the Study
3.4.1
Qualitative Analysis of y-Giutamylglutamine and 5-0xoproline in
3.4.2
Urine
3.4.3
Results
3.4.4
Discussion
SUMMARY AND IMPLICATIONS OF FINDINGS

STUDY IN PATIENTS WITH PHENYLALANINE HYDROXYLASE DEFICIENCY
4.1
4.2

4.3
4.4
4.5

INTRODUCTION
ANALYSIS OF PLASMA AND URINE SAMPLES
4.2.1
Samples for Study
4.2.2
HVE Analysis of Urine
4.2.3
Analysis of Plasma
RESULTS
DISCUSSION
SUMMARY AND IMPLICATIONS OF FINDINGS

64
65
65
65
66
68
68
70
70
70
71

72
75
75
76

77
78
80

81
82
83
83
83
84
84
85
89

PART II
CHAPTERS

ENZYME STUDIES

90

5.1
5.2

91
91
91
91

5.3

5.4

5.5

INTRODUCTION
y-GLUTAMYLTRANSFERASE IN HUMAN TISSUES
5.2.1
Objectives of the Study
5.2.2
Analysis of y-Giutamyltransferase Activity in Serum, Urine and
Cultured Skin Fibroblasts
5.2.3
Results
5.2.4
Discussion
y-GLUTAMYL AMINO ACID CYCLOTRANSFERASE IN RED CELLS
5.3.1
Introduction and Objectives of the Study
5.3.2
Measurement of y-Giutamyl Amino Acid Cyclotransferase Activity in
Red Cells
5.3.3
Results
5.3.4
Discussion
y-GLUTAMYL AMINO ACID CYCLOTRANSFERASE IN LENS
5.4.1
Introduction and Objectives of the Study
5.4.2
Measurement of y-Giutamyl Amino Acid Cyclotransferase Activity in
Human Lens
5.4.3
Results
Discussion
5.4.4
SUMMARY AND IMPLICATIONS OF FINDINGS

96
98
99
99
100
101
101
102
102
103
106
109
111

vi

CHAPTERS

DISCUSSION
6.1

6.2

6.3

PHYSIOLOGICAL SUBSTRATES OF THE y-GLUTAMYL TRANSFERASE/
y-GLUTAMYL AMINO ACID CYCLOTRANSFERASE SYSTEM
6.1.1
Physiological Substrates of y-GT in Urine
6.1.2
Physiological Substrates of y-GT in Plasma
THE PHYSIOLOGICAL ROLE OF THE y-GLUTAMYLTRANSFERASE/
y-GLUTAMYL AMINO ACID CYCLOTRANSFERASE SYSTEM IN THE
HUMAN KIDNEY
6.2.1
The Interrelationship Between y-Giutamyltransferase and y-Glutamyl
Amino Acid Cyclotransferase
6.2.2
The Role of Cysteine in the Renal y-Giutamyltransferase/y-Giutamyl
Amino Acid Cyclotransferase System
6.2.3
The Role of the y-Giutamyltransferase/y-Giutamyl Amino Acid
Cyclotransferase System in Glutamine Metabolism
6.2.4
Possible Joint Roles for the y-GT Hydrolase and Transferase
Reactions
SPECULATION

SEPARATION OF y-GLUTAMYL COMPOUNDS BY HIGH VOLTAGE
ELECTROPHORESIS AND THIN LAYER CHROMATOGRAPHY

A.1
A.2
A.3
A.4

APPENDIX B

Background and Objectives of the Study
Reference Compounds
High Voltage Electrophoresis Systems for Separation of y-Giutamyl
Compounds
A Thin Layer Chromatography System for Separation of y-Giutamyl
Compounds

DEVELOPMENT OF AN HPLC METHOD FOR THE QUANTIFICATION OF REDUCED
GLUTATHIONE, y-GLUTAMYLCYSTEINE AND CYSTEINE IN URINE
8.1
B.2
8.3
8.4

APPENDIX C

113
114
119
124

126
127

130
131

132
135

APPENDICES
APPENDIX A

112

Introduction and Objectives of the Study
Development of the Method
Results
Discussion

ISOLATION AND IDENTIFICATION OF y-GLUTAMYLGLUTAMINE FROM
CEREBROSPINAL FLUID
C.1
C.2
C.3
C.4

Objectives of the Study
Isolation and Identification of the Abnormal Compound
Results
Discussion

136

136

136
137

140
142

142

143
145
146
148

148
148
150
151

REFERENCES

154

LIST OF PUBLICATIONS

169

vii

TABLES
Facing
Page
4

1.1

Ranges for Plasma Free Reduced Glutathione Obtained in Normal Adult Patients

1.2

Results for Plasma Total Glutathione in Samples from Patients with
y-Giutamyltransferase Deficiency and Normal Patients

4

1.3

Specificity of Substrates for y-Giutamylcysteine Synthetase Purified from Bovine
Lens

8

1.4

Relative activities ofy-Giutamyltransferase in Human Tissues

10

1.5

Relative activities of y-Giutamyltransferase in Rat Kidney

10

1.6

Activity of y-Giutamyltransferase in Rat Kidney with Various y-Giutamyl Donors

11

1. 7

Apparent Km Value for y-Giutamyltransferase with Various Acceptors

11

1.8

Levels of Amino Acids reported in Serum and Urine from Two Previously Reported
Patients with y-Giutamyltransferase Deficiency

14

1.9

Specificity of Substrates for y-Giutamyl Amino Acid Cyclotransferase Purified from
Human Brain

15

1.10

Specificity of L-lsomers of Substrates for y-Giutamyl Amino Acid Cyclotransferase
Purified from Rat Kidney

15

2.1

Results of Simple Chemical Tests on Fractions Obtained by Preparative
!on-Exchange Chromatography

35

2.2

Major Ions Produced in Fast Atom Bombardment Mass Spectrometry for Reference
Compounds and Compounds Present in Fractions A to G

36

2.3

Retention Times, Area Ratios and Response Ratios for the Reference Panel of
y-Giutamyl Compounds Separated by Cation-Exchange Chromatography during the
Study

40

2.4

Reliability of Analysis of Urinary Amino Acids using Cation-Exchange
Chromatography

40

2.5

Volumes of Urine, BSTFA/1% TMCS and Internal Standard Used for the Organic
Acid Profile

41

2.6

Levels of Amino Acids, y-Giutamyl Peptides and y-Giutamylglutamine Obtained by
Cation-Exchange Chromatography of Stored from KW, BW and Their Parents

45

2.7

Results for Total Glutathione, Total y-Giutamylcysteine and Total Cysteine Obtained
by Direct HPLC-EC Compared with Those Calculated from the Disulphides and
Mixed Disulphides in Stored Urine

45

2.8

Retention Times, Area Ratios and Response Ratios for the Reference Panel of
Thiols, Overlapping Disulphides and Overlapping Amino Acids, Aspartate and
a-Aminoadipic Acid Separated by Cation-Exchange Chromatography during the
Follow-up Experiment on Urine

53

2.9

Reliability of Analysis of Amino Acids in Plasma by Cation-Exchange
Chromatography

53

2.10

Levels of Plasma Amino Acids and y-Giutamylglutamine Obtained in Freshly
Collected Capillary Blood

54

2.11

Levels of Amino Acids, y-Giutamyl Peptides and y-Giutamyl Amino Acids Obtained in
the 3 Hour Urine and in the Fresh Urine from BW

55

viii

TABLES CONTINUED
Facing
Page

56

2.12

Levels of Urinary Thiols, Disulphides and y-Giutamylglutamine During Incubation at

2.13

Levels of Urinary Amino Acids During Incubation at

2.14

Comparison of Levels of Total Thiols and y-Giutamylglutamine in Urines from BW

61

2.15

Excretion of Total Thiols or Total Glutathione and y-Giutamylglutamine in Urine from
Four Patients with y-Giutamyltransferase Deficiency

61

3.1

Concentrations (Jlmoi/L) of y-Giutamylglutamine, Glutamine, Citrulline and
Ammonium in Individual Samples of Plasma from Patients with Hyperammonaemia
Due to a Urea Cycle Defect

72

3.2

Results of Experiments Using HVE and Cation-Exchange Chromatography to Locate
y-Giutamylglutamine in Urine from a Subset of Patients with Elevated Levels of
Plasma y-Giutamylglutamine

78

4.1

Detection of y-Giutamylphenylalanine in Urine from Patients with Phenylalanine
Hydroxylase Deficiency When Their Plasma Phenylalanine Levels were Elevated

84

4.2

Urinary Phenylalanine and y-Giutamylphenylalanine in Patients with Phenylalanine
Hydroxylase Deficiency and Elevated Levels of Fasting Serum Phenylalanine
(Kamerling et al1 980)

85

4.3

Urinary Phenylalanine and y-Giutamylphenylalanine in Patients with Phenylalanine
Hydroxylase Deficiency and Elevated Levels of Blood Phenylalanine (Peck & Pollitt
1979)

85

5.1

Reaction Conditions for the Assays of y-Giutamyltransferase Activity

93

5.2

Volumes and Blanking System Used in the Rate Reaction

93

5.3

Volumes and Blanking System Used in the End-Point Reaction

95

5.4

y-Giutamyltransferase Activity in Serum, Urine and Cultured Fibroblasts

96

5.5

y-Giutamyl Amino Acid Cyclotransferase Activity in Erythrocytes

101

5.6

Percentage Water Content in Normal and Cataractous Lenses

103

5.7

y-Giutamyl Amino Acid Cyclotransferase Activity in Human Lenses

108

6.1

Summary of Findings in Urine and Plasma from Patient BW with
y-Giutamyltransferase Deficiency

114

A.1

Running Conditions for the High Voltage Electrophoresis Systems

139

A.2

Retention Data for y-Giutamyl Compounds Applied on Cellulose Thin Layer Plates
and Separated as Single or Double Developments

141

C.1

Concentrations (Jlmoi/L) of y-Giutamylglutamine, Glutamine, Citrulline and
Ammonium in Individual Samples of Cerebrospinal Fluid and Plasma from Two
Patients with Hyperammonaemia due to a Urea Cycle Defect

151

3rc

3rc

56

IX

FIGURES
Facing
Page
1.1

Kinetic Partitioning of Glutathione Synthetase and y-Giutamyl Amino Acid
Cyclotransferase in Erythrocytes Taken from Smith et a/1980

16

1.2

An Outline of the Biochemistry of Glutathione Meister 1988

17

1.3

Diagram of Membranes of the Cell of the Renal Convoluted Tubule Showing the Flux
of Amino Acids

18

2.1

An Outline of the Scheme Used to Isolate the Abnormal Compounds from Urine of
Both Patients Using Preparative ion-exchange Chromatography

32

2.2

Composite Diagram of the Abnormal Bands Separated on Five HVE Buffer Systems

33

2.3

Absorbance Tracings from Separations of Urine from Patient C Run on an Amino
Acid Analyser (Griffith and Meister 1980)

37

2.4

HVE Separation at pH 1.9 of Urine from Three Patients with y-Giutamyltransferase
Deficiehcy

42

2.5

Abnormal Compounds in Urine Eluted from Dowex 1X8 and Separated by HVE at pH
2.9

43

2.6

HVE Separation at pH 2.9 of Urine Samples Eluted from Dowex 1X8

44

2.7

Separation of Stored Urine from KW Using the Extended Program for Buffer A Read
at 570 nm

44

2.8

The HPLC-EC Separation Obtained on Urine from KW after Reductive Pretreatment
with Borohydride

45

2.9

Results for GSH, y-Giutamylglutamine and Cysteine Following Incubation of Fresh
Urine at 37"C

57

2.10

Results for GSSG and the Mixed Disulphides Following Incubation of Fresh Urine at
37"C

57

3.1

High Voltage Electrophoresis Separation of Plasma Ultrafiltrates at pH 1.9

68

3.2

FAB Mass Spectra of Compounds after the Dowex 1X8 Elution Step

69

3.3A

Separation of Amino acids and y-Giutamylglutamine in Plasma by Cation-Exchange
Chromatography

71

3.4

Relationship between y-Giutamylglutamine and Glutamine in Individual Samples of
Plasma from Patients with Hyperammonaemia Due to a Urea Cycle Defect (N 35)

73

5.1

Calibration Curve for Alanine Standard at 37"C and pH 7.4

107

5.2

y-Giutamyl Amino acid Cyclotransferase Activity in Human Lenses at 37"C and pH

108

&B

=

7.4
6.1

Reactions of y-Giutamyltransferase and y-Giutamyl Amino Acid Cyclotransferase with
Probable Physiological Substrates y-Giutamyi:X, y-Giutamyl-y-Giutamyi:X and
Cysteine in Humans

126

6.2

Possible Metabolic Consequences of Incorporating Cysteine into the
y-Giutamytransferase Pathway in the Human Kidney

127

6.3

Metabolism and Transport of Glutathione and y-Giutamylcystine by the Kidney

128

X

FIGURES CONTINUED
Facing
Page

6.4

Interrelationship of Methionine, Cysteine and Glutathione in the Liver

129

A.1

Composite Diagram Showing the Separation of y-Giutamyl Compounds by High
Voltage Electrophoresis at pH 1.9, 4000 V

139

8.1

Analysis of Disulphides and Thiols using Dual Mercury/Gold Electrodes in Series

144

8.2

Retention Times Obtained at pH 2.41 to pH 3.40 for Sodium Octyl Sulphate
Concentrations from 1 to 8 mmoi/L

145

8.3

Retention Times Obtained for Concentrations of 1 to 8 mmoi/L Sodium Octyl
Sulphate from pH 2.41 to pH 3.40

146

8.4

Standard Curves for GSH, y-Giutamylcysteine and Cysteine with the HPLC-EC Set
on 1DOnA Range

147

xi

ABBREVIATIONS
Abu
ADP
AEC
Ala
Arg
Asn
Asp
ATP
Cit
CSF

cv

Cys
(Cys)2
DSS

OTT
EDTA
FAB-MS
FAD
GC/MS
GLC
Gin
Glu
y-GiuAia
y-GiuCys
(y-GiuCys)2
y-GiuGin
y-GiuGiu
y-Giuy-GiuGiu
y-GiuGiy
y-Giulle
y-GiuLeu
y-GiuMet
y-GiuOrn
y-GiuTyr
Gly
GlyGiy
GSH
GSSG

y-GT
Hey
(Hcy)2
Hcy:Cys
HPLC
HVE
lie
Leu
Lys
Met
NADPH
NEM
NMR
OPA
Orn
Phe

a--aminobutyric acid
adenosine-5'-diphosphate
S-2-aminoethyl-L-cysteine hydrochloride
alanine
arginine
asparagine
aspartate
adenosine-5'-triphosphate
citrulline
cerebrospinal fluid
coefficient of variation
cysteine
cystine
2,2-dimethyl-2-silapentane 5-sulphonate
dithiothreitol
ethylenediamine tetraacetate
fast atom bombardment mass spectrometry
flavin-adenine dinucleotide
gas chromatography/mass spectrometry
gas liquid chromatography
glutamine
glutamate
y-glutamylalanine
y-glutamylcysteine
bis(y-glutamylcysteine)
y-glutamylglutamine
y-glutamylglutamate
y-glutamyl-y-glutamylglutamate
y-glutamylglycine
y-glutamylisoleucine
y-glutamylleucine
y-glutamylmethionine
y-glutamylornithine
y-glutamyltyrosine
glycine
glycylglycine
reduced glutathione
oxidised glutathione
y-glutamyltransferase
homocysteine
homocystine
homocysteine:cysteine disulphide
high pressure liquid chromatography
high voltage electrophoresis
isoleucine
leucine
lysine
methionine
nicotinamide-adenine dinucleotide, reduced
N-ethylmaleimide
nucleur magnetic resonance
o-phthalaldehyde
ornithine
phenylalanine

xii

ABBREVIATIONS CONTINUED
RT
SD
Ser
SSA
Thr
TLC
Tyr
Val

retention time
standard deviation
serine
sulphosalicylic acid
threonine
thin layer chromatography
tyrosine
valine

xiii

DECLARATION

I declare that the content of this thesis has not been submitted for a degree from any another
University or institution.

Judith Hammond

J

+tit t(

r0ln'il fll)

lr\e_n

xiv

ACKNOWLEDGMENTS

1 am indebted to my supervisor, Professor Roger Truscott for his patience in handling a
maverick part-time student.

Two other chemists, who are no longer here, Professor Bert

Halpern from Wollongong and Professor Ali Niederwieser from Zurich, acted as my mentors
and supervisors in the past. It is to them that I owe much, because they both shared their
enthusiasm, knowledge and experience with me and with each I discovered "new" ground.

1 am grateful to Dr. Tom Gaha and Dr. Bridget Wilcken, as directors of the Oliver Latham
Laboratory, for supporting my Churchill Fellowship and my part-time endeavours in chemistry
and biochemistry. I am also grateful for the support of past and present staff within the NSW
Biochemical Genetics Service.

This thesis would not have been possible without the participation and assistance of numerous
colleagues. I especially thank; Keow Giak Sim, who cheerfully ran samples and cared for the
Beckman 6300 on my behalf; Ana Matasovic at Kinderspital, Zurich who was my guide and
friend during the intensive work of isolating and identifying the abnormal urinary compounds;
Dr. Wilhelm Richter from CIBA-Geigy, Basel who did the initial FAB-MS on the fractions A to
G; Danny Sampson, then at Royal Prince Alfred Hospital, who offered assistance and the use
of her HPLC-EC; Dr. Michael York from the Biochemistry Department, Sydney University, who
ran the NMR cyclotransferase assay on the red cells and Professor Philip Kuchel and Dr.
Bogdan Chapman, who supported me during the NMR study on lens; Larry Hick from the
Department of Chemistry, Wollongong

University who ran the FAB-MS to

confirm

y-glutamylglutamine isolated from plasma and CSF; Marjorie Crawford at the Murdoch Institute,
Royal Children's Hospital who cared for the fibroblast cell lines and Robyn Goldsmith from the
Department of Biochemistry, Royal Alexandra Hospital for Children who generously ran the
y-glutamylglutamine isolated from CSF on her reversed-phase HPLC.

This thesis would not have been possible without the constant support of two people. Glenda
knew, better than I, how hard and long the final writing-up stage was going to be. She offered
her wonderful humour and diversions to carry me through and patient training in clear scientific
writing. Mary's contribution cannot be put into words. She not only believed it was possible but
she assisted its happening in every way, including support on the Beckman 6300, piercing
analytical questioning, careful documentation, editing and training in scientific design. She did
all that without ever intruding on its substance.

And finally thanks to the patients, especially KW (photograph) and BW, who, when aged 11
years, drew her family for me. Without them none of this would ever have been possible.

CHAPTER ONE

INTRODUCTION

1.1

PREAMBLE

1.2

y-GLUTAMYL COMPOUNDS IN HUMAN TISSUES

1.3

ENZYMES RELATED TO y-GLUTAMYL COMPOUNDS

1.4

RENAL HANDLING OF AMINO ACIDS, PEPTIDES AND y-GLUTAMYL
COMPOUNDS

1.5

ANALYSIS OF y-GLUTAMYL COMPOUNDS

1.6

ANALYSIS OF THIOLS AND AMINO ACIDS

1.7

SCOPE OF THE CURRENT STUDY

Introduction

2

INTRODUCTION

1.1

PREAMBLE

This study originated as a project to identify abnormal compounds excreted by two
Australian sisters. Six y-glutamyl peptides and a y-glutamyl amino acid were identified
and an investigation related to the metabolism of these y-glutamyl compounds
commenced.

The

enzymes

involved

in

their

degradation,

namely

y-glutamyltransferase or y-glutamyltranspeptidase (EC 2.3.2.2, y-GT) and y-glutamyl
amino acid cyclotransferase (EC 2.3.2.4), were assayed in tissues from the two
patients and their parents in order to define the "inborn error of metabolism" (IEM,
Garrod 1908) or inherited enzyme disorder carried in this family. The study was then
extended to investigate y-glutamyl compounds accumulated in plasma or excreted in
urine in other groups of patients and to look at the y-glutamyl amino acid
cyclotransferase in a tissue model, the human lens.

The introductory sections summarise our current knowledge of y-glutamyl compounds,
their metabolism, their renal transport, their analysis and specific problems related to
the analysis of mixtures of thiols and amino acids.

1.2

y-GLUTAMYL COMPOUNDS IN HUMAN TISSUES

1.2.1

Properties of y-Giutamyl Peptides and y-Giutamyl Amino Acids

gamma-Giutamyl compounds are peptides with the 5-carboxyl group, instead of the
1-carboxyl group, participating in the peptide bond.

The structure of y-glutamyl

compounds, that is shown below for glutathione (y-glutamylcysteinylglycine), allows
protection from most aminopeptidase and carboxypeptidase enzymes (Hanes et a/
1950, Griffith 1985).

0

0

II
II
HOOC-CH-CH2-CH2-C-NH-CH-C-NH-CH2-COOH
I
I
NH2
CH?SH

Glutathione (y-glutamylcysteinylglycine)
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gamma-Giutamyl amino acids are synthesised by the intracellular and relatively
non-specific enzyme y-glutamylcysteine synthetase (EC 6.3.2.2) or via transpeptidation
of amino acids by extracellular y-GT activity. The activity is accompanied by transport
of the product into the cell.

Metabolism of these compounds will be discussed in

Section 1.3.

Reduced glutathione (GSH) is the most abundant and most important y-glutamyl
peptide, the most prevalent cellular thiol and the most abundant peptide of low
molecular weight present in cells (Meister & Larsson 1995). GSH acts as a reducing
agent and an antioxidant, serves as a reservoir for cysteine, participates in
detoxification reactions for xenobiotics, is required for synthesis of some prostaglandins
and may be involved in cell cycle regulation and thermotolerance (Deneke & Fanburg
1989).

It plays a role in protection against tissue damage resulting from oxidising

environments, radiation and ultraviolet light.

The scope of GSH metabolism is such that reviewers have selected particular aspects
such as selective modification of GSH metabolism, regulation of cellular GSH or
hereditary defects of GSH metabolism for comment (Meister 1988, Deneke & Fanburg
1989, Meister & Larsson 1995).

1.2.2

y-Giutamyl Compounds in Plasma

y-Giutamyl Compounds in Plasma from Normal Patients

The y-glutamyl compounds detected in plasma prior to this study were also thiols or
disulphide compounds. Nomenclature used to describe the various species of these
compounds has been particularly confusing and has made it difficult to relate results
from different laboratories. The following list contains definitions of some of the terms
used in the literature of thiols:
•

reduced, that is the reduced form or thiol,

•

oxidised, that is the oxidised form or disulphide that may be of "mixed" content,

•

moiety, that is one half of a disulphide (Griffith & Meister 1980),

•

total glutathione 1 , as in reduced glutathione plus oxidised glutathione as defined by
Griffith (1985) for the analytical method of Tietze (1969) that uses glutathione
reductase recycling,

•

free, that is thiol not protein-bound,

1 Total will be used whenever the glutathione species, defined by Griffith (1985) as an operational term referring to all
species detected by the glutathione reductase assay of Tietze (1969), is referred to in this thesis. It approximates to [GSH]
2X[GSSG].

=

TABLE 1.1
Ranges for Plasma Free Reduced Glutathione Obtained in Normal Adult Patients
Results expressed in 1-!moi/L
Reference

N

Range
-2SD to +2SD

Hagenfeldt eta/ (1978)

7

0.79-8.20

Martensson (1987)

8

3.68-6.28

Aebi eta/ (1991)

10

5.1 -8.7

Porta eta/ (1991)

6

5-17

Mansoor eta/ (1992)

10 (F)
8(M)

1.30-6.90
3.54-6.74

de Quay eta/ (1992)

6

1.1 -10.7

Witschi et a/ ( 1992)

7

3.8-8.6

Trenti et a/ ( 1992)

23

3.15-8.63

Andersson et at (1993)

10

1.6-5.2

TABLE 1.2
Results for Total Glutathione in Samples from Patients with y-Giutamyltransferase
Deficiency and Normal Patients
Results recalculated and expressed in f!moi/L
Reference

Sample

Total Glutathione

Control Range

in y-GT Deficiency
Goodman et a/ ( 1971)

Plasma

7.9

Schulman eta/ (1975)

Serum

4.6

Wright eta/ (1979)

Plasma

20.8

Chawla eta/ (1984)

Plasma

1.1 - 1.7 (N = 4)

9.1 -16.9 (N = 9)
0.12-8.88 (N = 30)

Introduction

4

•

protein-bound, that is acid-precipitable thiol and

•

total, that is free thiol plus the product of chemical reduction of the disulphides plus
the protein-bound thiol.

Ranges reported for plasma free GSH in normal adults are shown in Table 1.1.
Oxidised glutathione (GSSG) levels are much lower than GSH with ranges reported of
0.1 - 0.28 J..Lmoi/L (Wendel & Cikryt 1980) and 0. 75 - 1.89 J..Lmoi/L (Mansoor et a/
1992a).

Plasma y-glutamylcysteine has been analysed with ranges that vary from 2.4 - 5.6
J..Lmoi/L (Hagenfeldt et a/1978), 1.3- 2.1 J..Lmoi/L (Martensson 1987) to 0.02- 0.1

~Lmoi/L

(Andersson 1993).

y-Giutamvl Compounds in Plasma of Patients with y-GT Deficiency

Total glutathione levels in plasma and serum have been analysed in two patients with
an inherited defect of the enzyme y-glutamyltransferase (McKusick 231950) and two
control populations (Goodman et a/ 1971, Schulman et at 1975, Wright et at 1979).
The results, recalculated as J..Lmoi/L, are shown in Table 1.2.

Levels on a normal

population, that were reported by Chawla et at (1984), were also obtained using the
method of Tietze (1969) and are included for comparison.

1.2.3

y-Giutamyl Compounds in Urine

y-Giutamyl Compounds in Urine from Normal Patients

Levels of urinary total glutathione, analysed by borohydride reduction followed by high
pressure liquid chromatography (HPLC), in adult controls was 0.3 ± 0.1 J..Lmol!mmol
creatinine (Aebi et al 1991 ).

The peptides y-glutamylvaline, y-glutamylleucine and y-glutamylisoleucine (Buchanan
et a/ 1962), y-glutamylornithine (Lou 1975), y-glutamylthreonine and y-glutamylglycine
(Tanaka & Nakajima 1978) have been identified in normal human urine. The levels of
these compounds appeared to be below the usual detection limits of systems designed
to quantify normal urinary amino acids. When more sensitive analytical systems were
employed, the mean level of urinary y-glutamylornithine was 0.48 J..Lmol/mmol
creatinine in normal children 3 - 10 years (N = 17) and 0.17 J..LmOI/mmol creatinine in
normal adults (N = 27) (Lou 1975). Data reported by Roesel eta/ (1984) gave similar

5

Introduction

y-glutamylornithine levels for 3 children of 0.11 - 0.79 1-lmol/mmol creatinine and 0 to
0.26 1-lmol/mmol creatinine for 3 adults.

GSH, y-glutamylcysteine and their disulphides and mixed disulphides with cysteine
have not been isolated and identified from normal human urine to date. However an
acidic compound,

reminiscent of GSSG, was identified

in

normal

urine

as

a,y-glutamylcystinyl-bisglycine (Lou & StOnge 1978).

y-Giutamyl Compounds in Urine of Patients with y-GT Deficiency

GSH,

and

glutathione:cysteine

y-glutamylcysteine:cysteine

were

located

by

co-chromatography in urine from an American patient with y-GT deficiency (Goodman
et a/ 1971, Goodman 1984).

The peak corresponding to GSH converted to one

corresponding with GSSG on standing.

By contrast, no GSH was found in three

samples of urine from the English patient (Wright et a/ 1979, Griffith & Meister 1980)
but the total glutathione, analysed by the method of Tietze (1969) was 66 and 57
1-lmol/mmol creatinine in two samples. Griffith and Meister (1980) found the moieties of
GSH and y-glutamylcysteine present when the urine was chemically reduced,
derivatised and separated by cation-exchange chromatography.

y-Giutamyl Compounds Excreted by Patients with Other Inherited Disorders

gamma-Giutamylphenylalanine was isolated and identified from urine from patients
with

phenylalanine

hydroxylase

deficiency

(McKusick

chromatography/mass spectrometry (Kamerling et al 1980).

261600)

using

gas

The levels have been

quantified using cation-exchange chromatography of urine from infants and older
patients (Peck & Pollitt 1979, Kamerling et a/1980). The levels reported were 7.9 to 78
1-lmol/mmol creatinine and 1.6 to 15.3 1-lmol/mmol creatinine respectively. There was a
weak correlation between the urinary levels of y-glutamylphenylalanine with urinary
phenylalanine

levels

(r

=

0.75).

No

attempts

were

made

to

estimate

y-glutamylphenylalanine concentrations in plasma (Kamerling et a/1980).

gamma-Giutamylornithine was isolated from urine from patients with HHH syndrome
(hyperornithinaemia, hyperammonaemia and homocitrullinuria; McKusick 238970) and
with gyrate atrophy associated with hyperornithinaemia (McKusick 258870) and
confirmed by acid hydrolysis and co-chromatography (Roesel et a/1984). The levels
obtained using cation-exchange chromatography were between 1.47 and 7.57
1-lmol/mmol creatinine, that is 10-15 times normal, and did not correlate with ornithine
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excretion. When a 100 mg/Kg load of ornithine was given to one affected patient, the
excretion of y-glutamylornithine increased by a factor of three.

Analysis of

y-glutamylornithine in blood was not attempted.

1.2.4

y-Giutamyl Compounds in Other Human Tissues

y-Giutamyl Compounds in Human Erythrocytes

The level of GSH in the red blood cell has been estimated as 2 - 3 mmoi/L cells (6.6
1-lmol/g haemoglobin) by Beutler (1975) and 1.79 - 3.79 mmoi/L cells by Hagenfeldt et

a/ (1978), while the level of GSSG was approximately 2% of this. Levels of erythrocyte
y-glutamylcysteine were 16- 114 1-lmoi/L cells (Hagenfeldt et a/1978).

y-Giutamyl Compounds in Human Lens

The lens, like the red blood cell, contains very high levels of GSH with reported values
depending on the location within the lens, the method of analysis, the age of the patient
and whether cataracts were present.

The concentration of GSH analysed by

cation-exchange chromatography showed that the level in the lens epithelium was 20
times that in the nucleus (Reddy et a/ 1980). Dickinson et a/ (1968) found levels of
GSH in a pair of normal human lens of 3.3 mmoi/Kg lens water and a range from 0.07 -

5.71 mmoi/Kg lens water in 12 cataractous human lens. Harding (1970) estimated the
level of GSH at -3.5 mmoi/Kg lens water from a 20 year old patient and found half that
level in a normal 65 year old.

Ophthalmic acid, an analogue of GSH with cysteine replaced by a-aminobutyrate to
give y-glutamyl-a-aminobutyrylglycine, was first isolated from calf lens (Waley 1956).
The levels of ophthalmic acid in human lens have since been shown to be one tenth
those of GSH. Dickinson eta/ (1968) found 340 and 360 1-lmoi/Kg lens water in a pair
of normal human lenses and from 40 to 700 1-lmoi/Kg lens water in 12 human
cataractous lenses.

Recalculated data from Tsuboi et a/ (1984) showed ophthalmic

acid levels of -86 1-lmoi/Kg lens water in a human cataractous lens.

Norophthalmic

GSH

to

acid,

another

analogue

of

with

alanine

replacing

cysteine

give

y-glutamylalanylglycine, has not yet been identified in human lens (Tsuboi et a/1984).

Recently protein-bound y-glutamylcysteine was identified in human cataractous and
aged lens (Dickerson & Lou 1993). Levels increased with age of the patient from <5
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nmol/lens in normal transparent lens to around 140 nmol/lens in patients with senile
cataract (70- 79 years).

y-Giutamyl Compounds in Human Brain

Several y-glutamyl amino acids have been isolated and identified from bovine brain
(Sano

et

at

1966)

y-glutamylglutamate,

including

y-glutamylglutamine,

y-glutamylglycine,

the

most

abundant,

y-glutamyi-L-~-aminoisobutyrate,

y-glutamylserine, y-glutamylvaline, y-glutamylalanine and S-methylglutathione.

In a

follow-up study the levels of y-glutamylglutamine were analysed in various areas of
human brain (range 2.9 - 130 11moi/Kg of tissue) and found to be widely distributed
(Kanazawa & Sano 1967).

y-Giutamyl Compounds and Intracellular Amino Acids in Human Fibroblasts in Culture

Bannai (1983) used human diploid fibroblasts in culture as an experimental model
system for the investigation of possible functions of GSH. The level of GSH was 30 to
40 J.!mol GSH/g cell protein and about 3 to 4 mmoi/L in concentration, comparable with
that of red cell and lens. The concentration of constituent amino acids of GSH were
glutamate 9.6 mmoi/L, cysteine 0.15 mmoi/L and glycine 1.1 mmoi/L. Glutamate and
glycine can be synthesised in the cells but the pool of cysteine is very small. It has
been suggested that availability of cysteine is rate-limiting in GSH synthesis.

Transport studies on fibroblasts from a patient with an inherited defect of y-GT showed
intracellular levels of GSH, phenylalanine, cystine and cysteine that were three times
higher than those in controls, while other amino acid levels were comparable
(Pellefigue

et at 1976). Apparently normal uptake kinetics for cystine, glutamine,

methionine and alanine were obtained in the mutant fibroblasts when compared with
that of normal human fibroblasts.

1 .3

ENZYMES RELATED TO y-GLUTAMYL COMPOUNDS

In the following section the enzymes related to the synthesis and degradation of
y-glutamyl compounds will be introduced.

Synthesis can occur within the cytosol

catalysed by y-glutamylcysteine synthetase or outside the plasma membrane by y-GT.
Degradation of y-glutamyl compounds may also be catalysed by y-GT. In the cytosol
they may be degraded by y-glutamyl amino acid cyclotransferase.

TABLE 1.3
Specificity of Substrates for y-Giutamylcysteine Synthetase Purified from Bovine Lens
Activity expressed as a percentage of that with L-cysteine (Rathbun 1967)

Substrate

Relative Activity

L-Cysteine

100

L-a-Aminobutyrate

69

L-Homocysteine

29

L-Aianine

7.1

L-Threonine

5.4

L-Leucine

1.5

L-Serine

0.4

L-Arginine

0

L-Aspartate

0

Glycine

0

L-Histidine

0

L-lsoleucine

0

L-Lysine

0

L-Methionine

0

L-Ornithine

0

L-Phenylalanine

0
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1.3.1

y-Giutamylcysteine Synthetase

Enzyme Activity

gamma-Giutamylcysteine may be synthesised by intracellular y-glutamylcysteine
synthetase, the first of two enzymes involved in GSH production. GSH substantially
inhibits y-glutamylcysteine synthetase activity (Richman & Meister 1975) and when
y-glutamylcysteine synthetase

L-Giutamate + L-Cysteine + ATP

B

y-Giutamylcysteine + ADP + Pi

GSH becomes depleted in vivo, y-glutamylcysteine production increases (Larsson &
Mattsson 1976). In glutathione synthetase deficiency (McKusick 266130) this leads to
overproduction of y-glutamylcysteine, that in turn is converted to 5-oxoproline by the
y-glutamyl amino acid cyclotransferase (Larsson et a/197 4, Wellner et a/197 4, Larsson

& Mattsson 1976).

Since intracellular synthesis of GSH is found

in virtually all

human cells,

y-glutamylcysteine synthetase is ubiquitous (Meister & Larsson 1995).

Catalytic Properties

The enzyme has been purified from rat liver (Sekura & Meister 1977) and bovine lens
(Rathbun 1967). The specificity for substrate amino acid is broad. An extensive study
of 80 cysteine analogues showed a requirement for a carbonyl group, a primary amine
group in the L-configuration and a hydrophobic group attached to the

~-carbon

(Rathbun 1967). Table 1.3 shows the activity for a number of amino acid substrates
relative to that with cysteine at 100%.

y-Giutamylcysteine Synthetase Deficiency

Two siblings with an inherited defect of y-glutamylcysteine synthetase (McKusick
230450) in erythrocytes have been reported. Their red cell GSH was <3% of normal
and the GSH content of muscle was 25% of normal.
generalised aminoaciduria (Meister & Larsson 1995).

Both patients exhibited a
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y-Giutamyltransferase

Enzyme Activity

Hanes

et

a/ (1950) demonstrated that y-glutamyltransferase, the enzyme solely

responsible for the degradation of GSH, was both a transferase [reaction 1] and a
hydrolase [reaction 2].
y-glutamyltransferase

y-Giutamylcysteinylglycine +Amino Acid

~

y-Giutamyl amino acid+ Cysteinylglycine (1]

y-glutamyltransferase

~

y-Giutamylcysteinylglycine + H2 0

Glutamate + Cysteinylglycine

[2]

Reactions [1] and [2] are not specific for GSH, but occur with all y-glutamyl compounds
including y-glutamyl amino acids, y-glutamyl peptides and S-substituted conjugates of
GSH (mercapturic acid precursors) (Meister 1988).

gamma-Giutamyltransferase may catalyse two other reactions.

Autotranspeptidation

[reaction 3] was shown to occur by Orlowski and Meister (1965). In this case, y-GT
transfers the y-glutamyl group from one y-glutamyl compound to itself or another
y-glutamyl compound.
y-glutamyltransferase

2 y-Giutamyl amino acid

~

y-Giutamyl-y-glutamyl amino acid + Amino acid

[3]

Glutamine may acts as a y-glutamyl donor as well as an acceptor [reaction 4] at 1 - 2%
of the rate of utilisation of GSH by y-GT (Tate & Meister 1975). This glutaminase
activity appears greatly stimulated in the presence of

10 - 15 mmoi/L maleate

(Curthoys & Kuhlenschmidt 1975) and hippurate (Thompson & Meister 1980).
y-glutamyltransferase

2 Glutamine

~

y-glutamyltransferase

y-Giutamyl-enzyme + NH\
+Glutamine

~

y-Giutamylglutamine

[4]

It is important to note that the enzyme activity of extracellular y-GT is also apparently
accompanied by the uptake or transport of the product, whether this is a y-glutamyl
compound, y-glutamyl-y-glutamyl compound, amino acid or other compound, across
the plasma membrane of cells (Orlowski & Wilk 1976). This function is similar to that
postulated for dipeptidases in the human intestine (Scriver & Rosenberg 1973).

TABLE 1.4
Relative Activities of y-Giutamyltransferase in Human Tissues
Results recalculated and expressed as a percentage of activity without acceptor substrate

Tissue

GlyGJy

(Cys) 2

L-Cys

D-Cys

Gin

Phe

20mM

2mM

20mM

20mM

20mM

20mM

512

Human Kidnef

1660

Human Kidneyb

598

480

244

Human Liverb

670

320

250

Human Fibroblastsc

306

204

Human lntestined

1500

533

a

Tate and Ross 1977.

b

Shaw et a/1978.

613

106

c

States and Segal1980.

d

Tissue preparation hydrolase-free, Smith and Heizer 1978.

331

90

TABLE 1.5
Relative Activities of y-Glutamyltransferase in Rat Kidney
Results recalculated as a percentage of the activity without acceptor substrate

GlyGiy

GlyGiy

GlyGiy

Gin

Gin

Gin

L-Cys

L-Cys

L-Cys

(Cys) 2

(Cys) 2

Phe

V.:K·

20mM

0.5mM

v.:K-

20mM

0.5mM

V.:K·

20mM

0.5mM

v.:K-

0.45mM

20mM

1067

Rat Kidneya

a

140

23

193

257
147

283

Rat Kidneyb
Rat Kid neve

344

105
4

163
250

Tate and Meister 1974, results with y-glutamyl-p-nitroanilide donor (2.5 mM)

b

Thompson and Meister 1975, results with y-glutamyl-p -nitroanilide donor (0.5 mM)

c

Thompson and Meister 1977, results with 0-y-glutamyl-p -nitroanilide donor (0.01 to 0.2 mM)
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Enzyme Location

Histochemical studies indicate that y-GT occurs widely in human tissues. The location
of the enzyme appears concentrated in epithelia involved in transport (Meister 1988),
including the kidneys, especially the luminal membrane of the proximal tubules,
pancreas, epididymis, seminal vesicle, jejunal epithelial cells, liver and spleen (Shaw
1983, Meister & Anderson 1983). It was also found in micro villus membranes such as
those of the human lymphoid cell (Marathe et a/1980).

Soluble forms of y-GT are found in the human plasma and these are regarded as being
liver-specific. Human urinary y-GT activity, derived from the kidney, resides partly in
the cell-containing sediment and partly in soluble form (Szasz 1970).

Erythrocytes are devoid of y-GT activity (Srivastava 1977, Board & Smith 1977) and
there is no detectable y-GT activity in rat or mouse plasma (Shaw 1983). Evidence for
y-GT activity in the renal basolateral membrane has not yet been clarified in humans.

The y-GT enzyme appears to be localised on the outer cell wall in close association
with aminopeptidase M (EC 3.4.11.2) [reaction 5], an enzyme with broad specificity,
that may hydrolyse the dipeptides generated during the metabolism of GSH and other
y-glutamyl peptides (Curthoys et a/1983).
Aminopeptidase M

Cysteinylglycine

~

Cysteine + Glycine

(5]

Catalytic Properties

Tables 1.4 and 1.5 summarise findings in reports of y-GT activity in purified
preparations from human tissues and rat kidney with substrate acceptors particularly
relevant to this study. The enzyme activity was highest with glycylglycine regardless of
the tissue source or substrate concentration.

Most amino acids were tested at 20

mmol/L concentration. L-Cysteine was a more active acceptor substrate than cystine,
tested at the limit of its solubility 2 mmoi/L, glutamine or phenylalanine in
hydrolase-free preparations of human intestine (Smith & Heizer 1978).

Tate and Ross (1977) compared the activity of purified preparations of the human
kidney y-GT and the rat kidney y-GT with various amino acid acceptors and reported
that the human enzyme showed a greater preference for L-glutamine as acceptor
re.lative to other amino acids tested. Smith and Heizer (1978) obtained similar results

TABLE 1.6

Activity of y-Giutamyltransferase in Rat Kidney with Various y-Giutamyl Donors
Activity expressed as Jlmol of product formed per minute per mg of enzyme (Tate & Meister 1974)

GSH

GSSG

y-GiuAbuGiy

y-GiuGin

y-GiuCys

(y-GiuCys)2

y-GiuPhe

5mM

5mM

5mM

10mM

10mM

10mM

10mM

1600a

ooaa

13ooa

1009a

BAa

401a

701a

901b

5o8b

a

Specific activity with 20mM L-[ 14C]methionine as acceptoL

b

Specific activity with 20 mM cysteine as acceptoL

TABLE 1.7

Apparent Km Value for y-Giutamyltransferase with Various Acceptors

Tissue

GlyGiy

Human Serum Enzymea

125mM

Human Liver'i

10o6mM

Human Kidney'!

10o7mM

Human Leucocytesb

Oo2mM

Rat Kidneyc

108mM

103mM

Gin

807mM
306mM

Rat Kidneyd

206mM

4o67mM

Rat Kidneye
Rat Kidnel

Met

(Cys) 2

Oo24mM
2096mM

Oo34mM

a

L-y-glutamyl-p-nitroanilide (02 to 600 mM), 0 to 150 mM GlyGiy (Tate

b

L-y-glutamyl-p-nitroanilide (1 mM) (Patrick

et a/1978)

et a/1979)

c

S-pyruvoylglutathione (205 mM), 1 to 20 mM acceptor (Tate & Meister 1974)

d

glutathione (2 mM), 005 to 6 mM acceptor (Eice & Broxmeyer 1976)

e

L-y-glutamyl-p-nitroanilide (005 mM), 0006 to OA5 mM acceptor (Thompson & Meister 1975)
0-y-glutamyl-p-nitroanilide (0001 to 002 mM) 005 to 40 mM acceptor (Thompson & Meister 1977)
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when they compared the activity of y-GT isolated from human intestinal brush border
and from rat intestinal brush border with a large number of amino acid acceptors.
Glutamine was the preferred acceptor, after cysteine and cystine, with the human
enzyme. Shaw

et

a/ (1978) also noted that both human liver y-GT and kidney y-GT

showed a greater preference for L-glutamine as acceptor, when compared with other
amino acids, excepting cystine.

In contrast phenylalanine appeared to be a less preferred acceptor, relative to the
activity with glycylglycine, when y-GT from human origin was compared with that of rat
origin (Smith & Heizer 1978, Tate & Meister 1974).

The data for Table 1.6 have been selected from those reported by Tate and Meister
(197 4) showing the activity of y-GT, purified from rat kidney, with either methionine or
cysteine as acceptor. Some of the y-glutamyl compounds investigated in the current
study were active y-glutamyl donors for the enzyme.

These included the y-glutamyl

amino acids y-glutamylcysteine, y-glutamylglutamine and y-glutamylphenylalanine, and
the y-glutamyl peptides GSH, y-glutamyl-a-aminobutyrylglycine (ophthalmic acid) and
bis(y-glutamylcysteine). GSSG was a poor substrate for y-GT.

Table 1.7 shows comparative data for the apparent Km value for various acceptors

reacting with y-GT from human serum, liver, kidney and leucocytes and rat kidney.
The Km values for glycylglycine as substrate indicate that enzyme from human
leucocytes has a higher affinity than that from the three other human sources that gave
similar results.

It is important to note that all of the data listed in Tables 1.4, 1.5, 1.6 and 1. 7, and the
full reports of the catalytic properties of y-GT, have dealt with the isolated enzyme or
tissue homogenates. The uptake of the products of y-GT activity into epithelial tissue
were not tested. The transport appears linked to the catalytic activity of y-GT rather
like the transport of amino acid and oligopeptide products of dipeptidases in the
intestine (Scriver & Rosenberg 1973).

y-GT Activity in the Human Kidney

Evidence for the in vivo activity of y-GT in human renal tissue may be obtained from
observations made in patients with a deficiency of the enzyme or in patients during
loading studies, when a comparison can be made between baseline and post-load
levels of the y-glutamyl compound.
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When a high-dose intravenous bolus of GSH (6.5 mmolfm2) was given to 10 normal
patients for pharmacokinetic studies (Aebi et a/ 1991), the half-life of GSH in the
circulation was 15 minutes. The urinary total glutathione was found to increase from
0.3 ± 0.1 1-Lmol/mmol creatinine (mean ± SD) to 100 ± 182 f.!mol/mmol creatinine.
However this -300-fold increase in excretion represented
administered dose.

only 0.8% of the

The urinary total cysteine also increased from 32.4 ±11.1

1-Lmol/mmol creatinine (levels approximating those of urinary cystine after reductive
treatment) to 434 ± 299 1-Lmol/mmol creatinine during the same 90 minute period after
the GSH load. The analytical method used for estimating total cysteine, however, did
not distinguish between cysteine, cystine and cysteine conjugates.

These results are particularly relevant to the current study. Since the load was via the
intravenous route and since GSH is not a substrate for y-glutamyl amino acid
cyclotransferase, the gross excretion of the cysteine moiety in urine indicates:
•

significant y-GT and aminopeptidase activity in the human kidney that has
hydrolysed the GSH and

•

"cysteine" production that has exceeded its renal threshold.

Oral loading with 0.15 mmoi/Kg GSH did not result in glutathionaemia or glutathionuria,
presumably because of intestinal and hepatic y-GT activity (Witschi et a/1992).

gamma-Giutamyl compounds have been given to normal patients intravenously with
the specific intention of targeting y-GT in the kidney. Orlowski pioneered the use of a
non-physiological substrate of y-GT, y-glutamyi-L-3,4-dihydroxyphenylalanine, in the
treatment of hypertension in rats (Orlowski & Wilk 1977) and later humans (Wilk et a/
1978, Worth et a/1985, MacDonald et a/1989, Cummings et a/1990). The soluble
peptide y-glutamyltyrosine (Hilton et a/1991) has been tested in animals and proposed
to replace the less soluble tyrosine for intravenous nutritional preparations for humans.
The stable peptide y-glutamylglutamine (Futuka & Hara 1990) has been proposed to
replace glutamine that is unstable in aqueous solution.

Animal experiments have been conducted to determine the decrease in plasma GSH
across the whole kidney (-80%) compared with that (-30%) via glomerular filtration
alone (Haberle et a/1979, Anderson et a/ 1980). It may be noted that these results do
not necessarily indicate the renal handling of y-glutamyl compounds by the human
, renal y-GT.

13

Introduction

y-GT Activity as a Liver Function Test

Elevated y-GT activity in human serum has been used as a "liver function" test in
clinical chemistry for at least two decades (Zilva & Pannall 1978).

The enzyme in

serum is derived from the endoplasmic reticulum of the cells of the hepatobilary tract.
As the reticulum proliferates, for example in response to prolonged intake of alcohol or
of drugs such as phenobarbitone and phenytoin, synthesis of the enzyme is induced
and the y-GT activity in the blood circulation increases (Mayne 1994). In fact the y-GT
in the human liver is only one tenth that in the kidney (Shaw et a/1978) and analysis of
y-GT activity in serum may not be a true indicator of liver function in any sense.

1.3.3

y-Giutamyltransferase Deficiency

Three patients with y-GT deficiency have been reported prior to this study. The Irish
patient (O'Daly 1968) appeared to excrete "glutathione" and was the subject of a brief
communication. Although y-GT deficiency was not documented, it was proposed as an
explanation of the abnormality in urine. The two other patients, one American and the
other English were both located via abnormal findings on a urine metabolic screen.

The American Patient with y-Giutamyltransferase Deficiency

Goodman eta/ (1971) reported the investigation of a moderately retarded 33 year old
institutionalised male (patient I) with y-GT deficiency during screening of inmates for
amino acid disorders.

His urinary levels of total glutathione were analysed on two

occasions giving levels of 280 and 408 J.lmoi/L (reference range 0.098 - 0.325 J.lmoi!L)
and excretion of 48.8 and 115 f!mol/h. An amino acid analyser peak corresponding to
GSH was noted to convert to one corresponding to GSSG after 24 hours at room
temperature.

Goodman indicated (personal communication 1984) that patient I

excreted glutathione:cysteine disulphide and y-glutamylcysteine:cysteine as well as
GSH.

The y-GT activity in serum from this patient was markedly decreased at 0.5 and 0.6
mU/mL, whilst that from 14 controls ranged from 4.3 to 15.1 mU/mL (Goodman et a/
1971 ). Analysis of y-GT activities in cultured skin fibroblasts with glycylglycine, cystine
and methionine as acceptors and two substrates, one artificial (y-glutamyl-nitroanilide)
and the other

35 S-glutathione,

controls (Schulman et a/1975).

showed extremely low levels when compared with

TABLE 1.8
Levels of Amino Acids Reported in Serum and Urine from Two Previously
Reported Patients with y-Giutamyltransferase Deficiency
Results expressed as Jlmoi/L

COMPOUND
Patient I

Patient C

Patient I

Patient C

Asp

16

26

<10

<10

Thr

137

131

76

92

Ser

101

143

140

257

Asn +Gin

174

472

310

573

Glu

429

145

<10

<10

Gly

275

231

312

963

Ala

384

500

242

379

Val

206

185

<10

34

(Cys)z

NO

12

NO

79

Met

23

27

NO

NO

lie

57

62

NO

NO

Leu

115

120

<10

27

Tyr

54

76

52

56

Phe

55

63

34

22

Orn

53

130

<10

80

Lys

143

240

11

438

His

100

92

30

615

Arg

81

85

<10

27

ABBREVIATION:
a
b

Schulman et a/1975
Wright et a/1979

NO- not detected
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Analysis of total glutathione in the American patient gave high results with a plasma
level of 7.9 J-Lmoi/L and serum level of 4.7 1-Lmoi/L when compared with those of four
plasma controls (1.1 - 1. 7 1-Lmoi/L) (Goodman eta/ 1971, Schulman et a/1975). The
levels of amino acids in serum and urine reported from this patient are listed in Table

1.8.

Renal reabsorption of amino acids from plasma appeared normal.

The low

glutamine and undetectable cystine levels in serum reported were probably artefacts of
sample handling and storage (Bremer et a/ 1981, personal unpublished laboratory
data). The detection limit of the analysis for urinary amino acids (1 0 1-Lmoi/L) was not
related to urine concentration and therefore the undetectable urinary cystine may or
may not be significant.

The English Patient with y-Giutamyltransferase Deficiency

Initial findings on the English patient, patient C, showed only GSSG and no GSH in her
urine, with a total glutathione of 488 )-Lmolll (reference range 0.2 - 1.2 1-Lmoi/L). Her
plasma total glutathione was 20.8 1-Lmoi/L, (controls 9.1 - 16.9 1-Lmoi/L, N = 9). Table

1.8 shows the levels of amino acids in serum and urine reported from this patient.
Renal reabsorption of amino acids from plasma appeared normal. Her y-GT activity
was undetectable in urine, plasma and cultured skin fibroblasts while that in leucocytes
was 0.6% of controls (Wright et a/1979).

Follow-up investigation by Griffith and Meister (1980) indicated that again, only
disulphides and no GSH, were found in two urines from patient C that had been stored
frozen for 3-10 days following collection. When the excretion of total glutathione was
analysed, levels of 2.10 and 0.83 mmolll, corresponding to 0.58 and 0.50 1-Lmol/mg
creatinine (66 and 57 1-Lmol/mmol creatinine) were obtained.

The levels of

y-glutamylcysteine moiety and cysteine moiety were 30-50% of that of GSH, but no
other quantitative data were reported.

Experimental y-Giutamyltransferase Deficiency in Animals

Contradictory evidence was obtained in animal experiments with various inhibitors of
y-GT. Moieties of GSH, cysteine and y-glutamylcysteine were found in urine obtained
when mice and rats were treated with a potent inhibitor of y-GT, acivicin,
(l-(cxS,SS)-cx-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, AT-125) (Griffith &
Meister 1979a, Griffith & Meister 1979b) and 30 to 70% of the glutathione was in the
form of GSH. Experiments with other inhibitors showed that, when mice were injected
with L- or D-y-glutamyl-(o-carboxy)phenylhydrazide (Griffith & Meister 1979a), 90% of

TABLE 1.9
Specificity of Substrates for y-Giutamyl Amino Acid Cyclotransferase Purified from
Human Brain
Activity expressed as a percentage of that with y-L-glutamyl- y-L-glutamyl-p-nitroanilide(Orlowski eta/
1969)
Relative Activity

Substrate
y-L-glutamyl-y-L-glutamyl-p-nitroanilide

100

y-L-glutamyl-L-glutamine

43

y-L-glutamyi-L-o.-alanine

56

y-glutamylglycine

14

y-L-glutamyi-L-n-aminobutyrate

11

y-L-glutamyi-S-methyi-L-cysteine

5

y-L-glutamyl-L-valine
y-L-glutamyi-L-leucine
y-L-glutamyi-L-tyrosine
y-L-glutamyi-L-pheylalanine

0.5

GSH

0

GSSG

0

Not tested

r-L-glutamyi-L-cysteine

NOTE- Assay using a substrate concentration 4 f.Lmoi/L and pH 8

TABLE 1.10
Specificity of L-lsomers of Substrates for y-Giutamyl Amino Acid Cyclotransferase
Purified from Rat Kidney
Taken from Taniguchi and Meister 1978
Substrate

Substrate

Relative Activity

Relative Activity

'Y-glutamyl-o.-aminobutyrate

100

y-glutamyl-y-glutamylalanine

200

y-glutamylglutamine

259

y-glutamyl-y-glutamylglutamine

155

y-glutamylalanine

140

y-glutamyl-y-glutamylglycine

196

y-glutamylmethionine

120

y-glutamyl-y-glutamylthreonine

108

y-glutamylglutamate

18

y-glutamyl-y-glutamylvaline

92

y-glutamylaspartate

13

"Y-glutamyl-y-glutamylleucine

85

y-glutamylglycine

6

y-glutamyl-y-glutamyltyrosine

84

y-glutamylvaline

<0.01

y-glutamyl-y-glutamylglutamate

69

y-glutamyltyrosine

<0.01

y-glutamyl-y-glutamylphenylalanine

73

y-glutamylisoleucine

<0.01

y-glutamyl-y-glutamyllysine

27

y-glutamylleucine

<0.01

y-glutamylproline

<0.01

y-glutamylphenylalanine

<0.01

y-glutamylcysteine

Not tested

NOTE- Assay using a substrate concentration 10 mmoi/L at pH 7.5
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the glutathione was GSSG and that the y-glutamylcysteine moiety was present at 30 to
60% of the GSSG level.

1.3.4

y-Giutamyl Amino Acid Cyclotransferase

Enzyme Activity

gamma-Giutamyl amino acid cyclotransferase (EC 2.3.2.4) was first described by
Connell and Hanes (1956) as an enzyme system in rat liver responsible for the scission
of the y-peptide bonds of y-glutamyl amino acids.

Later reports showed that the

enzyme was even more active with y-glutamyl-y-glutamyl compounds (Orlowski et a/
1969, Szewczuk & Connell 1975, Taniguchi & Meister 1978, York 1986). The products
of the reaction are 5-oxoproline and the amino acid or y-glutamyl compound.
y-glutamyl amino acid cyclotransferase

y-Giutamyl amino acid

~

5-0xoproline + Amino acid

y-glutamyl amino acid cyclotransferase

y-Giutamyl-y-Giutamyl amino acid

~

5-0xoproline + y-Giutamyl amino acid

The discovery of this enzyme was important because its activity and specificity
explained how the products of the transferase reaction of y-GT outside the cell were
degraded once translocated inside the cell.

Taniguchi and Meister (1 978) therefore

noted that y-glutamyltransferase and y-glutamyl amino acid cyclotransferase "function
in sequence as catalytic components of the y-glutamyl cycle".

Enzyme Location

gamma-Giutamyl amino acid cyclotransferase is an intracellular enzyme that is widely
distributed in the cytosol of human tissues including, in descending order of activity
given in mU/mg protein; brain (162), kidney (73), intestine (67 .5) and liver (60)
(Szewczuk & Connell 1975). The enzyme is also active in erythrocytes (6.4 mU/mg
protein) (Szewczuk & Connell 1975)

Catalytic Properties

Tables 1.9 and

1.10 show the relative activities of y-glutamyl amino acid

cyclotransferase purified from human brain (Orlowski et a/1969) and from rat kidney
(Taniguchi & Meister 1978) respectively. The enzyme requires a substrate with a free
a.-carboxy group on the amino acid linked to the glutamyl residue and in the

FIGURE 1.1

Kinetic Partitioning of Glutathione Synthetase and y-Giutamyl Amino Acid
Cyclotransferase in Erythrocytes
Taken from Smith et a/1980
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Predicted velocities in vivo for GSH synthetase and y-glutamyl amino acid cyclotransferase
(GCT) with y-glutamylcysteine as substrate. Dotted line represents the normal level of
intracellular y-glutamylcysteine, around 30 f.Lmoi/L.
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L-configuration. GSSG, GSH and y-glutamylphenylalanine are very poor substrates for
the enzyme, while y-glutamylglutamine and y-glutamylcysteine are excellent ones.

y-Glutamyl Amino Acid Cyclotransferase Activity in Human Tissues

No inherited defect of y-glutamyl amino acid cyclotransferase has yet been detected in
humans. However the function of the enzyme has been revealed in patients with a
generalised inherited defect of glutathione synthetase (McKusick 230450). Some 26
patients with this disorder have been reported and all excrete massive amounts of
5-oxoproline, even in the immediate neonatal period (Meister & Larsson 1995).
glutathione synthetase

y-Giutamylcysteine + glycine

-X~

y-Glutamylcysteinylglycine

Synthesis of glutathione is subject to a feedback mechanism on y-glutamylcysteine
synthetase, so that when GSH becomes depleted y-glutamylcysteine production
increases. In the case of patients with glutathione synthetase deficiency this leads to
overproduction of y-glutamylcysteine, that in turn is converted to 5-oxoproline by the
cyclotransferase (Larsson et a/197 4, Wellner et a/197 4, Larsson & Mattsson 1976).
y-glutamyl amino acid cyclotransferase

y-Glutamylcysteine

--+

5-0xoproline + Cysteine

The capacity of 5-oxoprolinase, the rate-limiting step in the "y-glutamyl" cycle (Meister

& Larsson 1995), is exceeded and 5-oxoproline appears in the urine.

y-Giutamyl Amino Acid Cyclotransferase Activity in Human Erythrocytes

Red cells contain an incomplete "y-glutamyl" cycle in that y-GT and 5-oxoprolinase are
not present (Srivastava 1977, Board & Smith 1977, Palekar et a/1974). This lack of
y-GT implies that, at least in erythrocytes, the cyclotransferase is not involved in amino
acid transport.

Studies on erythrocytes have focussed on the two intracellular enzymes, glutathione
synthetase and the cyclotransferase, both having y-glutamylcysteine as their preferred
substrate. Heinle and Wendel (1977) showed that, when membrane-free preparations
were incubated with cysteine, 5-oxoproline was only observed when y-glutamylcysteine
was elevated. Smith et at (1980) later postulated that in red cells the flux through the
cyclotransferase pathway was restricted by so-called kinetic partitioning of the
substrate y-glutamylcysteine.

Figure 1.1, taken from their paper, illustrates this in

FIGURE 1.2

An Outline of the Biochemistry of Glutathione
Meister 1988
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diagrammatic form. The predicted in vivo rate of the glutathione synthetase (A) was 24
times that of the cyclotransferase (8), while the Km for the cyclotransferase was 11
times higher than glutathione synthetase.

In order to study the function of the cyclotransferase further, York (1986) used NMR
and observed the transport of y-glutamylalanine at 0.5 mmol/h/L of cells, across the
membrane of intact erythrocytes. Since red cells are impermeable to glutamate and
glutamate is constantly required for GSH synthesis, the study was extended to observe
whether y-glutamylglutamate, that would release glutamate by the action of the
cyclotransferase, entered the cell intact.

The cleavage of y-glutamylglutamate

occurred so slowly that this would be an unlikely source of glutamate for GSH
production.

1.3.5

The "y-Giutamyl Cycle"

Orlowski and Meister (1970) developed a model for the synthesis and degradation of
GSH- the "y-glutamyl cycle". The model evolved from observations that:
•

y-GT was the sole enzyme responsible for the degradation of GSH,

•

y-GT reacted with GSH and amino acids to form y-glutamyl amino acids
that were apparently translocated across plasma membranes and

•

y-glutamyl amino acid cyclotransferase "recovered" the constituent amino
acids.

Figure 1.2, taken from a review article by Meister (1988), shows a revised version of

the original model of the "y-glutamyl cycle". One revision, particularly relevant to this
study, indicates that cystine has been incorporated as a specific acceptor for y-GT
[enzyme 3].

The

diagram

y-GiuCysGiy:X,

shows y-GT transferring
including

S-substituted

the y-glutamyl
conjugates

group

of GSH

from

GSH

(mercapturic

or
acid

precursors), to an amino acid or cystine.

Three products are illustrated:
•

the dipeptide cysteinylglycine, that is hydrolysed by an aminopeptidase

(enzyme 4] and may provide cysteine as a substrate for y-glutamylcysteine synthetase
(EC 6.3.2.2) [enzyme 1] as well as glycine as a substrate for glutathione synthetase
(EC 6.3.2.3) [enzyme 2];

FIGURE 1o3

Diagram of Membranes of the Cell of the Renal Convoluted Tubule Showing the Flux
of Amino Acids

Glomerular Filtrate ____________________ ...... Urine

PROXIMAL TUBULE MEMBRANE

BASOLATERAL
MEMBRANE
BASEMENT MEMBRANE
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a y-glutamyl amino acid that is shown as the model substrate for y-glutamyl

amino acid cyclotransferase [enzyme 5] forming L-5-oxoproline and the free amino
acid and
•

y-glutamylcystine, that is reduced by a thiol transferase (EC 1.8.4.2) [enzyme

10] to provide both cysteine for y-glutamylcysteine synthetase and y-glutamylcysteine
for GSH synthetase activity. Thiol transferase is an enzyme distinct from glutathione
reductase (EC 1.6.4.2) and requires NADPH and FAD.

Three of the steps in GSH synthesis are dependent upon the coupled cleavage of ATP
to ADP and inorganic phosphate. These steps are the y-glutamylcysteine synthetase
reaction, that is subject to a feedback regulation by GSH, the glutathione synthetase
reaction and the 5-oxoprolinase (EC 3.5.2.9) [enzyme 6] reaction that catalyses the
conversion of L-5-oxoproline to L-glutamate.

5-0xoprolinase is considered the

rate-limiting enzyme of the "y-glutamyl cycle".

1.4

RENAL HANDLING OF AMINO ACIDS, PEPTIDES AND y-GLUTAMYL COMPOUNDS

1.4.1

Renal Absorption of Amino Acids

Figure 1.3 shows the luminal and basolateral membranes in proximal tubule of the

kidney. Our understanding of renal function in normal human subjects stems largely
from in vivo clearance studies and complementary information has also been obtained
from patients in whom a particular renal function has failed. One of the difficulties in
the assessment of transepithelial transport is the examination of the transport
properties of the luminal and basolateral membranes in humans separately.

Plasma amino acids are normally 90 to 99% reabsorbed in the proximal tubule with 80
to 95% occurring initially and the remainder along the length of the tubule (Scriver &
Rosenberg 1973, Cogan 1982).

Reabsorption from the lumen occurs against a

concentration gradient. The flux of amino acids in the renal epithelium occurs via; (a)
an active system with an absolute requirement for sodium, (b) a system that is specific
for the sterioisomers of each amino acid or related groups of amino acids, (c) a passive
system of exit from the kidney cell through the basolateral membrane involving
facilitated diffusion, (d) active secretion into the lumen and (e) a small amount of leak
back from blood to the lumen.

When the filtered load rises, reabsorption increases

proportionally until the maximum absorption capacity is exceeded. The concentration
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when the amino acid is first excreted as the load progressively increases is termed the
"threshold".

Specific Amino Acid Transport Systems in the Renal Lumen

Five groups of amino acids are known to be associated with transport carriers present
in the renal lumen membrane (Scriver & Rosenberg 1973, Cogan 1982).

These include carriers for:
•

the neutral amino acids serine, threonine, glutamine, asparagine, alanine, valine,
leucine, isoleucine, phenylalanine, tyrosine, tryptophan, and histidine,

•

the acidic amino acids glutamate and aspartate,

•

the

basic amino

acids, lysine,

ornithine

and

arginine,

and

cystine

and

homocysteine:cysteine disulphide,
•

the iminoamino acids, proline and hydroxyproline together with glycine, and

•

the

~-amino

acids,

~-aminoisobutyrate, ~-alanine

and taurine.

In addition there are many examples of separate carriers for individual compounds
within the various groups, for example, the disorder of so-called "isolated" cystinuria
and the hyperglycinuria of heterozygotes for iminoglycinuria (Segal 1976). Different
amino acids within a group may also have different affinities for the carrier.

Transport of cysteine has not been studied in human kidney but evidence from human
fibroblasts shows that cysteine is transported along with the neutral amino acids
alanine, serine, threonine and glutamine (Bannai & Ishii 1982, Bannai 1983).

Specific Amino Acid Transport in the Human Basolateral Membrane

Uptake of L-glutamate from the circulation via the basolateral membrane has been
shown to occur against an intracellular glutamate concentration gradient and with a
sodium transport requirement (Sacktor 1981 ). Other weak acids and weak bases are
almost quantitatively extracted from the blood by active basolateral uptake and are
translocated across the luminal membrane (Cogan 1982).

Renal Transport of Amino Acids Involving :y-Giutamyltransferase

Orlowski and Meister (1970) published evidence of a cycle of enzyme reactions in rat
kidney that involved the uptake and release of amino acids from :y-glutamyl linkage.

20

Introduction

The enzymes included y-glutamyltransferase, y-glutamyl amino acid cyclotransferase,
y-glutamylcysteine synthetase and glutathione synthetase. They proposed that the
process be known as the "y-glutamyl cycle" and that glutathione served as a carrier in
amino acid transport.

However evidence from reports of the percentage tubular reabsorption of amino acids
in both the American patient (Schulman et a/1975) and the English patient (Wright et
a/ 1979) with generalised y-glutamyltransferase deficiency shows that neither appears
to have a defect of renal amino acid transport.

Peptide Transport in the Human Kidney

Oligopeptides present in the circulation are filtered at the glomerulus. Hydrolysis by
aminopeptidases presumably occurs in the brush border of the proximal tubule and the
amino acids are then absorbed into the epithelial cell.
present

in

urine.

0-aspartylglutamate,

Aspartylpeptides,
0-aspartylglycine,

However peptides are also

0-aspartylmethionine,

0-aspartylaspartate,

0-aspartylalanine,

0-aspartylserine,

0-aspartylthreonine, 0-aspartylleucine, 0-aspartylasparagine and 0-aspartylglutamine
were documented in a study of normal urine (Buchanan eta/ 1962, Tanaka & Nakajima
1978). Carnosine, 0-alanyi-L-histidine, and anserine, 0-alanyl-1-methyl-L-histidine, are
seen in urine from normal patients after a meal containing white meat (Bremer et a/
1981).

1.4.2

Renal Handling of y-Giutamyl Compounds

lnterorqan Flow of Glutathione

Although it is generally believed that all cells are equipped to synthesise GSH, the liver
is quantitatively the major site of GSH synthesis in humans (Meister & Larsson 1995).
The turnover of GSH in the liver is high because it is involved in redox reactions, in
irreversible detoxification mechanisms, including formation of GSH S-conjugates, and
in efflux as GSSG and GSH (Sies 1983). The level of GSH in the human circulation is
low and maintained by the role of y-GT in salvaging compounds from the glomerular
filtrate.

The kidneys take up GSH from the plasma filtrate via y-GT activity on the outer
membrane of the epithelial cells and possibly, although this has not been shown in
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humans, via direct uptake of intact GSH (Griffith & Meister 1979b, Anderson et at
1980).

lnterorgan Flow of Other y-Giutamyl Compounds

Orlowski pioneered the study of the renal metabolism of y-glutamyl compounds in mice
(Orlowski & Wilk 1975, 1976, 1978) and in rats (Orlowski & Wilk 1977). The results on
animals indicated that y-glutamyl derivatives of amino acids were extensively
metabolised and accumulated in the kidney and they suggested that the y-glutamyl
group could be used as a carrier for the introduction of compounds into kidney
metabolism.

This suggestion was followed by studies using infusions of y-glutamyl

L-3,4-dihydroxyphenylalanine, for the introduction of dopamine as a specific renal
vasodilator in rats (Wilk et a/1978) and in humans (Worth eta/ 1985, MacDonald eta/
1989, Cummings et a/1990).

GSH S-conjugates, synthesised in the liver, are transported to the kidney via the
circulation (Sies 1983, Ormstad & Orrenius 1983). The production of mercapturic acids
commences with hydrolysis of the y-glutamyl group by extracellular y-GT in the renal
tubule followed by hydrolysis of the glycyl group by the extracellular aminopeptidase.
The cysteine S-conjugate is then translocated into the epithelial cell, N-acetylated and
the N-acetylcysteine derivative is excreted.

This normally protective mechanism of

disposal as GSH S-conjugates by the kidney may result in sufficient loss of cysteine
from the liver, as in the case of Hawkinsinuria (Hocart et a/ 1983) and paracetamol
overdose (Pitt et a/1990), that systemic stores are depleted.

1.5

ANALYSIS OF y-GLUTAMYL COMPOUNDS

1.5.1

Identification Procedures

Preparative Isolation

Most procedures selected to obtain major fractions of unknown compounds from urine
used preparative columns containing Amberlite IR-120, Dowex 2X8 or Dowex 50X8
resins and volatile buffer such as pyridinium acetate or formate (Sano et a/ 1966,
Reichelt 1970, Tanaka & Nakajima 1978, Kamerling et a/ 1980). Lou (1975), on the
other hand, prepared desalted urine fractions following Sephadex-G10 gel filtration with
0.1 M acetic acid pH 3.0.
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Peck and Pollitt (1979) were able to isolate their single unidentified compound from
desalted urine by a two dimensional system using high voltage electrophoresis (HVE)
at pH 2.0 followed by paper chromatography using n-butanol/acetic acid/water.

Confirmatory Evidence

The identity of y-glutamyl compounds isolated from human or animal tissue has been
confirmed by (a) simple chemical testing such as acid hydrolysis followed by amino
acid chromatography or quantification, (b) chromatography or electrophoresis on
multiple systems (Lou 1975, Peck & Pollitt 1979), (c) colour reactions with ninhydrin
stain (Buchanan et at 1962), (d) derivatisation to determine the NH 2-terminal and
C-terminal amino acids (Buchanan eta/ 1962, Lou 1975, Lou & St Onge 1987) and (e)
derivatisation and separation by GC/MS (Kamerling eta/ 1980).

1.5.2

Separations of y-Giutamyl Compounds by Chromatography and HVE

Cation-exchange Chromatography

Qualitative and quantitative analysis of y-glutamyl amino acids and y-glutamyl peptides
have been carried out on human urine using cation-exchange chromatography
(Goodman et a/ 1971, Peck & Pollitt 1979), however some acidic y-glutamyl amino
acids appear sensitive to small changes in pH. Kasai and Sakamura (1975) reported
that their reference standard of y-L-glutamyi-L-aspartate ran as one or two peaks on a
cation-exchange system depending upon the volume of citrate loading buffer (pH 2.2)
applied.

et

Hammond

at

(1990)

and

Jaeken

(1994)

also

noted

that

y-glutamylglutamine, another acidic y-glutamyl amino acid, appeared as a double or
single peak depending on the pH of the sample loaded and that the retention time
varied.

Peck

and

Pollitt

(1979)

reported

that

the

retention

time

of

y-glutamylphenylalanine was extremely susceptible to small changes in the pH of the
initial buffer used on their amino acid analyser system. For quantitative analysis they
ran

each

patient

sample

with

and

without

the

addition

of

authentic

y-glutamylphenylalanine.

HVE of y-Giutamyl Compounds

Much of the work on the identification of y-glutamyl compounds in human tissue has
incorporated separations by HVE (Kakimoto et a/ 1964, Kanazawa et a/ 1965a,
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et a/1965b, Sana et a/1966, Kanazawa

& Sana 1967, Reichelt 1970, Lou

1975, Lou & StOnge 1978, Tanaka & Nakajima 1987, Peck & Pollitt 1979, Roesel

eta/

1984). The use of HVE buffers from pH 1.9 to 3.6 allowed the separation of y-glutamyl
compounds from aspartate and resolved multiple y-glutamyl compounds from each
other (Kakimoto et a/1964, Kanazawa et a/1965a, Kanazawa et a/1965b, Sano et a/
1966, Kanazawa & Sano 1967, Reichelt 1970). The volatile buffers employed could be
evaporated leaving the purified and largely desalted compounds.

1.6

QUANTITATIVE ANALYSIS OF THIOLS AND AMINO ACIDS

1.6 .1

Thiol Species in Plasma and Urine

The most abundant thiols in plasma are cysteine, homocysteine, reduced glutathione,
y-glutamylcysteine and cysteinylglycine.

Values for the pKa for cysteine (8.7),

homocysteine (8.66), reduced glutathione (8.63) and y-glutamylcysteine (9.1) were
reported by Jocelyn (1972). Munday (1989) gave slightly different values for cysteine
(8.5) and glutathione (9.2). The rate of oxidation of these thiols occurs roughly in order
of decreasing acidity.

The species of thiols and disulphides are defined in Section 1.2.2. The differentiation
between species has become possible with the use of sensitive systems that employ
fluorescent derivatives and high pressure liquid chromatography (HPLC) or HPLC with
electrochemical detection (EC). More than 50% of the total homocysteine, cysteine
and cysteinylglycine moieties present in normal plasma appear acid-precipitable or
protein-bound as disulphides with albumin (Wiley

et a/1988, Mansoor et a/1992b).

Thiols have not commonly been analysed in human urine. Bringham (1960) treated
urine with iodoacetate and found a peak that corresponded with the S-carboxymethyl
derivative of cysteine using cation-exchange chromatography. The levels found were
between 25 and 33 J.tmoi/L in three normal subjects.

1.6.2

Integrity of Samples

Quantitative analysis of thiols and amino acids has required that particular attention be
paid to the integrity of human plasma and urine samples. Attention has been drawn to
the following possibilities:
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chemical instability of thiols, particularly at alkaline pH (Jocelyn 1972, Martensson
1987, Griffith 1985, Munday 1989, Mansoor et a/1992a),

•

chemical instability of glutamine in plasma and urine stored at temperatures
>-sooc (Bremer et a/1981),

•

metabolic instability of homocystine, cystine and homocysteine:cysteine in plasma
samples (Bremer et a/1981, Chawla et a/1984, Wiley et a/1988),

•

an

artificial increase of taurine, aspartate and glutamate due to contamination of

plasma with leucocytes and platelets (Bremer et a/1981),
•

an artificial increase of GSH in plasma due to haemolysis (Wendel & Cikryt 1980,
Griffith 1985) or decrease of GSH due to storage at >-80°C (Griffith 1985),

•

an artificial decrease in arginine due to red cell arginase (unpublished observation)
and

•

the loss of many amino acids in urine due to bacterial contamination of the sample
(Vidler & Wilcken 1978).

Precautions taken in
•

an

effort to minimise such interference have included:

immediate centrifugation for ::0:30,000 g.min to prevent loss of arginine and remove
all leucocytes and platelets (personal observation),

•

collection, centrifugation, subsequent handling and additions within 3 to 4 min.
(Griffith 1985),

•

collection of the blood sample into evacuated tubes (Mansoor et a/ 1992a,
Andersson et a/ 1993),

•

immediate cooling of the sample to +1 o C (Wendel & Cikryt 1980, Andersson eta/
1993),

•

addition of serine/borate to inhibit y-GT activity (Martensson 1986, Aebi et a/1991,
Porta et a/1991, Witschi et a/1992),

•

prompt addition of iodoacetate to form S-carboxymethyl derivatives (Bringham
1960, Chawla et a/1984),

•

immediate preparation of N-ethylmaleimide derivatives of thiols (Mansoor et a/
1992a),

•

immediate addition of dithiothreitol (Hagenfeldt et a/1978, Martensson 1987a),

•

immediate addition of mercaptoacetic acid as a reducing agent (Martensson
1987b),

•

immediate addition of EDTA to inhibit thiol oxidation by metals (Martensson 1987b,
Mansoor et a/1992b),

•

collection into EDTA/sodium borohydride mixture followed by centrifugation and
addition of SSA (Griffith 1985),
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immediate derivatisation of thiols with monobromobimane (Aebi et a/ 1991,
Mansoor et a/1992a and 1992b, Andersson et a/1992),

•

immediate precipitation of proteins with SSA (Hagenfeldt et a/ 1978, Martensson
1987),

•

immediate precipitation of proteins by addition of metaphosphoric acid (Mills et a/
1990) or metaphosphoric acid containing EDTA (Wendel & Cikryt 1980) and

•

estimation of haemoglobin in plasma to check for low level haemolysis (Wendel &
Cikryt 1980).

Stability of analytes following storage of plasma at -80° C has been documented.
Chawla eta/ (1984) showed no significant changes in thiols and amino acids for up to 8
months, while unpublished data collected in our laboratory over 9 years indicates that
amino

acids,

including

homocystine,

cystine

and

homocysteine:cysteine, store

indefinitely at that temperature.

1.6.3

Quantification of Thiols and Amino Acids

Simultaneous Cation-exchange Chromatography of Thiols and Amino Acids

Cation-exchange chromatography using lithium buffers and post-column ninhydrin
reaction has provided the most generally useful separation of physiological amino acid
separations (Adriaens

et

a/1977, Bremer

et

a/1981, Lee & Slocum 1988). However

analysis of GSH, y-glutamylcysteine, cysteine, cysteinylglycine and homocysteine
amongst the normal amino acids has not been generally attempted. This has probably
occurred because of difficulties with co-chromatography, for example the level of GSH
is similar to that of aspartate and their retention times usually overlap (Bremer et a/
1981). The retention times for other thiols that are present at even lower concentration
in plasma suggest that these may either overlap with normal amino acids, as in the
case of y-glutamylcysteine with threonine and homocysteine between cystine and
methionine (Adriaens

et

a/ 1977).

The position of cysteine, although free of

interference, appeared to give a poor response with ninhydrin read at 570 nm (Adriaens

et a/ 1977). Acidic disulphides and mixed disulphides of GSH, y-glutamylcysteine,
cysteine appear to run as relatively broad peaks on cation-exchange chromatography
but cystine ran as a sharp peak in the pH 3.01 buffer (Adriaens

et a/1977).

Quantification of GSH and GSSG amongst the normal amino acids presents problems
because the peaks are difficult to integrate (Bremer et a/ 1981).

Cation-exchange

chromatography was, however, successfully used to estimate both GSH, ophthalmic
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acid and amino acids in human lens, probably because the levels of the y-glutamyl
compounds were high when compared with those of the amino acids (Dickinson et a/
1968).

Selective quantification of Thiols

Selective analysis of thiols such as GSH, y-glutamylcysteine, cysteine, cysteinylglycine
and homocysteine have been achieved using either (a) derivatisation followed by
cation-exchange chromatography or reversed-phase HPLC or (b) reversed-phase
HPLC-EC.

Griffith and Meister (1979a) prepared urine samples from their experiments on the
effect of y-GT inhibition by reduction with OTT followed by addition of 2-vinylpyridine to
derivatise the GSH, y-glutamylcysteine and cysteine moieties, that were then separated
by cation-exchange chromatography.

The high sensitivity required for quantitative analysis of thiols in plasma from normal
human subjects has influenced the choice of derivative prepared and the HPLC
system. Analysis of GSH, y-glutamylcysteine and cysteine, in particular, have tended
to be carried out using reversed-phase chromatography of fluorescent derivatives
prepared either prior to injection such as with monobromobimanes (Aebi et a/ 1991,
Mansoor et a/ 1992a, 1992b, Andersson et a/ 1992) or with mercaptoacetate and
o-phthalaldehyde (OPA) as post-column derivatisation (Martensson 1987).

Mills et a/ (1990) used an ODS (C-18) column with isocratic elution using 96%
monochloroacetic acid, pH 3.0, and 4% (v/v) methanol and ion-pairing reagent of 2.0
mmoi!L heptane sulphonic acid.

Mansoor et a! (1992a) also employed an

ODS-Hypersil (C 18) column but with three mobile phases, the first containing
tetrabutylammonium phosphate and acetic acid adjusted to pH 3.4, the second
containing a mixture of acetonitrile, tetrabutylammonium phosphate and acetic acid
also adjusted to pH 3.4 and the third containing just 75% acetonitrile. These were run
as gradients to separate cysteine, cysteinylglycine, homocysteine and GSH on the one
system. On the other hand Aebi eta/ (1991) used chromatography on LiChisorb RP-18
column with a mobile phase consisting of 4.3 mmoi!L octanesulphonic acid with 1%
(v/v) acetic acid and acetonitrile, 125 mLIL to separate GSH and cysteine in plasma.

Electrochemical detection has been used to sensitively and selectively estimate thiols
in a complex matrix containing other compounds such as amino acids (Saetre &
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Rabenstein 1978, Allison et a/ 1983, Wiley et a/ 1988).
electrochemical

detection

has been

used to quantify thiols

In particular dual
and

disulphides

simultaneously in the same sample of blood (Mills et a/1990) or urine (Sampson et a/
1986). This detection method suffers two disadvantages in that the mercury/gold layer
on the electrode requires daily recoating and stabilisation and the electrode response
varies between runs.
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SCOPE OF THE CURRENT STUDY

During the 70's and early 80's, investigations related to GSH metabolism focussed on
the thiol group and largely disregarded the y-glutamyl group. As a result assumptions
about the y-GT/y-glutamyl amino acid cyclotransferase pathway have persisted until the
present day.

The aim of this project has been to investigate y-glutamyl compounds in human tissues
in order to determine;
•

their presence in tissues from patients with y-GT deficiency, urea cycle defects,
phenylalanine hydroxylase deficiency and a normal population and

•

their metabolism by y-GT and y-glutamyl amino acid cyclotransferase.

The scope of this project has been confined to the investigation of patients with
inherited disorders, "experiments of nature" (Garrod 1908) and a small normal
population. This has allowed unique but restricted human data to be obtained. The
role of the y-GT/y-glutamyl amino acid cyclotransferase system in humans may be
appreciated by the study of patients in whom the role appears defective. The same
approach has been used to elucidate the recycling role of biotinidase in biotin
metabolism of patients with biotinidase deficiency (Suormala 1985) and the recycling
role of hypoxanthine-guanine phosphoribosyltransferase in purine metabolism of
patients with Lesch-Nyhan syndrome (Rossiter & Caskey 1995).

PART I y-GLUTAMYL COMPOUNDS

This study has presented observations in (a) three patients with y-GT deficiency,
including one patient previously investigated by two other groups (Chapter 2) and (b)
patients in whom aspects of the role of y-GT/y-glutamyl amino acid cyclotransferase
system are shown by the accumulation of y-glutamylglutamine in patients with urea
cycle

defects

(Chapter

3

and

Appendix

C)

and

by

the

excretion

of

y-glutamylphenylalanine in phenylketonuria (Chapter 4).

PART II

ENZYME STUDIES

This study has included the analysis of y-GT activity in tissues from the Australian
family in order to confirm the defect and the analysis of y-glutamyl amino acid
cyclohydrolase in the red cells from the Australian family by nucleur magnetic
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Analysis of y-glutamyl

amino acid cyclohydrolase activity was also conducted in normal and cataractous
human lens by NMR to show the extent and limitations on the activity (Chapter 5).

DISCUSSION

Chapter 6 gathers together the major findings of the study and discusses their

implications, including some speculation and suggested areas for further study.

APPENDICES

Three auxiliary studies are presented including: (a) location of y-glutamyl compounds
separated by high voltage electrophoresis and by chromatography (Appendix A), (b)
development of an HPLC system using electrochemical detection for the analysis of
thiols in urine (Appendix B) and (c) the isolation, identification and analysis of
y-glutamylglutamine in cerebrospinal fluid obtained from patients with defects of the
urea cycle (Appendix C).

PART 1----- y-GLUTAMYL
COMPOUNDS

CHAPTER TWO

STUDIES IN PATIENTS WITH y-GLUTAMYLTRANSFERASE DEFICIENCY

2.1

INTRODUCTION

2.2

IDENTIFICATION OF ABNORMAL COMPOUNDS EXCRETED

2.3

ANALYSIS OF ABNORMAL COMPOUNDS IN URINE

2.4

ANALYSIS OF FRESHLY OBTAINED URINE AND PLASMA

2.5

SUMMARY AND IMPLICATIONS OF FINDINGS
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STUDIES IN PATIENTS WITH y-GLUTAMYLTRANSFERASE DEFICIENCY

2.1

INTRODUCTION

Between 1964 and 1981 a urine survey for disorders of amino acid metabolism and
transport was undertaken in over one million infants in New South Wales (Wilcken et a/
1980). Urine from one infant (KW) showed an abnormal compound that appeared as a
large low-running, ninhydrin-positive, iodoplatinate-positive spot by ascending paper
chromatography. At the time a diagnosis of cystinuria was considered possible and
KW was monitored each year as part of routine follow-up. Discrepancies between the
qualitative and quantitative results for urinary cystine and her normal levels of lysine,
ornithine and arginine led to the further investigation of her urine.

Urine from KW was referred to our laboratory because of our experience in the
diagnosis of symptomatic patients with inborn errors of metabolism. When the sample
was separated by HVE on paper at pH 1.9, the amino acid pattern itself appeared
normal but three additional bands that were low-running and ninhydrin-positive were
present. These additional bands on HVE were thought to derive from the "abnormal
compound"

on

ascending

paper chromatography.

Two

of the

three were

iodoplatinate-positive. During a family study the three bands were also found in urine
from her sister (BW). Case reports of the family have been published (Hammond eta/
1995).

2.2

IDENTIFICATION OF ABNORMAL COMPOUNDS EXCRETED

2.2.1.

Objectives of the Study

This study, designed to identify the abnormal compounds excreted by KW and BW,
was conducted in four stages. First the abnormal compounds were isolated in seven
fractions using preparative ion-exchange chromatography of large volumes of urine.
Simple chemical procedures, including acid hydrolysis, carboxypeptidase A hydrolysis
and desulphuration, were carried out on the fractions to indicate the probable amino
acid sequence and functional groups present.

A panel of y-glutamyl peptides was

synthesised or purchased for use as reference compounds during confirmatory testing
and

finally

the

identity

of the

compounds

bombardmenUmass spectrometry (FAB-MS).

was

confirmed

by

fast

atom

RECONSTITUTED
URINE
pH 2.34

I

Dowex 50X8
Hydrogen Farm

I
I
I
I
I
I
I
I
I
I

0.2M
Prdinium
ormate
pH 2.9

0.2M
P~ridinium

ormate
pH 2.9

o/
FRACTIONS
110-119

FRACTIONS
120-145

FRACTIONS
146-290
Dowex 1XB
Acetate Form

Dowex 1X8
Acetate Form

D.2M

0.4M

0.2M

0.7M

1.4M

1.6M

3.0M

FRACTIONS

FRACTIONS

FRACTIONS
100-128

FRACTIONS
160-182

FRACTIONS
246-280

FRACTIONS
300-341

FRACTIONS
389-401

D

E

F

G

47-54

A

55-65

8

c

FIGURE 2"1
An Outline of the Scheme Used to Isolate the Abnormal Compounds from Urine
of Both Patients Using Preparative !on-exchange Chromatography
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This urine, of

necessity, was lyophilised, reconstituted and often handled at room temperature for
more than 24 hours.

2.2.2.

Isolation and Identification of y-Giutamyl Amino Acids and Peptides

Isolation of the Abnormal Compounds from Urine

Samples Twenty four hour urine collections were obtained from both KW and BW and

lyophilised.

Reagents

General reagents and amino acids were of reagent grade or better and

purchased from Merck, Darmstadt, Germany or BDH Chemicals Ltd, Poole, UK.
Milli-Q (Millipore, Bedford, MA, USA) organics-free water was used throughout.

Preparative column chromatography Figure 2.1 shows an outline of the scheme used

to isolate the abnormal compounds. The lyophilised urine was reconstituted, acidified
with 26 moi/L formic acid to pH 2.34, diluted to an osmolality of 315 and loaded onto a
preparative column of Dowex 50X8, hydrogen form, 200-400 mesh. The separation
was carried out using 0.2 moi!L pyridinium/formate buffer at pH 2.9. Fractions of 24
ml were collected and each fifth fraction was monitored by separation on HVE paper at
pH 1.9 and staining with ninhydrin, with fractions 110 through to 119 and fractions 146
through to 290 containing seven major and a number of minor peptide components.

A second purification stage was required on the pooled fractions #11 0-119 and
#146-290.

Each was taken through a separate Dowex 1X8 column pre-equilibrated

with 0.2 moi/L acetic acid.

Elution of the abnormal compounds was achieved with

increasing concentrations of acetic acid. Twenty ml fractions were monitored by HVE
as above.

When fraction #11 0-119 was eluted from Dowex 1X8, sub-fractions 47 through to 54
and 55 through to 65 were found to each contain an unidentified compound, named A
and 8 respectively.

When fraction #146-290 was eluted from Dowex 1X8,

sub-fractions 100 through to 128, 160 to 182, 246 to 280, 300 to 341 and 389 to 401
each contained an unidentified compound, named C, D, E, F and G. The volumes of
eluting buffer in A to G were removed by rotary evaporation and concentrated solutions
of each made up in water were taken through the identification procedures.

FIGURE 2.2
Composite Diagram of the Abnormal Bands Separated on Five HVE Buffer Systems

0
pH 1.9
17 min

pH 2.8
30min

pH4.0
17min

pH5.2
17 min

pH7.4
17min
ORIGIN

The figure shows the abnormal bands detected when fractions were run together (Figure
2.1). Conditions of HVE separations were from top to bottom (i) pH 1.9 for 17 min, (ii) pH
2.8 30 min, (iii) pH 4.0 for 17 min, (iv) pH 5.2 for 17 min and (iv) pH 7.4 17 min.
violet
colour
with
the
Crosshatched
bands
indicate
those
staining
a
ninhydrin/collidine/copper sulphate stain. The clear bands stained blue.
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Simple Chemical Testing of Fractions A to G

High Voltage Electrophoresis Systems Details of the HVE systems are outlined in

Appendix A.

Five different buffers and running conditions were used during

identification procedures. These included (a) pH 1.9, (b) pH 2.8, (c) pH 4.0, (d) pH
5.15 and (e) pH 7.4. Figure 2.2 is a composite diagram of the bands obtained when
fractions were run together using each of these five HVE buffers.

Thin Layer Chromatography Details of the thin layer chromatography system (TLC) are

outlined in Appendix A. A separation using cellulose acetate and a solvent system
containing butanol/18 moi/L acetic acid/water (2: 1:1, v/v) was used to confirm the purity
and identity of fractions A to G, against the panel of y-glutamyl peptide reference
standards.

Reference Compounds GSH, GSSG and cysteine were purchased from Merck. All

other y-glutamyl amino acids and y-glutamyl peptides including y-glutamylglutamine,
y-glutamylglutamate, y-glutamylalanine and y-glutamyl-a-aminobutyrylglycine were
purchased

from

Sachem,

glutathione:y-glutamylcysteine,

Bubendorf,

Switzerland

glutathione:cysteine,

except

for

bis(y-glutamylcysteine)

and

y-glutamylcysteine:cysteine that were synthesised.

Glutathione:cysteine was prepared by reacting 32.6 f-lmoi/L of GSH with 163 1--lmoi/L of
cysteine in the presence of 200 f-lmoi/L of iodine and 476 11moi/L sodium bicarbonate
pH 8.0. The product was purified by collecting onto a Dowex 1X8 column, washing the
impurities

through

with

water

gamma-Giutamylcysteine:cysteine
glutathione:cysteine with

and
was

eluting

with

prepared

4
by

moi/L

acetic

incubating

100 U carboxypeptidase A (Serva,

acid.
purified

Feinbiochemica,

Heidelberg, Germany) in 0.2 moi/L Tris buffer at pH 7.5 overnight at 37°C and
removing the glycine impurity by ion-exchange chromatography as above.

Glutathione:y-glutamylcysteine and bis(y-glutamylcysteine) were prepared using GSSG
as substrate for 200 U of carboxypeptidase A in 0.2 moi/L Tris buffer at pH 7.3. The
reaction was interrupted at 120 min and half of the digest was removed, acidified with
acetic acid to stop the reaction and evaporated to dryness.
glutathione:y-glutamylcysteine.

This portion contained

The remaining half of the reaction mixture was
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incubated for a further 240 min to take the reaction to completion and it contained the
bis(y-glutamylcysteine). The products were purified on Dowex 1X8 column as before.

Acid hydrolysis

Portions of fractions A to G, the synthesised reference standards,

GSSG, y-glutamylglutamate and y-glutamyl-cx,-aminobutyrylglycine were transferred to
individual hydrolysis tubes, constant boiling point hydrochloric acid (Pierce, Rockford,
IL, USA) was added and the tubes were sealed. The tubes were heated overnight at
100°C. After cooling, the seals were broken and the contents transferred to Quickfit
tubes for evaporation. The products were separated on HVE at pH 1.9 alongside an
aliquot of the original fraction and an amino acid mixture containing 1 mg/ml of Gly,
Ala, Ser, Glu, Asp, Abu and cysteic acid.

Desulphuration Procedures

Active nickel was prepared from 4 g nickel chloride

dissolved in 100 ml water to which was slowly added a solution of 1.6 g sodium
borohydride in 100 ml of water (Niederwieser et a/ 1973).

The black sediment

containing the nickel catalyst was then washed with water. Just prior to use the water
was filtered off. Desulphuration of 1 mg each of the isolated fractions A to G and of the
reference panel of y-glutamyl standards was carried out in individual Quickfit tubes to
which -200 mg of damp catalyst was added followed by water to just cover the nickel.
Each cap was tightened and the tubes placed in an oven at 1oooc for 2 hours. The
tubes were removed, cooled and centrifuged.

Initially each supernatant was transferred to an individual round bottomed flask and
evaporated to dryness. Each residue was taken up in 1 ml of water and 20 J..LL was
applied to a sheet of HVE paper and separated at pH 1.9 for 17 min (Appendix A).
The staining with ninhydrin indicated lower yields of the di- and tri-peptides than
expected.

In order to improve the yield, the sediment of each original desulphuration reaction was
washed twice with 5 ml of 0.5 moi/L pyridinium acetate at pH 4.5 and these washings
were taken to dryness.

A portion of each desulphuration product was then

reconstituted and applied to a sheet of HVE paper as before. The separation on HVE
at pH 1.9 and visualisation with ninhydrin/collidine/copper sulphate showed that the
extra washing step increased the yield.

Two additional reference standards,

y-glutamylalanine and alanine (1 mg/ml), were run on the left hand side of each HVE
sheet for comparison.

TABLE 2.1
Results of Simple Chemical Tests on Fractions Obtained by Preparative !on-Exchange
Chromatography
Fraction

A

Staining
Reaction

Staining
Reaction

Ninhydrin

lodoplatinate

Blue

Negative

Products of
Desulphuration

Products of
Acid
Hydrolysis

Products of
Carboxypeptidase
A Hydrolysis

Probable
Structure

NC

Glu, Abu,
Gly

y-GiuAbu

y-GiuAbuGiy

+ Gly

B

Blue

Negative

NC

Glu

NC

y-GiuGiu &/or
y-GiuGin

c

Violet

Positive

y-GiuAiaGiy

Glu, (Cys) 2 ,
Gly

y-GiuCys

y-GiuCysGiy

I
Cys

I
Cys

+Ala
+ Gly

D

Violet

Positive

y-GiuAia

Glu, (Cys) 2

NC

y-GiuCys

I
Cys

+Ala

E

Blue

Positive

y-GiuAiaGiy

Glu, (Cysho

y-GiuCysGiy

Gly

I
y-GiuCys

y-GiuCysGiy

I
y-GiuCysGiy

+ Gly +
y-GiuCys

I
y-GiuCys

F

Blue

Positive

y-GiuAiaGiy

Glu, (Cys) 2 ,

y-GiuCys

Gly

y-GiuCys

I

y-GiuCysGiy

I
y-GiuCys

+ y-GiuAia
+ Gly

G

Blue

Positive

y-GiuAia

Glu, (Cys) 2

NC

y-GiuCys

I
y-GiuCys

ABBREVIATION:

NC =no change
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Fast Atom Bombardment Mass Spectrometry (FAB-MS)

Underivatised samples of the reference panel of y-glutamyl amino acids, y-glutamyl
peptides and of fractions A to G were analysed by Professor Ritcher from CIBA-Geigy,
Basel using a ZAB-HF mass spectrometer (VG Analytical Ltd, Manchester, UK)
equipped with a saddle field atom gun (lon Tech Ltd, Teddington, UK).

Samples

dissolved in 1-thioglycerol as the liquid matrix were bombarded with a beam of 10-keV
xenon atoms.

For FAB-MS/MS analyses, the MIKES (mass analysed ion kinetic

energy spectroscopy} technique was used. In these experiments, [M + Ht parent ions
were mass selected and daughter ions formed by spontaneous unimolecular
dissociation were recorded.

2.2.3

Results

Analysis of compounds A, B, C, D, E, F and G Provisional identification of these
compounds

was

obtained

by

comparing

the

results

of

acid

hydrolysis,

carboxypeptidase A hydrolysis, desulphuration and the staining reactions with ninhydrin
and iodoplatinate. A summary of these results is shown in Table 2.1. The results of
desulphuration and carboxypeptidase A hydrolysis were obtained in assays run in
parallel with reference standard compounds. These gave products that were identical
on HVE to those in the unknowns. gamma-Giutamylglutamine could be distinguished
from y-glutamylglutamate by thin layer chromatography (Appendix A) and was
identified

as

a

major

new

finding

in

urine

from

these

patients.

gamma-Giutamyl-a-aminobutyrylglycine was a minor component in the abnormal urine
profile.

Fast atom bombardment mass spectrometry Major ions mainly of the [M + Ht type
produced by FAB-MS from the panel of reference compounds are listed in Table 2.2.
As is often observed for S-S linked compounds, the disulphide linkages were, to
variable extents, reduced by the liquid matrix (1-thioglycerol) and consequently RS1 H
and RS2H were observed as independent [M + Ht ions. The observation of these ions
also in the spectra of samples of fractions A to G provided confirmation of the
proposed y-glutamyl structures.

In the case of y-glutamyl-a-aminobutyrylglycine and

y-glutamylglutamine, the structural assignments were additionally confirmed by
FAB-MS/MS. In these experiments highly characteristic t::i_-terminal bn +and .Q-terminal
Yn + sequence ions were generated from the [M + H]+ parents.

TABLE 2.2
Major Ions Produced in Fast Atom Bombardment Mass Spectrometry for Reference
Co"'!pounds and Compounds Present in Fractions A to G
[R 1SH]
Reference Compound

[M+H]+

[R2SHt

Compound Confirmed

mtz

mfz

in Fraction

y-GiuAbuGiy

290

A*

y-GiuGin

276

B*

y-GiuCysGiy

427

308

c

370

251,
122

D

613

308

E

556

308,
251

F

499

251

G

I
Cys

y-GiuCys

I
Cys

y-GiuCysGiy

I
y-GiuCysGiy

y-GiuCysGiy

I
y-GiuCys

y-GiuCys

I
y-GiuCys

• also confirmed by FAB-MS/MS on [M + H]+ ions using the MIKES technique
fraction A: m/z - - » m/z 215 (b2 + ion) and m/z 161 (y/);
fraction B: m/z---» m/z 147 (y1+).
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2.2.4

Discussion

The first indication that the urine contained more than one ninhydrin-positive and more
than two ninhydrin-positive, sulphur-containing compounds came in the experiments
using HVE at pH 1.9, 2.8, 4.0, 5.15 and 7.4 (Figure 2.2). At pH 2.8 six abnormal
bands were found. Two of these six could be distinguished because they appeared
violet

instead

of

the

more

usual

blue

ninhydrin/collidine/copper sulphate mixture.

colour

when

stained

with

the

Once the large scale fractions and

reference compounds were available, the identification of the peptides was relatively
straightforward, except for Fraction B that was at first supposed to contain
y-glutamylglutamate.

Positive identification of y-glutamylglutamine was obtained by

FAB-MS. This type of comprehensive analysis of the metabolites excreted in y-GT
deficiency has not been reported on the urine from the other patients with this disorder.

It was noted that the disulphides of GSH and y-glutamylcysteine and the mixed
disulphides of GSH, y-glutamylcysteine and cysteine were excreted in large amounts,
but that cystine was not significantly elevated. It is possible and even probable that the
thiols GSH, y-glutamylcysteine and cysteine may have predominated in the freshly
excreted urine.

Oxidation may have occurred in the bladder and during sample

collection and handling. Investigation of this possibility is described in Section 2.4.

The identity of the glutathione-related compounds excreted by patients with y-GT
deficiency has been the subject of previous reports. Goodman eta! (1971) gave some
chromatographic evidence from amino acid analysis that the American patient excreted
GSH in fresh urine and that this GSH converted to GSSG on standing at room
temperature

overnight.

Peaks

corresponding

to

glutathione:cysteine

and

y-glutamylcysteine:cysteine (Goodman personal communication 1984) were also seen
on cation-exchange chromatography.

Urine from the English patient was at first

thought to contain only "glutathione" (Wright et a/ 1979), however a further report
(Griffith & Meister 1980) indicated that the urine contained a more complex mixture.
They found no GSH present but, when the urine from patient C was reduced with
dithiothreitol and the 2-vinylpyridine derivatives of the thiols prepared, peaks
corresponding with the derivatives of GSH, y-glutamylcysteine and cysteine were
obtained on an amino acid analyser (Figure 2.3). No quantitative data related to the
reduction products or the original disulphides was presented.

However the total

glutathione levels, as analysed by the glutathione reductase method of Tietze (1969),
were reported in two samples as 66 and 57 r.tmol/mmol creatinine. The proportions of

Absorbance Tracings from Separations of Urine from Patient C Run on an Amino Acid
Analyser
Taken from Griffith and Meister 1980
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The figure shows the photometric absorbance of the ninhydrin reaction obtained for amino
acids in urine from Patient C. Chromatogram I shows untreated urine. Chromatogram II was
obtained after treating the urine with 2-vinylpyridine. Chromatogram Ill was obtained after
treating the urine with dithiothreitol and then 2-vinylpyridine derivatisation. In chromatogram
IV, the sample was treated as for /II except that the derivatisation mixture was supplemented
with 1mM cysteine and 0.5 mM bis-y-glutamylcystine. Peaks A, B and C correspond to the
2-vinylpyridine derivatives of y-glutamylcysteine, glutathione and cysteine.
(Griffith &
Meister 1980).
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the thiol derivatives were indicated by peak areas on the analyser tracing with the level
of y-glutamylcysteine moiety and cysteine moiety given as 30 to 50% of glutathione.

Identification of two new non-thiol y-glutamyl compounds in urine, y-glutamylglutamine
and y-glutamyl-cx-aminobutyrylglycine (ophthalmic acid), in the current study is
significant. Neither of these compounds was recorded in previous reports on patients
with y-GT deficiency (Goodman et a/1971, Wright et at 1979, Griffith & Meister 1980).
Nor were they found in previous studies when peptides in normal human urine were
isolated and identified (Buchanan et a/1962, Lou & St Onge 1975, Tanaka & Nakajima
1978).

The presence of y-glutamylglutamine and ophthalmic acid in the urine of KW and BW
strongly suggests that these, along with the thiols and possibly the disulphides and
mixed disulphides, are physiological substrates of y-GT in the human kidney.
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2.3

ANALYSIS OF ABNORMAL COMPOUNDS IN URINE

2.3.1

Objectives of the Study

Once the major abnormal compounds were identified in the Australian patients, a
literature review was conducted.

Three patients had been reported with proven or

probable y-glutamyltransferase deficiency (O'Daly 1968; Goodman

et at 1971; Wright

et a/ 1979). All excreted glutathione-related metabolites and all three suffered from
psychiatric disturbance or behavioural abnormalities.

In order to establish the enzyme defect in the Australian sisters, the y-GT activity was
analysed in serum, urine and fibroblasts and in serum and urine from both parents
(Chapter 5).

In addition, red cell y-glutamyl amino acid cyclotransferase activity in

KW, BW, their parents and a control was analysed by nuclear magnetic resonance
spectroscopy (NMR)(Chapter 5).

Contact was made with the English patient, patient C, (Wright

et a/1979) and a urine

sample obtained for analysis in order to confirm whether the excretion of
y-glutamylglutamine

and

ophthalmic acid,

as well

as the

glutathione-related

metabolites, was similar in another patient with y-GT deficiency.

The quantification of the disulphides and mixed disulphides, an analysis not attempted
previously, and that of y-glutamylglutamine and the urinary amino acids was carried out
by conventional amino acid analysis. Direct quantification of total GSH, total cysteine
and total y-glutamylcysteine was obtained using reductive pretreatment and an
HPLC-EC method developed specifically for this task (Appendix 8).

A urinary organic acid profile by gas liquid chromatography/mass spectrometry was
also obtained to look for 5-oxoproline and any other unusual metabolite.

2.3.2

Qualitative and Quantitative Analysis

Samples for Study

Timed three hour urine collections were obtained from KW and BW and stored at
-20°C until analysis. A random urine from the English case, patient C (Wright
1979), was lyophilised prior to transport and reconstituted on arrival.

et at

Control urine

samples for the HVE separations were obtained from patients referred for diagnosis of
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inherited disorders from hospitals in Victoria and New South Wales and in whom no
defect was identified.

Urinary creatinine was analysed by the Beckman Creatinine

Analyser 2.

Reagents and Reference Compounds

General reagents were purchased from Merck, Darmstadt, Germany or BDH
Chemicals, Poole, UK and were of reagent grade or better. GSSG and cystine were
also purchased from Merck.

Glutathione:y-glutamylcysteine, glutathione:cysteine,

y-glutamylcysteine:cysteine and bis(y-glutamylcysteine) were synthesised (Section

2.2.2).

The y-glutamyl compounds, y-glutamylglutamine and ophthalmic acid, were

purchased from Sachem, Bubendorf, Switzerland.

Lithium buffers and physiological

standard mixtures of amino acids from Beckman Instruments (Palo Alto, CA) were
used for quantification with the addition of A grade glutamine (Calbiochem, La Jolla,
CA).

Sepramar grade S-2-aminoethyi-L-cysteine hydrochloride (AEC) was obtained

from BDH Chemicals Ltd, Poole, UK for use as the internal standard.

Millipore,

Bedford, MA supplied the Ultrafree®-MC 10,000 NMWL ultrafiltration units and the
system for Milli-Q organics-free water production that was used throughout the study.
Qualitative Separation of y-Giutamyl Peptides, y-Giutamyl Amino Acids and Amino
Acids
High Voltage Electrophoresis Systems Methods used in the running and staining of

HVE sheets have been described in Appendix A. Untreated urine equivalent to -40
nmol creatinine was applied to each channel on the paper sheet for HVE at pH 1.9. In
the second experiment aliquots of urine were eluted from a Dowex 1X8 column with 4
moi/L acetic acid, taken to dryness, reconstituted and then a volume equivalent to

-800 nmol creatinine run on HVE at pH 2.9.
Quantification of the y-Giutamyl Disulphides, y-Giutamyl Amino Acids and Amino Acids
Sample Preparation Urines were ultrafiltered through an Ultrafree®-MC 10,000 NMWL

filter at 1900 X g for 15 min at 20°C. Fifty 11L of each ultrafiltrate was mixed with 50 11L
of buffered 50 11moi/L AEC then buffered 25 11moi/L AEC was used for further dilution
as

required

(according

to

creatinine).

Sample

preparations

stored

at

-aooc were stable for at least six years.
Cation-exchange Chromatography

Separation and quantification of the disulphides

and mixed disulphides of the glutathione-related metabolites, y-glutamylglutamine and
amino acids in the urine from KW and BW and controls were carried out on a Beckman

TABLE 2.3
Retention Times, Area Ratios and Response Ratios for the Reference Panel of
y-Giutamyl Compounds Separated by Cation-Exchange Chromatography during the
Study
Range of Retention Times

Area Ratio at

Response Factor at 570 nm

min

570 nm/440 nm

Relative To Internal Standard

y-GiuGin

7.1-7.4

9-12

1.0-1.1

y-GiuAbuGiy

7.5-7.6

8-10

1.2- 1.4

GSSG

20.7-21.7

10-14

0.56-0.62

GS:y-GiuCys

24.3-25.5

10- 15

0.59-0.68

(y-GiuCys)2

30.7-32.0

10-15

0.58-0.70

GS:Cys

35.8-36.5

2.3-2.8

0.70-0.82

y-GiuCys:Cys

45.3-46.9

2.4- 2.8

0.80-0.89

Standard Compound

Results obtained using the Beckman 6300 Buffer A run at 20 mllhr.
Internal standard =S-2-aminoethyi-L-cysteine hydrochloride

TABLE 2.4
Reliability of Analysis of Urinary Amino Acids using Cation-Exchange
Chromatography
Precision between-run for a normal urine over a 2 year period {N = 16)
Compound

Standard

CV%

Compound

Standard

CV%

Deviationa

Deviationa
Tau

2.3

2.6

Val

0.3

12.3

Asp

0.4

7.0

(Cys)2

0.4

3.2

Thr

0.5

2.9

lie

0.5

21

Ser

1.2

3.3

Leu

0.4

12.4

Asn

0.7

7.6

Tyr

0.9

10.1

Glu

0.2

13.8

Phe

1.5

5.5

Gin

0.9

2.1

Orn

0.3

4.5

Gly

2.7

1.6

Lys

1.4

2.5

Ala

1.1

4.0

His

3.8

4.9

Arg

0.2

2.8

a

J.tmol/mmol creatinine
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6300 amino acid analyser using a 10 em X 4 mm lithium cation-exchange column
(Beckman Instruments, Palo Alto, CA, USA).

The operating conditions of the Beckman 6300 varied slightly over the period of the
study but were generally based on the method of Hubbard eta/ (1988). The buffer flow
rate was kept constant at 20 mllmin. The routine program for physiological amino acid
separations used four lithium buffers, with buffer A running for 32 min, buffer D, with
1.98 g lithium chloride (BDH) added, running for 42 min, buffer E for 12 min and an
equal mixture of buffers F and C for 50 min.

A modification of this program that

extended the running time of buffer A to 56 min, was used to analyse the disulphide
and mixed disulphide compounds.

Integration Beckman System Gold™ integrating software was used for the quantitative

analysis.

The broad peaks (4-5 min wide) of the abnormal disulphides and mixed

disulphides

complicated

integration

of

both

the

ordinary

amino

acids,

y-glutamylglutamine and the glutathione-related compounds. Levels were checked by
subtraction of chromatograms (a) test urine minus a mixture of abnormal compounds
prepared at the same levels as estimated in the urine and (b) test urine minus a normal
urine with similar levels of ordinary amino acids.

Naming Peaks and Peak Integrity Peaks were named by comparing the retention time,

response at 570 nm or 440 nm relative to the internal standard AEC, 570/440 area
ratios and most importantly the area/height ratio at either wavelength, with those of
standard mixtures run in the same batch. Table 2.3 shows the retention times, area
ratios for the colour reaction with ninhydrin at 570nm/440nm and response factors
relative to AEC for the panel of standard compounds run on the extended program with
buffer A.

Reliability A urine sample was prepared and run with each batch as a general quality

control check on the assay. Table 2.4 gives the data for the between-run precision of
quantification of urinary amino acids in that sample over a 2 year period (N = 16).

Quantification of the Products of Borohydride Reduction

Sample Preparation Urine and standard mixtures of the oxidised compounds GSSG,

bis(y-glutamylcysteine) and cystine, 100 f-1-L, were reduced with 50

~L

of freshly

prepared sodium borohydride (120 mg made up in 1.2 mL 0.1 moi/L sodium hydroxide)
at 37°C for 1 hour. After cooling, the reduced urine or reduced standard mixtures were

TABLE 2.5
Volumes of Urine, BSTFAf1% TMCS and Internal Standard Used for the Organic
Acid Profile
Creatinine

Urine Volume for

BSTFA/1% TMCS

Heptadecanoic Acid

mmoVL

Extraction

~L

~L

ml

0.1-0.5

2x1

50

5 to each tube

0.5-0.9

2X1

[Creatj x 100

1Ox[Creat] to each

1.0 ~ 10.0

1

(C[eat) l.! 100

10x[Creat)

2

>10.0

0.5

[Crel!l] x l 00

4
ABBREVIATIONS: BSTFA- N, 0-bis-(trimethylsilyl)-trinuro-acetamide
TMCS - trimethyl chlorosilane
Creal - creatinine

5x[Creat]
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diluted with 250 Ill of a 20 g SSA in 100 ml water reagent , 50 I-LL of a solution
containing 0.1 g disodium ethylenediamine tetraacetate (EDTA) in 100 ml of water and
500 or 2000 Ill of water respectively. The efficiency of reduction was 100% for the
standard compounds and between 77 and 100% for urine.

Reversed phase chromatography of the thiols A separative method was developed for

the quantification of total GSH, total y-glutamylcysteine and total cysteine using
reversed-phase HPLC-EC with a mercury-gold amalgam electrochemical detector.
Details of method development are described in Appendix B.

All preparations were taken through a Millex-GS 0.22

~-tm

filter (Millipore Corporation,

Bedford, MA). Five to 30 J..ll were injected on column. Thiols were separated on a
Spherisorb S1 o ODS2 column (25 em X 4.6 mm) (ICI Instruments, Dingley, Australia)
using a mobile phase containing 0.1 moi/L chloroacetic acid, 4% methanol (v/v), 4
mmoi/L sodium octyl sulphate with the pH adjusted to between 2.75- 2.80 and sparged
with helium prior to and during chromatography. Thiols eluted from the column were
measured using a BAS LC-4B electrochemical detector (Bioanalytical Systems Inc.,
West Lafayette, IN) with a mercury gold amalgam working electrode held at a potential
of +0.1 V versus a Ag/AgCI reference electrode. The detector was set for 50 or 100 nA
full scale detection.

Retention times for cysteine, GSH and y-glutamylcysteine were 6.6, 10.2 and 11.6 min
respectively. The detector response was measured as peak height and was linear for
cysteine, GSH and y-glutamylcysteine (r = 0.999, 0.998 and 0.999 respectively) from at
least 10 to 800 pmole at 50 nA and at least 200 to 1100 pmole at 100 nA. Analysis of
each batch of standard compounds and urines was completed within three hours of
reductive pretreatment.

Qualitative Analysis of Organic Acids in Urine

The volumes of urine and reagents were varied to adjust the final concentration of
organic acids and internal standard in each derivative relative to the urinary creatinine
(Table 2.5).

One ml or 2 X 1 ml of urine was acidified with hydrochloric acid 6 moi/L and saturated
with 0.5 g sodium chloride Analar grade (BDH).

Heptadecanoic acid (Sigma), the

internal standard, was made up as 20 mmoi/L in ethanol and added to the urine aliquot
according to the creatinine value. The urine was extracted twice with two ml of ethyl

FIGURE 2.4
HVE Separation at pH 1.9 of Urine from Three Patients with y-Giutamyltransferase
Deficiency
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The figure shows a separation of urine by HVE on paper at pH 1. 9 at 4000 V 80 mA for 17
min, dried, stained with ninhydrin/collidine/copper sulphate and heated for 3 min at 105°C.
Samples from left to right: (i) patient C, (ii) patient KW with elevated Gly, (iii) patient BW
and (iv) a control. Samples were applied to give -400 nmol creatinine equivalents in each
channel. Normal amino acids from anode to cathode: His, Gly, Ala, Ser and Gin. Arrows
mark the abnormal bands 1, 2 and 3.
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acetate Analar grade (SOH) and once with two mL diethyl ether containing 2% ethanol
as stabiliser (Merck). The pooled extracts were dried under a stream of nitrogen and
derivatised with a volume of N, 0-bis-(trimethylsilyl)-trifluro-acetamide with 1%
trim ethyl chlorosilane (BSTFA/1% TMCS) (Regisil RC-2, Regis Chemical Company) at
60°C for 30 min.

The original screen of samples from KW and BW was obtained by separation of 1 ~-tL of
the derivative on a CP-Sil 19CB capillary column 25 m X 0.25 mm ID (Chrompak)
using a Packard 436 gas chromatograph (GLC) with a flame ionisation detector (FlO).
Under these conditions 5-oxoproline ran free of other urinary metabolites with a
methylene unit range of 17.07-17.11.

The limit of detection was 230

~-tmol/mmol

creatinine. A normal urine with weighed-in 5-oxoproline to 1 mmol/mmol creatinine
was extracted as a quality control check for each batch of urine extractions.

Later in the study the urine samples were rerun on a Hewlett Packard 5971A gas
chromatograph using an HP1 column and a mass selective detector, when this became
available. The identity of di-trimethylsilyl 5-oxoproline could be confirmed by finding a
large characteristic ion of mlz 156 and two minor ions at 230 and 258 at the correct RT
in the quality control check.

2.3.3

Results

Qualitative Comparison of Urine Patterns from the Three Affected Patients

Figure 2.4 shows the separation of urine samples from patients KW, BW, C and a
normal control run on HVE at pH 1.9 and stained with ninhydrin in acetone.

The

moderately elevated glycine seen in KW was almost certainly secondary to mild
hyperglycinaemia caused by her anticonvulsant medication (dipropylacetate) (Jaeken

et al 1977). The proportions of the three abnormal bands in all three y-GT deficient
patients are similar. Bands 1 and 2 reacted with iodoplatinate reagent giving a cream
colour against the peach background indicating the presence of the disulphides and
mixed

disulphides.

Band

contained

glutathione:cysteine

and

y-glutamylcysteine:cysteine and stained violet with the ninhydrin/collidine/copper
sulphate.

Band

2

containing

GSSG,

glutathione:y-glutamylcysteine

and

bis(y-glutamylcysteine) and band 3 containing y-glutamylglutamine and trace amounts
of y-glutamyl-a-aminobutyrylglycine stained blue. This group of three extra bands had
not been obseNed in more than 65,000 urine samples from patients tested using this
HVE method.

FIGURE 2"5

Abnormal Compounds in Urine Eluted from Dowex 1X8 and Separated by HVE

at pH 2.9

CysSSG

GSSG
lr-Glu-Gln
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~

lr-Glu-Cys2
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lr-Glu-Cys-Gly ·
~-Glu-~ys
4

The figure shows the separation on HVE at pH 2.9 at 4000 V 80 mA for 45 min, dried,
stained with ninhydrin/collidine/copper sulphate and heated for 3 min at 105°C. Samples
from left to right: (i) mixture of six reference standards including GS:Cys, GSSG,
y-glutamylglutamine, y-GiuCys:Cys, GS:y-GiuCys and (y-GiuCys)2 and (ii) urine from KW
eluted from a Dowex 1X8 column by 4 moi/L acetic acid.
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An HVE separation run at pH 2.9 (Figure 2.5) showed the six bands corresponding to
the

five

y-glutamyl

disulphides,

GSSG,

glutathione:y-glutamylcysteine,

glutathione:cysteine, bis(y-glutamylcysteine) and y-glutamylcysteine:cysteine as well as
y-glutamylglutamine in the second experiment on urine from KW.

Although

y-glutamyl-a-aminobutyrylglycine ran slightly faster than glutathione:cysteine it was not
visible in this separation because the level was below the detection limit of the HVE
ninhydrin stain (5 1-lmol/mmol creatinine).

When the urine from patient C was separated at pH 2.9 (Figure 2.6), a band clearly
corresponding to the y-glutamylglutamine in urine from KW was obtained along with the
other five glutathione-related compounds.
corresponded with y-glutamylglutamate.

Neither urines contained a band that

The absence of y-glutamylglutamate was

confirmed using the TLC separation (Appendix A).

Quantification of y-Giutamyl Disulphides and y-Giutamylqlutamine

Quantification of the y-glutamyl disulphides by conventional amino acid analysis using
cation-exchange chromatography showed low, broad peaks that were difficult to
integrate without interference from

urinary amino acids and conversely the

glutathione-related peptides interfered with ordinary amino acid quantification (Figure

2.7). This interference was largely overcome by using the strategy of chromatogram
subtraction (Section 2.3.2) made possible with the Beckman System Gold™ integration
software during post-run analysis.

Glutathione:cysteine and y-glutamylcysteine:cysteine eluted at the buffer change from
A to D.

When the time for buffer A was extended these compounds appeared as

well-separated peaks and were easily quantified in urine (Figure 2.7).

Levels obtained for the disulphides and mixed disulphides are shown along with the
amino acids and y-glutamylglutamine in Table 2.6.

Values for total GSH, total

y-glutamylcysteine and total cysteine were calculated by adding the results for the
GSH, y-glutamylcysteine and cysteine moieties of these disulphides and these were
compared with those measured directly by HPLC-EC (Table 2.7).

FIGURE 2.6
HVE Separation at pH 2.9 of Urine Samples Eluted from Dowex 1X8
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The figure shows the HVE separation of urine from KW and patient C, that had been taken
through a Dowex 1X8 column prior to application and then separated at pH 2.9 at 4000V 80
rnA for 45 min. Samples from left to right: A a mixture of reference standards including 1.
cystine, 2. GS:Cys, 3. GSSG, 4. y-glutamylglutamate (not present in the urine samples), 5.
y-GiuCys:Cys, 6. GS:y-GiuCys, 7 (y-GiuCys)z. B KW and C patient C each equivalent to
-1200 nmol creatinine in the original urine, D y-glutamyl-a.-aminobutyrylglycine (ophthalmic
acid), E y-glutamylalanine and A the reference mixture repeated.
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Separation of Stored Urine from KW Using the Extended Program for Buffer A Read at 570 nm
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Fifty microlitre of prepared sample containing -10 nmol creatinine and 1.25 nmol of internal standard (AEC) was injected (arrow). 1, Tau; 2, urea; 3, y-GiuGin +
trace y-GiuAbuGiy; 4, trace GSH +Asp; 5, Thr; 6, Ser; 7, Gin; 8, GSSG; 9, GS:y-GiuCys; 10, Gly; 11, Ala+ trace (y-GiuCys)2; 12, GS:Cys; 13 y-GiuCys:Cys; 14,
ammonium; 15, AEC. y-GiuCys would run on the downward slope of Asp and Cys would sit at the high valley between GSSG and GS:y-GiuCys.
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TABLE 2.6
Levels of Amino Acids, y-Giutamyl Peptides and y-Glutamylglutamine Obtained by
Cation-Exchange Chromatography of Stored Urine from KW, BW and Their Parents
Results expressed as J-Lmol/mmol creatinine

Compound

Urine

Urine

Reference

Urine

Urine

Reference

'rWV

BW

Ranges•

Mother

Father

Ranges•

10-13 '{_ears
Tau

60

62

y-GiuGin

43

r-GiuCys

>13_years
61

68

41

ND

ND

ND

ND

ND

NO

GSH

INT

INT

ND

ND

Asp

12b

gb

1 -10

10

9

2-7

Thr

22

17

8-28

16

15

7-29

Ser

43

36

23-67

23

29

21-50

Asn

11

8

0-18

ND

ND

0-23

0-9

2

20-112

28

42

Glu

18-176

16- 180

0-12

Gin

40

52

GSSG

23

36

ND

ND

Cys

NO

2

ND

ND

GS:y-GiuCys

20

8

NO

ND

Gly

920

140

64-165

90

126

43 -173

Ala

72

29

21 -62

16

24

16-68

NO

ND

{y-GiuCys)2

2

20-76

GS:Cys

38

59

NO

ND

r-GiuCys:Cys

26

50

ND

ND

Val

4

6

3-17

2

3

3-13

(Cys)2

19

12

3-11

3

5

3- 17

lie

3

2

0-6

ND

ND

0-4

Leu

4

5

3-14

4

3

2- 11

Tyr

16

25

6-25

4

11

2-23

Phe

7

11

5-17

5

6

2-19

Om

NA

4

0-6

11

10

0-5

Lys

5

15

10-56

10

26

7-58

His

43

42

43-159

42

83

26-153

Arg

2

2

0-6

3

2

0-5

ABBREVIATIONS:

N D - not detected

• Reference ranges for first morning urine (Parvy et a/1 988)
b Includes a trace of GSH

NA - not analysed

I NT - interference
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TABLE 2.7
Results for Total Glutathione, Total y-Giutamylcysteine and Total Cysteine
Obtained by Direct HPLC-EC Compared with Those Calculated from the
Disulphides and Mixed Disulphides in Stored Urine
PATIENTKW

PATIENTBW

Cation-exchange

HPLC-EC

Lmollmmol creatinine

)lmol/mmol creatinine

TOTALGSH

TOTAL 1-GiuCys

TOTAL Cys

Cation-exchange
_illllallmmol creatinine

HPLC-EC
mol/mmol creatinine

105

115

139

130

48

60

59

45

102

100

135

120

ABBREVIATIONS: Cation-exchange- amino acid analysis using Beckman 6300 system
HPLC-EC- pre-column reduction, reversed-phase HPLC with electrochemical detection

FIGURE 2.8
The HPLC-EC Separation Obtained on Urine from KW after Reductive
Pretreatment with Borohydride

100nA

0

10

20

Time (min)

The figure shows peaks corresponding to peak 1 cysteine, peak 2 reduced glutathione
and peak 3 y-glutamylcysteine.
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Quantification of the Products of Borohydride Reduction

Aliquots of the urine samples from KW and BW were reduced with borohydride and
separated by HPLC-EC. Figure 2.8 illustrates the HPLC-EC separation of reduction
products in urine from KW.

Levels for total GSH, total cysteine and total

y-glutamylcysteine for this method were obtained directly (Table 2.7).

Quantification of Amino Acids

The timed urine collections on KW, BW and their parents were taken mid-morning.
Little published data is available for urinary amino acid levels expressed per mmol
creatinine on random samples from a reference population.

Quantitative levels of

urinary amino acids (Table 2.6) were therefore compared with the published ranges
found for untimed early morning collections from 40 age-matched controls in each age
group (Parvy et a/ 1988). The results were within the reference intervals with two
exceptions. The level for cystine was slightly higher than normal, KW 19 !-Lmol/mmol
creatinine and BW 12 !-Lmollmmol creatinine (range for 10 - 13 year olds, 3 - 11). The
glycine and alanine levels in KW were also abnormal, 920 and 72 !-Lmol/mmol
creatinine respectively,

but were almost certainly caused

by her medication

(dipropylacetate) (Jaeken et a/1977) and her petit mal.

Qualitative Analysis of Organic Acids in Urine

The organic acid profile showed no detectable 5-oxoproline or other abnormal organic
acid in the urine of either KW or BW.

2.3.4

Discussion

The excretion patterns on HVE at pH 1.9 showing a normal amino acid profile with the
three additional peptide bands were similar in proportion and quite characteristic in all
three patients with y-GT deficiency.

The normal urinary amino acid levels were verified by quantification (Table 2.6).
Neither of our patients, followed over 19 and 15 years, has ever had a generalised
aminoaciduria and neither has either of the two other confirmed cases (Schulman et a/
1975, Wright et a/1979). In 1970 Orlowski and Meister proposed that y-GT could be
responsible for transport of amino acids across cell membranes. Their model involved
the transfer of the y-glutamyl group from extracellular GSH to amino acids in the
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glomerular filtrate, transport of the y-glutamyl amino acid into the cell and intracellular
hydrolysis by the y-glutamyl amino acid cyclotransferase (Orlowski & Meister 1970).
Observations reported from the American and English patients with y-GT deficiency
centered around evidence against (Schulman

et at 1975) or for (Griffith & Meister

1980) this amino acid transport system. The normal levels of amino acids found in our
patients support the findings of Schulman eta/ (1975).

The disulphides and mixed disulphides present in urine from KW and BW were
quantified using cation-exchange chromatography (Table 2.6). Although broad peaks
were obtained and a complex process of integration was required, the quantitative data
appear reliable because the levels for total GSH, total y-glutamylcysteine and total
cysteine derived from these results obtained by cation-exchange chromatography
compared favourably with the direct analysis of thiols using the HPLC-EC separation
after borohydride pretreatment of the urines (Table 2.7).

The excretion of total GSH and of total cysteine in urine from KW (1 05 and 102
1-1mol/mmol creatinine) and BW (139 and 135 1-1mol/mmol creatinine), exceeded the
levels of each of the normal urinary amino acids, except for glycine. The level of total
GSH in normal urine was, by contrast, below the detection limit of both quantitative
methods employed in this study (<1 1-1mol/mmol creatinine), a level agreeing with that

et at (1991). The normal level of total urinary cysteine has been reported to be
between 10 and 55 1-1mol/mmol creatinine (Aebi et a/1991).

of Aebi

Griffith and Meister (1980) found levels of total glutathione at 66 and 57 1-1mol/mmol
creatinine in two samples from the English patient with y-GT deficiency, with
y-glutamylcysteine and cysteine moieties approximately 30 - 50% of glutathione. The
level of

total glutathione excreted by the American patient with this disorder was

analysed, using the glutathione reductase method of Tietze (1969), on two occasions
and found to be 280 and 408 1-1moi/L (Schulman

et a/1975).

Unfortunately no data for

creatinine was reported, so these values cannot be compared with those obtained from
the other patients.

The levels of total y-glutamylcysteine and y-glutamylglutamine were similar in both KW
(48 and 43 1-1mollmmol creatinine) and BW (59 and 41 1-1mollmmol creatinine). Griffith
and Meister (1980) gave no quantitative data for total y-glutamylcysteine following their
investigation of two urines from patient C. Amino acid analyser tracings (Figure 2.3)
indicate that the peak representing the total y-glutamylcysteine in her urine is, like that
in the Australian patients (Figure 2.8), the smallest of the three thiol moieties. The
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authors did not comment on a large peak running after urea on the same
chromatogram. This peak did not disappear after reduction and derivatisation and it is
possible that it represented the y-glutamylglutamine apparent in the urine of patient C
run on HVE at pH 2.9 (Figure 2.6).

Evidence from the current study and from Griffith and Meister (1980) shows that renal
loss of the cysteine moiety, but not cystine, is associated with y-GT deficiency. The
cellular and metabolic origins of this cysteine moiety have not been reported, so it may
arise from cystine, cysteine or both.

Comparisons between the preference of renal y-GT for cystine and cysteine as an in
vitro acceptor are difficult to assess. No reports were found comparing activities with
both cystine and cysteine at 2 mmoi/L. The concentration at which most amino acid
acceptors including cysteine were tested (20 mmoi/L) is 10 times the solubility limit for
cystine and impractical.

Cystine is a proven in vitro substrate for human y-GT.

It was the best amino acid

acceptor in studies on y-GT isolated from human kidney and from human liver (Shaw et
a/ 1978). In addition, the y-GT activity in fibroblasts from the American patient with

y-GT deficiency was shown to be undetectable when 2 mmoi/L cystine was used as the
acceptor substrate, whereas the y-GT activity in normal cultured fibroblasts was
between 54 and 116 nmol/hour/mg protein (Schulman et a/ 1975).

In view of this

evidence it is curious that cystine is not excreted in higher than normal amounts by
KW, BW and the American and English patients with y-GT deficiency (Schulman eta/
1975, Wright et a/1979, Griffith & Meister 1980).

Cysteine is also a good acceptor for human y-GT.

gamma-Giutamyltransferase

purified from human intestinal brush border was twice as active with cysteine at 20
mmoi/L, when compared with glutamine at the same concentration and at least five
times more active than with any other amino acid tested (Smith & Heizer 1978). They
investigated cystine at the limit of its solubility 2 mmoi/L and at that concentration it
showed 87% of the activity obtained with cysteine at 20 mmoi/L.

Tate and Meister (1974) reported that the rat kidney enzyme was also active with
cysteine

as

acceptor

with

results

comparable

with

those

obtained

using

a-aminobutyrate, alanine and serine, that is around 75% of the activity with glutamine.
In addition, Thompson and Meister (1975) found that when cysteine, cystine and
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glutamine were tested as acceptor substrates at 0.45 or 0.50 mmoi/L, y-GT purified
from rat kidney gave activities of 49, 76 and 68 1-Lmol/min/mg enzyme respectively.

It is interesting to note that transport studies on cultured fibroblasts from the American
patient with y-GT deficiency (Pellefigue et a/ 1976) showed apparently normal uptake
kinetics for cystine, glutamine, methionine and alanine in the mutant fibroblasts when
compared with that of normal fibroblasts.

Intracellular amino acid levels were also

comparable with those of controls, except for phenylalanine, cystine and cysteine that
were

hiilll~r.

suggesting normal uptake and reduced metabolism.

These complex renal transport systems and the chemical interactions of thiols make
definitive experiments in humans, and particularly in patients with y-GT deficiency,
ethically impossible. It would entail a dangerous operative procedure that could only
be contemplated in animal models. Even if it were possible to collect urine from the
renal tubule itself, this may even be metabolically too late.

The only feasible alternative appeared to be immediate analysis of freshly excreted
urine from a patient with y-GT deficiency. This might help to clarify whether:
•

the three thiols, GSH, y-glutamylcysteine and cysteine, as well as all the
disulphides and mixed disulphides, including cystine, were excreted initially,

•

only GSH and cysteine were excreted initially and the y-glutamylcysteine moiety
was derived from carboxypeptidase activity on GSH or

•

GSH and cystine were excreted initially and the other thiols and disulphides were
derived via enzymatic and/or chemical reactions.

2.4

ANALYSIS OF FRESHLY OBTAINED URINE AND PLASMA

2.4.1

Introduction and Objectives of the Study

Although Goodman et a/ (1971) had remarked on the probable presence of GSH in
freshly excreted urine from the American patient with y-GT deficiency, Griffith and
Meister (1980) found no free thiols in two urine samples obtained from patient C, so it
was not clear whether GSH was necessarily excreted.

It was also not clear whether urinary cystine levels were low or normal in these
patients. Schulman et a/ {1975) had indicated that urinary cystine was not detected
{«1 0 J.Lmoi/L), while the report by Wright eta/ (1979) gave a level of 79 1-Lmoi/L, but no

50

Studies in Patients with y-Giutamyltransferase Deficiency

creatinine concentration. If indeed cystine were such a good acceptor for human renal
y-GT in vivo as it was in vitro (Shaw et a/ 1978), it was curious that cystine was not
elevated in the urine of these patients. Results of the quantitative analysis of stored
urine samples showed that GSH and cysteine were the major moieties excreted by the
two Australian patients with y-GT deficiency (Section 2.3).

It therefore appeared

important to clarify whether the thiols and cystine were elevated in freshly excreted
urine and, if present, whether they were the source of the disulphides and mixed
disulphides.

Another aspect that required clarification was the assumption that glutathionaemia was
a hallmark of y-GT deficiency. Three previous reports (Goodman

et a/1971,

Schulman

et a/ 1975, Wright et a/ 1979) gave levels of plasma glutathione, analysed as total

glutathione by the glutathione reductase method of Tietze (1969), that indicated an
elevation in their patients with y-GT deficiency when compared with controls. These
findings agreed with experimental studies in mice and rats by Griffith and Meister
(1979a), Griffith eta/ (1979) and Anderson eta/ (1980) which showed that inhibition of
y-GT also resulted in substantial glutathionaemia and glutathionuria, as well as
excretion of y-glutamylcysteine and cysteine moieties. An increase in plasma level is
not a precondition of high excretion in the urine when the lesion is related to the renal
tubular uptake. Now that y-glutamylcysteine, cysteine and y-glutamylglutamine, as well
as GSH, were likely physiological substrates of the enzyme, it seemed that
investigating the plasma may give useful information. Analysis of y-glutamylglutamine,
a stable non-thiol compound, would be particularly useful in clarifying this point.

The current investigation sought to analyse GSH, y-glutamylcysteine, cysteine and
y-glutamylglutamine in fresh urine and plasma, with sample collection and handling
planned to be completed in the minimum possible time. A fresh urine sample and a
single capillary blood sample were collected from BW. Results were compared with
those from a control handled similarly and with data from a reference population.

Once the levels of thiols were established in the freshly collected urine specimen, an
experiment was conducted to investigate possible enzymatic or chemical changes
between GSH and cystine under conditions similar to those found in the bladder. Fresh
urine was compared with ultrafiltered urine without its renal enzymes.
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2.4.2

Methods

Sample Collection and Handling

Blood was obtained from a freely-flowing finger prick collection into a Microtainer™
tube (Becton Dickinson C/N 5969) containing lithium heparin and plasma separator.
The samples from BW and a control were handled identically. Both were centrifuged at
11 ,000 X g for 3 min, separated and ultrafiltered through Ultrafree®-Mc 10,000 NMWL
supplied by Millipore at 1900 X g for 15 min at 20°C.

A portion was prepared for

immediate analysis by taking 20 J..LL of ultrafiltrate and adding 20 J..LL 50 J..Lmoi/L AEC
plus 120 J..LL buffered 25 J..Lmoi/L AEC. The excess ultrafiltrate was stored at -80°C.

Venous plasma from a normal adult, prepared as multiple aliquots and stored at -80°C,
is used in the laboratory as part of a routine quality control program. It was run in each
batch as a general quality control during the current investigations.

The freshly excreted random urine (pH 5.9) from BW was divided into two portions.
One was immediately ultrafiltered as described above for plasma.

Fifty J..LL of

ultrafiltrate was mixed with 50 J..LL of buffered 50 J..Lmoi/L AEC and buffered 25 J..Lmoi/L
AEC was used for further dilution as required (according to creatinine).
ultrafiltrate was stored as 1 mL aliquots in cryovials in liquid nitrogen.

Excess

The second

portion was not ultrafiltered but stored immediately as 1 mL aliquots at -80°C.

Reference Compounds

gamma-Giutamylcysteine was prepared by borohydride reduction of the stock standard
bis(y-glutamylcysteine) as described in Section 2.3.2 and stored as aliquots at -80°C.
Stock solutions of GSH and cysteine were prepared from solid reagents supplied by
Sigma Chemical Co. St. Louis, MO, dissolved in Beckman Li-S loading buffer and
stored as aliquots at -80°C.
Section 2.2.2.

All other compounds were obtained as described in

Working standards of GSH, y-glutamylcysteine and cysteine were

prepared with minimal time at room temperature.

Quantification in Plasma and Urine

Samples for Study Freshly collected plasma from BW and a control were injected onto

the Beckman 6300 immediately following removal of the cells and ultrafiltration with
the total time from collection to injection being 28 and 30 min respectively.
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Reference ranges for amino acids were obtained on selected venous samples from
paediatric in-patients older than 4 weeks of age with no overt symptoms but in whom
an inborn error of metabolism had been suspected. The minimum time from collection
to transport or storage at -sooc on these was usually 30 min and the sample
preparation time from thawing to injection was a further 45 min (total 75 min).

Freshly collected, ultrafiltered and diluted urine from BW was injected on column within
30 min of collection. Urinary creatinine was analysed by a rate reaction with alkaline
picrate using a Beckman creatinine analyser 2.

Amino Acid Chromatography

Separation and quantification of the GSH, cysteine,

y-glutamylcysteine, y-glutamylglutamine, y-glutamyl disulphides and amino acids in the
plasma and urine were carried out on a Beckman 6300 amino acid analyser using
Beckman System Gold™ integrating software (Section 2.3.2).

The peak retention

times, area ratios for the colour reaction with ninhydrin at 570nm/440nm, area/height
ratios and response factors relative to the internal standard AEC for the thiol standards
GSH, y-glutamylcysteine and cysteine were obtained with the normal 4-buffer program
for physiological amino acids and with the program using an extended time for buffer A
(Section 2.3.2).

Follow-up Study on Urine

The original freshly collected urine had been stored immediately in liquid nitrogen and
at

-Booc as both unfiltered and ultrafiltered portions.

One tube of each unfiltered and

ultrafiltered portion was thawed and the two sets were incubated at 37°C foro, 1, 2 or 4
hours in order to trace any changes in levels of the thiols and disulphides both with and
without the presence of urinary enzymes. At the end of each time period the relevant
samples were prepared for analysis by cation-exchange chromatography as described
in Section 2.3.2.

Analysis of all samples was completed in the same series of

injections.

A second set of aliquots of the ultrafiltered and unfiltered portions of fresh urine were
cooled to room temperature (21.5°C) at the end of their incubation period and their pH
was measured on an Orion pH meter SA 720 (Orion Research Incorporated, Boston,
MA) set with Radiometer pH buffers at pH 7.011 and pH 4.002.

TABLE 2,8
Retention Times, Area Ratios and Response Ratios for the Reference Panel of Thiols,
Overlapping Disulphides and Overlapping Amino Acids, Aspartate and a.-Aminoadipic
Acid, Separated by Cation-Exchange Chromatography during the Follow-up
Experiment on Urine
Standard Compound

Retention Time

Area Ratio at

Response Factor at

min

570 nm/440 nm

570 nm Relative to

440 nm Relative to

the Internal Standard

the Internal Standard

6.65

1.76

1.95

GSH

(i) 8.7

(double peak)

(ii) 10.8

Response Factor at

Aspartate

11.0

6.86

1.06

1.29

y-Giutamylcysteine

11.0

5.20

2.08

1.54

GSSG

21.7

12.15

0.58

1.42

Cysteine

23.6

0.25

16.7

0.69

a-Aminoadipic Acid

24.0

7.96

1.41

1.17

GS:y-GiuCys

25.5

9.69

0.64

1.12

TABLE 2.9
Reliability of Analysis of Amino Acids in Plasma by Cation-Exchange Chromatography
Reproducibility within-run for 5 consecutive injections of a single venous plasma
Precision between-run for a single normal plasma over a one year period (N = 56)

Compound

Reproducibility Within-run
Whole Range as
Average of 5 Results
%of Average
Jl.lllOI/L

Tau

88.8

Between-run Precision
Standard Deviation

CV%

mof/L

1.7

0.7

1.3
7.5

y-GiuGin

5.1

8.7

0.6

Asp

5.5

15.3

0.3

12

Thr

157.6

1.2

2.1

1.2

Ser

118.5

2.0

1.8

1.2

Asn

85.7

4.5

2.2

3.7

Glu

46.7

3.3

0.6

3.8

Gin

660.7

1.2

9.2

1.3

Gly

207.2

2.3

2.2

1.1

Ala

590.0

1.2

3.3

1.0

Cit

38.0

2.0

0.7

1.6

Val

311.5

1.1

4.0

1.6

63.5

0.9

1.0

2.0

Met

(Cys)2

0.5

1.6

lie

1.1

1.3

Leu

1.5

1.0

Tyr

0.9

1.5

Phe

3.2

4.5

Orn

1.0

1.9

Lys

2.4

1.1

His

3.8

3.6

Arg

1.5

1.6
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Results
Chromatography of Cysteine. :y-Giutamyl Thiols and :y-Giutamyl Disulphides

Table 2.8 shows the retention times and response ratios for the thiol standards and
compounds that may overlap. The identity of cysteine was assured by matching the
characteristics of the peak in the run of the standard mixture with that in each sample
including:
•

retention time,

•

response at 440 nm compared with that at 570 nm,

•

an area ratio at 570 nm/440 nm of 0.25 and

•

area/height ratio at 440 nm.

Reliability of the Analysis of Amino Acids. Cysteine, :y-Giutamylglutamine. :y-Giutamyl
Thiols and y-Giutamyl Disulphides in Plasma and in Urine

Plasma An estimate of the within-run reproducibility for amino acids was obtained from
five consecutive injections of a venous sample using the Beckman 6300 program with
extended time for buffer A (Table 2.9). The between-run precision of analysis in a
routine quality control plasma analysed over a one year period (N

=56)

is also shown

in Table 2.9.

Under our standard conditions, the detection limit in

~moi/L

was 5 for GSH, 3.0 for

y-glutamylglutamine, 2.5 for cysteine, 1.0 for y-glutamylcysteine:cysteine, 0.6 for GSSG
and 0.4 glutathione:y-glutamylcysteine.

Urine The within-run reproducibility for amino acids may be gauged by scanning Table

2.13 (page 56). The between-run precision in a normal of amino acids, analysed over
a 2 year period (N

=16), is given in Table 2.4 (facing page 40).

Within-run reproducibilty for the y-glutamyl compounds in the urines from KW and BW
may be assessed from the results of duplicate injections in four different series of
injections. The greatest difference between duplicates as

~mol/mmol

creatinine was

1.6 for y-glutamylglutamine, 1.5 GSSG, 1.3 for glutathione:y-glutamylcysteine, 1.1 for
glutathione: cysteine, 1.8 for y-glutamylcysteine:cysteine and 1.0 for cystine.

TABLE 2.10
Levels of Plasma Amino Acids and y-Giutamyl Amino Acids Obtained in Freshly
Collected Capillary Blood
Results expressed as Jlmoi!L

Compound

Patient BW

Control

Reference Ranges
(N

=155)

2

Tau

41

46

30-109

y-GiuGin

3.5

5.3

<8

GSH

<5

<5

Asp

12

9

3-12

Thr

140

172

56-249

Ser

116

113

72- 192

Asn

39

58

23-85

Glu

91

63

12-104

Gin

529

585

405-907

GSSG

<1.0

Cys

<2.5

GS: y-GiuCys

<0.5

Gly

152

294

125-387

Ala

451

374

138-632

Between 3 & 10

NO

y-GiuCys:Cys

7.3

3.1

Cit

57

37

10-47

Val

473

249

114-330

(Cys)2

56

69

25-70

Met

36

22

13-45

lie

133

62

36-112

Leu

253

122

59-187

Tyr

145

62

34-120

Hcy:Cys

3

3

0-3

Phe

96

52

32-79

Orn

98

44

27-107

Lys

217

183

88-274

His

NA

83

49-119

Arg

87

71

36-124

GS:Cys

ABBREVIATIONS:

<2.5

DET - detected

NO- not detected

NA - not analysed
a Unpublished reference ranges obtained from in-patients samples referred for the

diagnosis of a possible inherited disorder
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Quantification of Amino Acids. Cysteine. y-Giutamylqlutamine. y-Giutamyl Thiols and
y-Giutamyl Disulphides in Plasma

The results for freshly collected capillary plasma from BW and from the control are
shown in Table 2.10. The levels of Cit, Val, lie, Leu, Tyr and Phe in plasma from BW
were all

elevated suggesting that the sample,

collected

mid-afternoon, was

post-prandial (unpublished laboratory data).

Even though the times from sample collection to removal of plasma protein for BW
and the control were less than 15 min, the level of free cysteine was below the
detection limit of the method, that is <2.5 f.lmoi/L.

Plasma free GSH and y-glutamylglutamine in BW were <5 and 3.5 f.lmoi/L respectively
and similar to those in a capillary sample collected under the same conditions from the
control patient, namely free GSH <5 and y-glutamylglutamine 5.3 f.lmoi/L. Levels for
plasma free GSH analysed using ultrafiltration for the removal of protein have not been
reported but levels for plasma free GSH using acid-precipitation of plasma protein
range from 1 to 10.7 f.lmoi/L (Table 1.1 facing page 4). The upper limit of normal for
plasma y-glutamylglutamine obtained for children and adults in this study was 8 f.lmoi/L
(N

=130) (Section 3.3.3).

In order to check whether the results for the plasma thiols were due to the effect of
sample collection and handling or a loss during the analysis itself, amounts of GSH and
cysteine, equivalent to 10.02 and 10.20 f.lmoi/L in plasma respectively, were added to
the ultrafiltrate of plasma from a patient with cystathionine

~-synthase

deficiency

(McKusick 236200). These additions were readily detected giving recoveries of 99.4
and 102.4% respectively and indicate that the analytical system was capable of
estimating levels of thiols in the normal range. Insufficient capillary plasma from BW
was available to test for losses due to sample collection and handling.

It is important to note that the plasma from BW contained glutathione:cysteine and also
y-glutamylcysteine:cysteine, a compound possibly not reported in plasma. These may
have been derived from initial thiol-thiol oxidation and then carboxypeptidase activity
on free GSH and free cysteine during sample collection and handling.

Unfortunately glutathione:cysteine could not be quantified precisely due to interference
from the high level of valine (473 f.lmoi/L) and partial overlap with

~-aminobutyrate

but

recovery experiments on the routine quality control plasma indicated that the level was
between 3 and 10 f.lmoi/L.

TABLE 2"11
Levels of Amino Acids, y-Giutamyl Peptides and y-Giutamyl Amino Acids
Obtained in the 3 Hour Urine and in the Fresh Urine from BW
Results expressed as J.imol/mmol creatinine

Compound

3 Hour Urine

Reference Ranges"

Fresh Urine

Reference Rangesb

(Mid-morninQ)

(Early morninQ)

(Mid-afternoon)

(Early morninQ)

Tau

62

18-176

12

16-180

y-GiuGin

41

51

GSH

INT

71

Asp

8

1 - 10

8

2-7

Thr

17

8-28

20

7-29

Ser

36

23-67

37

21-50

Asn

8

0-18

12

0-23

0-9

2

0-12

20- 112

54

20-76

Glu
Gin

52

GSSG

36

29

Cys

2

37

GS:y-GiuCys

8

23

Gly

140

64- 165

205

43-173

Ala

29

21 -62

40

16-68

INT

(y-GiuCys)2
GS:Cys

59

52

y-GiuCys:Cys

50

53

Val

6

3-17

12

3- 13

(Cys)2

12

3-11

16

3- 17

Leu

5

3-14

6

2- 11

Tyr

25

6-25

32

2-23

Phe

11

5-17

10

2-19

Orn

4

0-6

2

0-5

Lys

15

10-56

15

7-58

His

42

43-159

68

26-153

Arg

2

0-6

8

0-5

ABBREVIATION:
INT- interference
a Reference ranges for first morning urine for ages 10- 13 years (Parvy et a/1988)
b

Reference ranges for first morning urine for ages >13 years (Parvy et a/1988)
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Levels of y-glutamylcysteine:cysteine found in the capillary blood collections were 7.3
f.lmoi/L for BW and 3.1 11moi/L in the control.

These findings were confirmed by

recovery experiments on the routine quality control sample.

The baseline level of

y-glutamylcysteine:cysteine was estimated at 4.0 llmoi/L. Addition of 7.8 llmoi/L and
15.2 llmoi/L y-glutamylcysteine:cysteine to this plasma gave recoveries of 103 and 97
%respectively.
Quantification of Amino Acids. Cysteine. :y-Giutamylqlutamine. :y-Giutamyl Thiols and
y-Giutamyl Disulphides in Urine

Results from the freshly excreted urine, when BW was 19 years of age, are shown in
Table 2.11. Urinary amino acids in BW were largely normal compared with the early

morning samples from an age-matched control population, including cystine 16
11mol/mmol creatinine (reference range for age >13 years, 3- 17), however glycine and
tyrosine were slightly elevated on this occasion. The cystine level in the initial timed
urine from BW, collected at age 11 years, had been 12 llmol/mmol creatinine
(reference range for age 10- 13 years, 3- 11) (Section 2.3.3).

Cysteinuria of at least 37 11mol/mmol creatinine was found in freshly excreted urine
from BW. GSH at 71 llmol/mmol creatinine was higher than any normal amino acid
excepting glycine. gamma-Giutamylcysteine was detected but unable to be quantified
because of the overlap of GSH, aspartate and y-glutamylcysteine peaks. The level of
y-glutamylglutamine, 51 f.tmol/mmol creatinine, in this sample was slightly higher than
that found when BW was 11 years of age (41 f.tmol/mmol creatinine) (Section 2.3.3).

Follow-up Study on Urine

Table 2.12 shows the levels of thiols and disulphides in freshly excreted "native" urine

and freshly excreted ultrafiltered urine from BW during incubation at 37°C for four
hours. Table 2.13 shows the levels of urinary acidic and neutral amino acids over the
time course of the same experiment.

The levels of GSH and cysteine decreased at similar rates in freshly excreted urine
containing urinary enzymes and freshly excreted ultrafiltered urine (Figure 2.9) and to
around 40% of the level prior to the incubation.

Cystine did not decrease via

thiol-disulphide interchange with GSH, but rather increased. However the increase in
cystine was 6.4 llmoi/L in "native" urine containing urinary enzymes compared with an

TABLE 2.12
Levels of Urinary Thiols, Disulphides and y-Glutamylglutamine During Incubation at 37°C
Results expressed as )lmol/mmol creatinine
60min

Zero Time

120 min

240 min

Change over 0 - 240 min

Non-filtered

Ultra filtered

Non-filtered

Ultrafiltered

Non-filtered

Ultrafiltered

Non-filtered

Ultrafiltered

Non-filtered

Ultrafiltered

y-GiuGin

51.9

50.7

52.1

49.9

52.2

49.9

51.4

51.5

-0.5

+0.8

GSH

71.7

70.4

58.5

50.9

41.6

40.6

29.8

27.8

-41.9

-42.6

GSSG

29.5

28.7

32.7

32.1

32.0

33.1

35.2

35.4

+5.7

+6.7

Cys

37.4

37.1

31.2

28.7

22.1

22.4

14.9

14.6

-22.5

-22.5

GS:y-GiuCys

22.6

23.5

26.6

25.6

28.9

28.7

30.4

30.6

+7.8

+7.8

GS:Cys

52.4

52.0

54.6

53.0

55.7

52.6

57.6

54.6

+5.2

+2.6

y-GiuCys:Cys

52.4

54.2

49.8

50.2

48.5

47.9

49.8

47.9

-2.6

-6.3

Cystine

16.7

16.5

19.8

16.9

21.8

17.7

23.1

19.2

+6.4

+2.7

I

!!2.
c:

TABLE 2.13

c.

iJi"

Levels of Urinary Amino Acids During Incubation at 37°C
Results expressed as ~mol/mmol creatinine
60min

Zero Time
Non-filtered

:r

Ultra filtered

Non-filtered

120min

Ultra filtered

Non-filtered

Change

240 min

Ultrafiltered

Non-filtered

Ultra filtered

iJ
~

co·

over 0 - 240 min

Non-filtered

~

Ultrafiltered

§.......
::::;

Taurine

11.5

11.5

12.0

11.6

11.6

11.9

11.9

12.1

+0.4

+0.6

Phosphoethanolamine

14.1

13.4

13.5

14.2

13.0

14.0

14.1

14.0

0

+0.6

c......
'<

"1

G)
0)

3

Aspartate

8.0

8.0

8.0

8.0

8.0

8.0

8.0

8.0

0

0

Threonine

20.2

21.1

19.3

20.9

19.7

19.8

19.8

20.0

-0.4

-1.1

Serine

36.9

37.9

36.4

38.3

36.6

37.2

37.3

38.1

+0.4

+0.3

;:;

iil

::s
(J)
CD'

iil
(J)
CD

0

CD

Asparagine

15.9

17.6

12.5

16.3

12.7

13.4

14.5

18.7

-1.4

:::!l

+1.1

"

(ii"

Glutamate

2.3

2.2

2.2

2.5

2.4

2.5

2.4

2.4

+0.1

+0.2

Glutamine

53.5

53.7

53.2

54.1

52.8

54.1

53.5

54.5

0

+0.8

205.6

206.2

208.2

211.4

206.7

214.2

210.7

214.1

+5.1

+7.9

Alanine

40.1

40.9

40.7

42.0

41.4

+2.9

Valine

12.8

12.9

11.8

12.6

12.1

-0.1

Glycine

I

::s

-2

I

-

42.3

42.3

43.8

+2.2

12.3

12.1

12.8

-0.7

--

~

FIGURE 2.9
Results for GSH, Cystine, y-Giutamylglutamine and Cysteine Following Incubation of Fresh Urine at 37°C
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Results for GSSG and the Mixed Disulphides Following Incubation of Fresh Urine at 37°C
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increase of 2.7 J.Lmoi/L in the ultrafiltered urine, indicating enzymatic oxidation as well
as thiol-thiol oxidation. The y-glutamylglutamine level remained constant over the four
hours in both the "native" and the ultrafiltered sample types.

The changes in disulphide concentrations during incubation appear to be real as they
are outside the within-run differences obtained in duplicate analyses (Section 2.4.3
page 53).

Oxidised glutathione and glutathione:y-glutamylcysteine increased by similar amounts
in both "native" and ultrafiltered urine (Figure 2.10), whereas glutathione:cysteine
showed a larger increase of 5.2 1-Lmoi/L in "native" urine when compared with the
ultrafiltered urine 2.6 J.Lmoi/L, inferring that two types of oxidation may occur.

In contrast y-glutamylcysteine:cysteine decreased over the four hours in both "native"
urine 2.6 J.LmOI/L and ultrafiltered urine 6.3 1-Lmoi/L.

Calculation of the combined moieties containing GSH were obtained for the levels at
zero time and those at the end of the four hour incubation. There was an apparent net
"Joss" of GSH moiety of -18 !lmol/mmol creatinine over the time course of the
experiment for both "native" urine and ultrafiltered urine. In other words the decrease
in the level of GSH could not be fully accounted for by the increase in GSSG and other
glutathione-related disulphides.

Similarly the combined moieties of cysteine were obtained for the levels at zero time
and those at the end of the four hour incubation. There was also an apparent "loss" of
cysteine of -7 1-Lmol/mmol creatinine for urine containing urinary enzymes and -21
J.Lmollmmol creatinine for ultrafiltered urine over the time.

On the other hand the combined moieties of y-glutamylcysteine increased by -5
1-Lmol/mmol creatinine in the "native" urine, but not the ultrafiltered urine. This increase
could have occurred via urinary carboxypeptidase action on GSH and account for
portion of the loss of GSH moiety.

Analysis of the acidic and neutral areas of the chromatogram showed that no other
unidentified ninhydrin-positive metabolic product(s), and in particular no extra cysteic
acid appeared to be formed during the experiment.
ninhydrin-negative products was attempted.

No investigation of possible
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There were no apparent differences in the levels of the urinary amino acids analysed in
"native" and ultrafiltered urine except for glycine (Table 2.13). As precision within-run
would be narrower than the between-run precision at SO ±2.7 1-lmoi/L (Table 2.4), the
increase in glycine is outside the analytical error.

The pH of the urine aliquots did not vary significantly over the incubation period, being
between pH 5.90 and 5.92 for freshly excreted urine and between pH 5.93 and 5.94 for
freshly excreted ultrafiltered urine. This indicated that the decrease in thiols was not
due to a significant increase in alkalinity of the urine resulting from ammonium
formation.

2.4.4

Discussion

The finding of a low-normal level of y-glutamylglutamine in plasma from BW is
important.

The observation shows that y-glutamyl compounds in plasma are not

necessarily elevated in y-GT deficiency.

The reference interval for plasma

y-glutamylglutamine was obtained on a large normal population (N

= 130)

and

y-glutamylglutamine is a stable non-thiol compound.

Plasma free GSH and free cysteine in the ultrafiltered sample obtained from BW and
from the control were below the detection limit of the analytical system, that is <5 and
<2.5 1-lmoi/L respectively. These results are difficult to interpret. Three factors need to
be considered.

Firstly the use of a capillary blood collection and ultrafiltration of plasma proteins was
unavoidable but was conducted as rapidly as possible. It may have resulted in falsely
low levels of the free thiols due to thiol-thiol oxidation. Thiols are chemically unstable,
particularly at pH 7 the pH of plasma (Jocelyn 1972, Martensson 1987, Mansoor et a/
1992, Winkler et a/1994).

Secondly, two compounds that may have derived from free GSH and free cysteine
were present. Initial thiol-thiol oxidation of the two would produce glutathione:cysteine.
Carboxypeptidase activity, especially in a capillary blood sample containing tissue
exudate, · could

then

form

y-glutamylcysteine:cysteine.

The

levels

of the

y-glutamylcysteine:cysteine in plasma from BW and the control were 7 and 3 1-lmoi/L
respectively and 4 1-lmoi/L in a second quality control venous sample.
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Thirdly GSH and cysteine were recovered in good yield following their addition to
plasma ultrafiltrate. This suggests that the process of sample collection and handling
rather than sample preparation and analysis may be associated with loss, if any.
Disappearance of free GSH due to y-GT activity within the plasma, a factor foreseen by
workers estimating GSH (Griffith 1985, Martensson 1986, Aebi et af 1991, Porta et af
1991, Witschi et af 1992), could not have occurred in the sample from BW.

Published values for normal levels of free GSH have been variable (Table 1.1 facing
page 4)and those for plasma free cysteine are as follows:
•

1.9- 15.9 ,....moi/L in 10 fasting adults (Aebi & Lauterburg 1991),

•

2.8 - 11.4 ,....moi/L in 8 fasting adult males and 6.8 - 16.7 ,....moi/L in 10 fasting adult
females (Mansoor et af 1992a)

2.2- 12.2 ,....moi!L in 6 fasting adults (Mansoor et af 1992b).

The current results probably indicate normal or even marginally increased levels of
thiols in vivo.

This would not be unexpected in a post-prandial sample.

They are

difficult to relate to the claimed "glutathionaemia" in y-GT deficiency (Goodman et af
1971, Schulman et af 1975, Wright et af 1979)(Table 1.2 facing page 4). This will be
discussed further in Chapter 6.

Excretion of GSH, cysteine and y-glutamylglutamine in y-GT deficiency has now been
documented. Results from the experiment that mimicked and continued the conditions
in the bladder for a further 4 hours, suggest that at pH 5.9 any excess of urinary cystine
above normal levels in BW is a product of thiol-thiol oxidation. It was fortuitous that
the urine pH in this particular sample was such that the Gs- moiety active in redox
coupled reactions (Winkler et af 1994) would not have been present to complicate the
interpretation.

The results from the incubation of fresh urine at 37"C indicate that the reactions related
to cystine and the mixed disulphides containing cysteine are complex. The increase in
the levels of cystine and glutathione:cysteine were higher in urine containing urinary
enzymes than ultrafiltered urine, suggesting that a urinary "oxidase" is present. On the
other hand levels y-glutamylcysteine:cysteine decreased over the 4 hours, with the
larger decrease occurring in the urine without enzymes.
instead

of thiol-thiol

oxidation,

thiol-disulphide

y-glutamylcysteine:cysteine has occurred.
levels could not be obtained to confirm this.

This could indicate that,

exchange

between

GSH

and

Unfortunately precise y-glutamylcysteine

TABLE 2.14
Comparison of Levels of Total Thiols and y-Giutamylglutamine in Urines from BW
Results expressed as J.lmol/mmol creatinine

Fasting Urine

Relative

Post-Prandial Urine

Relative

(aged 11 years).

Proportion•

laaed 19 vears)

Proportion•

Total GSH

139

3.4

204

4.0

Total y-Giutamylcysteine

59

1.4

76

1.5

Total Cysteine

135

3.3

174

3.4

y-Giutamylglutamine

41

1.0

51

1.0

a

Proportions calculated relative to y-glutamylglutamine

TABLE 2.15
Excretion of Total Thiols or Total Glutathione and y-Giutamylglutamine in Urine from
Four Patients with y-Giutamyltransferase Deficiency

BW
11mol/mmol creatinine
~J,mOI/h

y-GiuGin

Total GSH or Total
Glutathione

Total y-GiuCys

Total Cys

41
7.7

139
26.1

59
11.1

135
25.4

43
15.4

105
37.6

48
17.2

102
36.6

KW
~J,mol/mmol

creatinine

11mol/h
American patient
IJ,mOI/h
English patient
11mol/mmol creatinine

49.

57 and 66b

Schulman et a/1975, glutathione reductase method of Tietze 1969
Griffith & Meister 1980, glutathione reductasemethod of Tietze 1969.
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The marked thioluria, as GSH and cysteine, in BW suggests that these are related to
the decreased y-GT activity in the renal epithelium. The source or sources of these
thiols in humaos are not known with certainty but the most likely would be in the
glomerular filtrate under normal circumstances.

A mechanism of GSH translocation from the renal epithelium to the lumen has been
reported to occur in experimental y-GT deficiency in rats and mice (Griffith
Griffith & Meister 1979a).

et a/1978,

However no published evidence for this or for cysteine

translocation to the lumen in similar manner in humans could be found.

Table 2.14 shows the combined sets of results obtained in urine from BW and

previously recorded in Table 2.7 and Table 2.11. Thiol moieties have been calculated
by addition of the relevant GSH, y-glutamylcysteine and cysteine in the disulphide,
mixed disulphide and thiols. The initial urine was collected as a fasting three hour
mid-morning collection, while the second (fresh) sample was collected mid-afternoon
and was post-prandial. The proportions of total GSH, total y-glutamylcysteine, total
cysteine and y-glutamylglutamine in the urine are remarkably constant.
3.4:1.4:3.3:1 and 4.0:1.5:3.4:1 (Table 2.14).

They are

Such constant proportions strongly

support the proposal in this study and Orlowski and Wilk (1975, 1976, 977, 1978) that
the physiological substrates of human renal y-GT are filtered from the circulation at the
glomerulus. It might be expected that the proportion of GSH would be much higher in
urine in y-GT deficiency if the proposition that GSH is translocated from the renal
epithelium to the y-GT in the lumen, as indicated by inhibition experiments on animals,
were correct (Griffith & Meister 1979a).

Table 2.15 shows the available data for the excretion of abnormal metabolites in

J..tmollmmol creatinine and in J..tmollhr for the four patients with y-GT deficiency. The
differences in excretion rate (J..tmol/hr) between BW and KW suggest that this indicator
may be misleading. BW who has Prader-Willi syndrome is obese, while her sister has
voluntarily limited her protein intake since childhood and is slender.

Perhaps the

excretion of these compounds would be better expressed per muscle mass.
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SUMMARY AND IMPLICATIONS OF FINDINGS

Abnormal compounds were found that were not detected in more than 65,000 urine
samples submitted for metabolic screening, including those showing gross generalised
aminoaciduria

•

Seven abnormal compounds were isolated from stored urine from both sisters and
were positively identified;

•

1.

bis(y-glutamylcysteinylglycine) or oxidised glutathione (GSSG)

2.

glutathione:y-glutamylcysteine disulphide (GS:y-GiuCys)

3.

glutathione:cysteine disulphide (GS:Cys)

4.

y-glutamylcysteine:cysteine disulphide (y-GiuCys:Cys)

5.

bis(y-glutamylcysteine) (y-GiuCys)2

6.

y-glutamyl-a.-aminobutyrylglycine (y-GiuAbuGiy) and

7.

y-glutamylglutamine (y-GiuGin)

Patterns of the urinary y-glutamyl disulphides and y-glutamylglutamine were similar in
three patients with y-GT deficiency

•

Abnormal compounds were not detected in the urine of either parent of the Australian
patients

•

No generalised aminoaciduria was found over 20 years of monitoring both Australian
patients

•

Urinary cystine was at the top of the normal range in both patients

•

The initial timed urine from both Australian patients contained high levels of total
y-glutamylcysteinylglycine and total cysteine and moderately high levels of total
y-glutamylcysteine and of y-glutamylglutamine

•

Freshly collected capillary plasma from one Australian patient contained a normal level
of y-glutamylglutamine at 3.5 flmoi/L(reference range <8 flmOI/L)

•

The

plasma

contained

a

previously

unrecognised

metabolite,

y-glutamylcysteine:cysteine at 7 J..l.moi/L (controls 3 and 4 J..l.moi!L), that may have been
formed during sample collection by thiol-thiol oxidation of GSH and cysteine followed
by carboxypeptidase activity
•

Plasma free GSH, y-glutamylcysteine and cysteine were below the detection limit of the
method at <5 J..l.moi!L, <10 flmoi/L and <2.5 J..l.moi!L respectively.

•

Freshly collected urine from one Australian patient contained at least 37 J..l.mol cysteine
per mmol creatinine and 71 J..l.mol GSH per mmol creatinine, as well as the disulphides,
and 51 J..l.mol y-glutamylglutamine per mmol creatinine . gamma-Giutamylcysteine was
probably present.

•

Incubation of this urine at 37°C showed a decrease in GSH and in cysteine and a slight
increase in the disulphides and mixed disulphides including cystine.

Studies in Patients with y-Giutamyltransferase Deficiency

63

The implications of the findings include:

•

GSH, y-glutamylcysteine, y-glutamylglutamine, y-glutamyl-a-aminobutyrylglycine and
cysteine are probable physiological substrates for human renal y-GT

•

Cystine may be a physiological substrate of human renal y-GT but cystine is not
elevated in urine from patients with y-GT deficiency

•

The other disulphides and mixed disulphides excreted by these patients may be
products of thiol-thiol oxidation in the urine and not physiological substrates for human
renal y-GT

•

The low-normal level of y-glutamylglutamine in plasma of one of the Australian patients
contrasts with the reports of elevated total glutathione in the American and the English
patients with y-GT deficiency. Plasma was not available from the second Australian
patient.
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STUDY IN PATIENTS WITH HEREDITARY DEFECTS OF THE UREA CYCLE

3.1

INTRODUCTION

During our laboratory investigations using cation-exchange chromatography we
measured amino acid levels in plasma of newborn infants with hyperammonaemia and
noted a stable unidentified compound that appeared as a large flattened or double
peak amongst the acidic amino acids.

The study of compounds excreted by the

patients with y-GT deficiency (Chapter 2) had shown that this region of the
chromatogram contained reduced glutathione, ophthalmic acid, y-glutamylglutamine
and y-glutamylglutamate and that peaks of these compounds sometimes appeared as
doublets. It seemed probable that the unidentified compound present in plasma might
also be a y-glutamyl compound.

This chapter describes the identification of that compound in plasma.

Follow-up

investigations were designed to analyse the levels present and to determine whether
the compound was excreted in urine collected at that time.

3.2

ISOLATION AND IDENTIFICATION OF y-GLUTAMYL GLUTAMINE FROM PLASMA

3.2.1.

Objectives of the Study

This section describes the steps leading to the identification of an unknown compound
isolated from small volumes of plasma collected from patients with hyperammonaemia
due to a defect of the urea cycle (Hammond

et a/1990).

A similar abnormal compound

was also noted in cerebrospinal fluid (CSF) from two of these patients and this was also
isolated and identified (Appendix C).

The study was conducted in three stages.

Firstly the compound was isolated using

preparative HVE. The compound in this desalted fraction was provisionally identified
by collating the results of acid hydrolysis, retention relative to reference standards on
cation-exchange chromatography and TLC and migration relative to reference
standards on HVE at pH 3.0. The compound was positively identified by fast atom
bombardment mass spectrometry carried out by Larry Hick, Department of Chemistry,
Wollongong University.
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Isolation and Identification of the Abnormal Compound

Samples and Reference Compounds

Samples for Study Plasma samples were obtained from a patient (LP) with carbamoyl
phosphate synthetase deficiency (McKusick 237300), a patient (AD) with ornithine
carbamoyl transferase deficiency (McKusick 311250) and a patient

ss with

a defect of

argininosuccinate synthetase activity (McKusick 215700).

Instructions for collection of plasma included use of lithium heparin (not EDTA),
centrifugation at +4°C and 3,000 X g for 10 min to remove red cells, leucocytes and
platelets and freezing at -80°C within 30 min.
laboratory on dry ice.

Samples were transported to the

Plasma was stored at -80°C in the laboratory either in a

low-temperature freezer or on the bench packed in dry ice and with minimal time at
room temperature. Urine was stored at -20°C.

Reference Compounds

Serva, Feinbiochemica, Heidelberg, FRG and Sachem

Bubendorf, Switzerland supplied the y-glutamylglutamine and L-y-glutamylglutamic
acid.

Cation-exchange Chromatography

Details of the removal of protein, sample preparation and the Beckman 6300 amino
acid analyser system are outlined in Sections 2.3.2 (urine) and Section 2.4.2
(plasma).

HVE of Plasma

The HVE systems run at pH 1.9 and 3.0 are described in Appendix A.

Plasma

ultrafiltrates of 40 f..LL were applied to HVE paper sheets and separated at pH 1.9, 4500
V, 100 rnA for 17 min. The sheets were stained with 0.1 g ninhydrin in 100 ml acetone
and heated at 105°C for 3 min.

Preparative HVE of Plasma

Two of the plasma samples were used for separate preparative procedures.
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In the first procedure 5.0 mL of plasma from the patient (LP) with carbamoyl phosphate
synthetase deficiency was used to prepare a fraction containing the unknown
compound according to the method outlined for CSF (Appendix C).

The yield, as

judged by cation-exchange chromatography, was 38%.

Plasma (3.1 mL) from the patient (AD) with ornithine carbamoyl transferase deficiency
was used in a revised procedure. This sample was taken through prewashed Millipore
Ultrafree®-MC 10,000 NMWL filters at 1900 X g for 120 min at 20°C. The ultrafiltrates
(2.3 mL) were pooled and the unknown compound was isolated by HVE at pH 1.9 from
this preparation. Approximately 500 J.!L of ultrafiltrate was applied as a fine band of
liquid across the origin of each of four HVE sheets of paper (Appendix A).

The procedures, as outlined in Appendix C for the location and elution of the unknown
from CSF, were repeated for plasma. The unknown was eluted from the macerated
areas of HVE paper by standing overnight in Milli-Q organics-free water.
supernatant was aspirated, filtered and lyophilised.

The

The residue was desalted on

Bio-Rad micro-columns of AG 1XB resin, chloride form, 100-200 mesh (Bio-Rad,
Richmond, CA, USA), eluted with 5 moi/L acetic acid and lyophilised. The final yield,
as shown by cation-exchange chromatography, was 31%.

Identification Procedures

The identity of the isolated compound was established using reference standards in
three separative systems: cation-exchange chromatography under standardised
conditions (Section 2.3.2), TLC cellulose acetate plates (Merck) with butanol/18 moi/L
acetic acid/water (2:1 :1, v/v) and HVE at pH 3.0 (Appendix A).

The isolated compound, reference standards and water blank were each hydrolysed for
16 hours using Pierce constant boiling point hydrochloric acid (Sequanal Grade) sealed
under nitrogen at 112°C. The products of hydrolysis were analysed on the Beckman
system.

The isolated compound (26 J..lg) was dissolved in methanol/water (1 :1, v/v), 1 J.!L was
mixed with 1 f.LL of thioglycol, applied and dried on the target of a VG 12-12 mass
spectrometer. A fast atom beam of xenon was generated at 8 kV and 2 rnA. Spectra
were collected from 10-500 amu at 2 s/scan.

-

+

1 2

•

- 4. -

5 6

FIGURE 3.1
High Voltage Electrophoresis Separation of Plasma Ultrafiltrates at pH 1.9

The conditions were 4500V, 100mA, 17 min; 40 ~-tl application, stained with ninhydrin and
heated at 105°C. 1, normal plasma; 2, patient LP; 3, patient AD; 4, patient SS; 5, normal
plasma plus 12.5 nmol y-glutamylglutamine; 6, normal plasma. Arrows indicate the position
of y~glutamylglutamine.
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Results

Identification Procedures Initially some plasma samples were run on HVE at pH 1.9 to

test the suspicion that the unknown might be a y-glutamyl amino acid or y-glutamyl
peptide (Figure 3.1). An unknown compound was present in an area of y-glutamyl
compounds that had been shown by experience to be clear of other ninhydrin-positive
compounds. Preparative HVE at pH 1.9, the technique that had been used during the
latter stages of the isolation of y-glutamyl compounds from fractions collected from
urine (Section 2.2.2), was therefore likely to be useful also in this case.

Provisional identification of the abnormal compound as y-glutamylglutamine was
obtained using the following results; the isolated compound appeared as a single peak
on

the

Beckman

6300

system

with

a

retention

time

agreeing

with

the

y-glutamylglutamine standard, the peak response ratios at 570 nm/440 nm were 12.0
and 11.9 for the isolated compound and for y-glutamylglutamine reference standard, on
TLC a single band co-chromatographed with the y-glutamylglutamine standard (Rf
0.28) and not with y-glutamylglutamate (Rf 0.34). gamma-Giutamylglutamine and the
unknown gave single bands that also migrated to the same position on HVE at pH 3.0.

The products of acid hydrolysis for the unknown and the y-glutamylglutamine standard
were two moles of glutamic acid to one of ammonia, while y-glutamylglutamate gave
two moles of glutamic acid only.

Figure 3.2 shows the FAB mass spectra obtained for the isolated compound and for

the y-glutamylglutamine standard taken through the final elution step. The fragments
at

mlz 217, 221, 237, 239, 261, 276 and 298 ions are common to both. The ion mlz

181 is derived from the thioglycol matrix.

gamma-Giutamylglutamine was also isolated from cerebrospinal fluid (Appendix C)
and identified positively by FAB mass spectrometry.

3.2.4

Discussion

gamma-Giutamylglutamine was first identified as an acidic dipeptide in bovine brain
(Kakimoto et a/ 1964) and later located in many areas of human brain (Kanazawa &
Sano 1967). It had not been recorded in plasma, or cerebrospinal fluid, until this study
(Hammond et a/1990). The high levels of y-glutamylglutamine present in plasma and
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FIGURE 3..2

FAB Mass Spectra of Compounds after the Dowex 1x8 Elution Step
A, the unknown compound isolated from plasma; B, the y-glutamylglutamine reference
standard,
Key:
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in cerebrospinal fluid during hyperammonaemia were sufficient to allow isolation from a
few millilitres of sample and positive identification.

No other y-glutamyl amino acid, and in particular no y-glutamylglutamic acid, was
isolated from the samples used in this study. The TLC separation on cellulose acetate
with butanol/acetic acid/water (Appendix A) was the most sensitive and convenient
method of monitoring for the presence of other y-glutamyl amino acids and for other
contaminating ninhydrin-positive compounds.

Later in the study access to the

reversed-phase HPLC system using pre-column derivatisation with o-phthalaldehyde
(OPA) (Goldsmith et a/ 1987) became available (Appendix C).

The resolution

obtained with this surpassed the other chromatographic methods for the identification
and quantification of acidic y-glutamyl amino acids (Hammond et a/1991, Orwar et a/
1991, Andine et a/1991). Unfortunately the pre-column derivatisation step required the
use of OPA/mercaptoethanol so that samples containing disulphides and mixed
sulphides, including cystine, could not be analysed without obscuring the level of thiol,
if present.
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An investigation of the relationship between plasma levels of y-glutamylglutamine,
glutamine, glutamate and ammonium ion, in patients with hyperammonaemia due to an
inherited defect of the urea cycle was planned.

Quantitative analysis of all four compounds was possible using cation-exchange
chromatography and plasma samples from the laboratory archives were available. Our
laboratory had stored all plasma samples received since 1985 at -80°C, a temperature
which preserved glutamine and ammonium indefinitely (unpublished data).

As a

consequence a total of 35 plasma samples from 15 hyperammonaemic patients with
inherited defects of the urea cycle were selected for further study.

3.3.2

Quantification of y-Giutamylglutamine and Amino Acids in Plasma

Patients Investigated

For the purpose of this study hyperammonaemia was defined as occurring when the
plasma glutamine was >11 00 iJmoi/L, where the upper limit of the reference range for
our laboratory was 1015 j.lmoi/L in newborns from 1 to 7 days of age and 907 j.lmoi/L in
infants and older children (unpublished data). Plasma free ammonium was not always
elevated.

Fifteen patients with proven or proposed defects of the urea cycle were

investigated.

The brief case report of the unresolved diagnosis {patient CG) was

outlined by Hammond eta/ (1990).

The other patients in the group all had biochemical or enzymatic findings that were
typical of the particular urea cycle disorder:

LP and NP with carbamoyl phosphate

synthetase deficiency (EC 6.3.4.16, CPS, McKusick 237300), BL 1, BL2, BL4, EC, AW,
AD, RA and JK with a defect of ornithine carbamoyltransferase deficiency (EC 2.1.3.3,
OCT, McKusick 311250), SS, KH and Jl with a defect of argininosuccinate synthetase
activity (EC 6.3.4.5, ASS, McKusick 215700) and JM with a defect of argininosuccinate
lyase activity (EC 4.3.2.1, ASL, McKusick 207900).
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FIGURES 3,3A and 3.38

Separation of Amino Acids and y-Giutamylglutamine by Cation-Exchange
Chromatography.
Analytical conditions were 50 ~L injected, ninhydrin detection, 0.200AUFS, 1.25 nmol AEC.
Fig, 3,3A,
Plasma from patient LP showing the unusual double shape of the
y-glutamylgluta.mine peak (Arrow) when SSA is used for protein precipitation. Fig. 3.38.
The same plasma run after ultrafiltration showing the symmetrical peak (Arrow). 1,
y-glutamylglutamine; 2, glutamic acid; 3, glutamine; 4, ammonium; 5, AEC internal
standard.
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Control Population

Plasma samples were referred to our laboratory for diagnosis of inherited disorders
from hospitals in New South Wales and instructions for collection, handling and
transport were as described (Section 3.2.2).

Our reference ranges for amino acid

analysis were obtained using plasma samples from patients who were hospitalised but
not acutely ill at the time. The groups included those of one to seven days of age and
those from forty days to adulthood.

Removal of Protein

Originally 20 J-LL of 2.0 moi/L Sequanal grade sulphosalicyclic acid (SSA) from Pierce,
Rockford, IL, USA was added to 200 J-LL of plasma, the mixture was left to stand at +4°
C for 10 min then 30 J-LL of 0.5 moi/L lithium hydroxide was added to partially neutralise
excess acid before centrifugation at +4°C and 11,000 X g for 5 min.

Subsequently ultrafiltration was used to remove protein when anomalous behaviour of
y-glutamylglutamine during cation-exchange chromatography dictated that acid be
excluded from the preparation. The samples were prepared as described in Section
2.4.2.

Cation-exchange Chromatography

Quantification of y-glutamylglutamine, amino acids and ammonium ion was carried out
on the Beckman 6300 system (Section 2.3.2). Cell-free samples stored at -80°C were
stable for at least seven years.

3.3.3

Results
Variable Peak Shape and Retention Time fory-Giutamylglutamine in Samples

Figure 3.3A and Figure 3.38 show chromatography separations of amino acids in the

plasma in which y-glutamylglutamine was first observed. The upper tracing (Fig. 3.3A)
demonstrates the unusual, double appearance of the peak. The retention time (RT) for
y-glutamylglutamine in SSA preparations of fourteen different plasma samples varied
between 7.85- 8.48 min, while aspartate ran at 11.46 - 11.86 min. Residual acid in the
preparation appeared to cause these wide variations.

When an ultrafiltrate of the

plasma was prepared, y-glutamylglutamine ran as a symmetrical peak (Fig. 3.38). The
RT of y-glutamylglutamine in ultrafiltrates of the fourteen different plasma samples was

TABLE 3.1
Concentrations (J.Lmoi/L) of r-Giutamylglutamine, Glutamine, Citrulline and Ammonium
in Individual Samples of Plasma from Patients with Hyperammonaemia due to a Urea
Cycle Defect
Patient

Diagnosis

CG

?NAGS

Age

v-G\uG\n

Glutamine

Citrulline

4d

43
40

3790
5140

NO
ND

750
1030

3d

Ammonium

LP

CPS

6d
6d

188
180

5660
5160

ND
<1

1020
1130

NP

CPS

6h
12h
25h
46h
7d
7m

16
39
21

8

1047
1509
1359
2164
1129
1207

<2
ND
3
3
ND
277

127
184
NA
250
NA
130

44
16

BL1

OCT

44h
64h

94
92

3730
4590

<1
<1

2070
1860

BL2

OCT

14h
33h

44
22

2080
1420

NO
ND

220
820

1h
7h
14h
18h
24h

17
20
14
37
24

1132
1124
1137
1568
1664

<1
ND
ND
ND

ND

120
150
240
180
258

1m
1m
1m
20m

16
14
18
21

1158
1146
1209
1552

9
15
15
18

200

BL4

EC

OCT

OCT

NA
NA
110

AW

OCT

4d

124

5677

<2

1100

AD

OCT

3d
3d

169
214

7000
7500

NO
NO

770
1340

JK

OCT

10y

21

1210

22

60

RA

OCT

5y
6y

17
13

1195
1214

24
18

90
NA

ss

ASS

4d
4d

111
128

7580
7480

2780
2990

400
470

KH

ASS

2d

117

6688

2261

1170

Jl

ASS

4d

55

2784

2241

650

JM

ASL

5d
13d

59
20

1590
1320

320
180

430
90

ABBREVIATIONS:
N D - not detected
NAGS - N-acetylglutamate synthetase deficiency
OCT - Ornithine carbamoyl transferase deficiency
ASL - Argininosuccinate lyase deficiency

NA - not analysed
CPS -Carbamoyl phosphate synthetase deficiency
ASS - Argininosuccinate synthetase deficiency
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7.34- 7.49 min (aspartate 10.10- 10.33 min). In contrast, urea ran at 4.69- 4.74 min
for both types of preparations.

y-Giutamylqlutamine and Amino Acids in Clinical Samples

Reference ranges for a control population of in-patients from one to seven days of age
were y-glutamylglutamine 9 - 21 f.Lmoi/L (N = 24), glutamine 329 - 1015 f.Lmoi/L (N = 57)
and citrulline 12- 20 f.Lmoi/L (N = 14), while for patients older than 40 days to adulthood
the ranges were y-glutamylglutamine <8 f.Lmoi/L, glutamine 405 - 907 f.Lmoi/L and
citrulline 10- 4 7 f.Lmoi/L (N

=50) (unpublished data).

Table 3.1 lists the results obtained in 35 samples from 15 patients with urea cycle

disorders, grouped according to the disorder.

A graph of the relationship between

plasma y-glutamylglutamine and plasma glutamine is shown in Figure 3.4. There was
no apparent difference between the results obtained from patients with enzyme defects
expressed only in liver compared with those with generalised enzyme defects. The
Spearman rank correlation coefficient (Siegal 1956) for the 35 results showed that
there was a strong positive relationship between y-glutamylglutamine and glutamine

(P<O.OOOS), compared with y-glutamylglutamine and ammonium (P<0.05) and
y-glutamylglutamine and glutamate (P>0.1).

3.3.4

Discussion

In this study elevated levels of y-glutamylglutamine ranging from 8 to 214 J.!moi!L were
obtained in thirty five plasma samples from a patient population with urea cycle
disorders and primary hyperammonaemia, that had been defined as a plasma
glutamine level greater that 1100 f.Lmoi/L.

The strong correlation between plasma

y-glutamylglutamine and plasma glutamine suggested that the synthesis of both
compounds may be linked.

Glutamine synthetase (EC 6.3.1.2) is located in the cytosol. This study included twelve
patients with an enzyme defect that was expressed in mitochondria, including
N-acetylglutamate

synthetase,

carbamoyl

phosphate

synthetase

and

ornithine

carbamoyl transferase, as well as four patients with inherited disorders of enzymes
expressed in the cytosol. There was no significant difference between the levels of
y-glutamylglutamine obtained amongst these two groups of patients.

Presumably

accumulated ammonium diffuses immediately from the mitochondria in the periportal

FIGURE 3.4
Relationship between y-Giutamylglutamine and Glutamine in Individual Samples of
Plasma from Patients from Patients with Hyperammonaemia Due to a Urea Cycle Defect
(N 35)
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hepatocytes to the cytosol of the perivenous hepatocytes, the major site of glutamine
synthesis in the liver (Souba 1992).

gamma-Giutamylglutamine, present in plasma, may be synthesised by either of two
enzyme systems (a) via the intracellular y-glutamylcysteine synthetase or (b) via
extracellular y-GT activity.

At first glance the most likely source of plasma

y-glutamylglutamine might be via the reaction of glutamate with glutamine catalysed by
y-glutamylcysteine synthetase in the cytosol. This enzyme is responsible for the first
step in the synthesis of GSH, requires ATP and is presumably highly active in liver.
Glutamine levels in perivenous hepatocytes of the patients with urea cycle defects in
this study were also presumably high.

However, although y-glutamylcysteine

synthetase is known to be relatively non-specific, reports that y-glutamylglutamine is
formed from glutamate and glutamine are not available. Orlowski and Meister (1971 a)
did not find glutamine to be a substrate for the highly purified y-glutamylcysteine
synthetase from rat kidney, nor did Rathbun (1967) with that from bovine lens.
Unfortunately no data was found for human tissues.

One possible source of

y-glutamylglutamine may be via the common intermediate, y-glutamyl phosphate,
shared by glutamine synthetase and y-glutamylcysteine synthetase (Orlowski & Meister
1971 b). Perhaps these two enzymes, although distinct in their activities, cooperate to
synthesise y-glutamylglutamine or even that y-glutamylglutamine is formed by
glutamine synthetase, when intracellular levels of glutamine become saturating.

Extracellular synthesis of y-glutamylglutamine by the transferase reaction of y-GT is
also possible. Apart from the activity with cystine/cysteine acceptors, glutamine is the
next most preferred amino acid substrate for the enzyme in human liver and kidney
(Shaw et a/ 1978), human intestine (Smith & Heizer 1978) and human leucocytes
(Patrick et a/ 1979).

On the other hand y-glutamylglutamine is the most favoured

y-glutamyl donor for y-GT, after GSH and ophthalmic acid (Tate & Meister 1974). The

Km for hydrolysis of y-glutamylglutamine in one study on the enzyme from rat kidney
was 18 J.Lmoi/L (Mcintyre & Curthoys 1979), whereas that for glutamine was 2.6 mmoi/L
(Tate & Meister 1974).

Presumably any y-glutamylglutamine so formed must be

transported immediately into the cell, or else be hydrolysed by renal y-GT.

Extracellular synthesis of y-glutamylglutamine in plasma by the transferase reaction of
y-GT acting on plasma glutamine may contribute in part to the level present in plasma
(Tate & Ross 1977, Dass 1983, Dass & Wu 1985). The proposed reaction is shown
below.
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y-glutamyltransferase

---+

y-Giutamyl-enzyme + NH+ 4
+Glutamine

y-Giutamylglutamine

But this reaction cannot account for all of the y-glutamylglutamine in plasma.

This

study has shown that patients with a generalised defect of the y-GT, that is a deficiency
in

serum,

urine

and

cultured

fibroblasts,

still

have

low-normal

levels

of

y-glutamylglutamine in their plasma and excrete large amounts in their urine (Chapter
2).

The identification of y-glutamylglutamine as a major component of human CSF
(Appendix C) during hyperammonaemia is significant, especially since the levels may
exceed

those

in

plasma

(patient

BL1

Table

C.1).

This

y-glutamylglutamine is synthetised independently in the brain.

suggests

Indeed, one of the

patients with hyperammonaemia due to secondary causes (Hammond
patient FR, was found to have a normal level (<8

~-tmoi/L)

plasma even though his plasma glutamine was 10,000

et

at 1990),

of y-glutamylglutamine in

~-tmoi/L,

level of y-glutamylglutamine was significantly elevated at 97

that

whereas in CSF his

~-tmoi/L.

Hydrolysis of his

plasma y-glutamylglutamine by y-GT in plasma, in the fashion proposed by da
Fonseca-Wollheim (1990) for the deamidation of glutamine by y-GT during collection
and handling, could explain these findings but his plasma y-GT activity was normal and
not elevated.

Recently Jaeken (1994) reported the detection of y-glutamylglutamine in CSF from
patients with transient neonatal hyperammonaemia syndrome, but gave no quantitative
data.

Evidence for whether y-glutamylglutamine contributes to or alleviates the

symptomatology and brain damage of hyperammonaemia also remains to be
determined. Since y-glutamylglutamine is a stable compound, unlike glutamine, it may
be useful to gauge hyperammonaemia in post-mortem plasma and CSF samples.

In the current study, all the patients with urea cycle defects had documented or
supposed "normal" liver function and there was a strong correlation between plasma
levels

of

y-glutamylglutamine

and

glutamine.

Normal

levels

of

plasma

y-glutamylglutamine in hyperammonaemia may indicate lowered ATP levels, reduced
function of liver y-glutamylcysteine synthetase/glutamine synthetase and possibly be a
sensitive indicator of abnormal liver function.
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3.4

ANALYSIS OF y-GLUTAMYLGLUTAMINE AND 5-0XOPROLINE IN URINE

3.4.1

Objectives of the Study

gamma-Giutamylglutamine

had

been

isolated

from

plasma

in

patients

with

hyperammonaemia due to urea cycle defects and the levels reached as high as 214
J.Lmoi/L. In order to investigate the physiological functions of y-glutamyltransferase in
the kidney it was important to establish whether the levels of y-glutamylglutamine were
also elevated in the urine at that time.

In this study the urine from a subset of eight out of the fifteen patients with urea cycle
defects studied in Section 3.3.2, in whom levels of plasma y-glutamylglutamine had
been analysed, were investigated. Urine of these patients was investigated using HVE
at pH 1.9 and 3.0 and cation-exchange chromatography conducted at 34 and 40°C.
5-0xoproline was also analysed in these samples by gas chromatography and gas
chromatography/ mass spectrometry.

5-0xoproline is the product of intracellular y-glutamyl amino acid cyclotransferase
activity (EC 2.3.2.4). It is known to accumulate and be excreted in glutathione
glutathione synthetase

y-Glutamylcysteine + glycine

-X~

y-Giutamylcysteinylglycine

y-glutamyl amino acid cyclotransferase

y-Giutamylcysteine

5-0xoproline + Cysteine

4

synthetase deficiency (McKusick 266130) when the feedback inhibition by glutathione
on the enzyme y-glutamylcysteine synthetase (EC 6.3.2.2) cannot occur and
y-glutamylcysteine overproduction results. The gross levels of y-glutamylglutamine in
plasma present in hyperammonaemia may also result in 5-oxoprolinuria from a renal
overload effect.
y.glutamyl amino acid cyclotransferase

y-Giutamylglutamine

---+

5-0xoproline + Glutamine

To test this, the same urine specimens were analysed for organic acids and
5-oxoproline in particular.
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Qualitative Analysis of y-Giutamylglutamine and 5-0xoproline in Urine

Samples for Study

Urine samples were obtained from eight of the hyperammonaemic patients studied in
Section 3.3.2; that is CG with probable NAGS deficiency, LP with CPS deficiency,
BL 1, BL2, AD and JK with OCT deficiency, SS with ASS deficiency and JM with ASL
deficiency. These urine samples were selected so that they corresponded as closely as
possible to the peak level of plasma y-glutamylglutamine. All were stored at -20°C until
analysis.

Qualitative Separation by HVE

Details of sample preparation of urine for HVE analysis and the separation and staining
techniques are described in Appendix A. Samples were run at pH 1.9 and 3.0. The
detection limit for y-glutamylglutamine at pH 1.9 was 15 f.!mollmmol creatinine, but the
limit was lower, around 5 f.!mollmmol creatinine, for the pH 3.0 separation when
y-glutamylglutamine ran clear of other metabolites.

Quantitative Analysis of Urine by Cation-exchange Chromatography

Details of sample preparation of urine for cation-exchange chromatography and the
Beckman amino acid analyser system are described in Section 2.3.2. The detection
limit for y-glutamylglutamine using the standard Beckman program for physiological
separations, that is using Buffer A and a column temperature of 34.0°C, was 5
f.!mol/mmol creatinine.

In order to sharpen the peaks in the acidic region and improve the resolution even
further, a short program that ran for 12 min of buffer A and with an increased column
temperature of 40°C was employed. The increase in temperature from 34°C to 40°C
changed the RT of urea and Asp in the reference urine from 4.73 to 4.55 and from
10.47 to 10.39 respectively, whilst y-glutamylglutamine standard moved from 8.06 to
7.06 min. These measures dropped the detection limit to 2 1-1mol/mmol creatinine.

Qualitative Analysis of Organic Acids in Urine

An initial screen of samples was obtained by separation of 1 f.!L of the derivative on a
CP-Sil 19CB capillary column 25 m X 0.25 mm ID (Chrompak) using a Packard 436
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Under these

conditions 5-oxoproline ran free of other urinary metabolites with a methylene unit
range of 17.07-17.11. The limit of detection was 230 J.Lmol/mmol creatinine. A normal
urine with weighed-in 5-oxoproline to 1 mmol/mmol creatinine was extracted as a
quality control check for each batch of urine extractions.

Details of sample preparation of urine for organic acid analysis by gas liquid
chromatography and gas liquid chromatography/ mass spectrometry and the particular
detection of 5-oxoproline are described in Section 2.3.2. The limit of detection of the
by gas liquid chromatography was 230 1-lmollmmol creatinine while that for gas liquid
chromatography/mass spectrometry system was 180 1-lmol/mmol creatinine.

3.4.3

Results

The evidence for the presence or absence of y-glutamylglutamine in urine of patients
required information from one or other of the three separative systems used,
depending upon metabolite or drug interference.

High Voltage Electrophoresis at pH 1.9 Although y-glutamylglutamine ran as a tight
band on HVE at pH 1.9, separations of urine in critically ill infants often contain drug
metabolites that obscure the area between hydroxyproline and paracetamol thus
interfering with the resolution of y-glutamylglutamine.

High Voltage Electrophoresis at pH 3.0

The HVE system at pH 3.0 distinguished

between y-glutamylglutamine and drug artefacts more clearly than at pH 1.9. Results
were recorded as "not increased" if a faint band was visible but the amount was
insufficient to quantify by cation-exchange chromatography.

Cation-exchange Chromatography

On the other hand y-glutamyl compounds are

sensitive to very slight variation in pH. We had already found that when plasma was
deproteinised with sulphosalicyclic acid (Hammond et a! 1990) y-glutamylglutamine
sometimes ran as a double peak on cation-exchange chromatography. So it was not
surprising to find in this experiment that even when the urine concentration was high
and when sample preparation involved ultrafiltration, y-glutamylglutamine was still
sometimes difficult to positively identify amongst other acidic urinary metabolites. The
short program at the higher column temperature of 40°C sharpened the acidic peaks
and allowed positive identification of lesser amounts.

TABLE 3.2
Results of Experiments Using HVE and Cation-Exchange Chromatography to Locate
y-Giutamylglutamine in Urine from a Subset of Patients with Elevated Levels of Plasma
y-Giutamylglutamine
Patient

Diagnosis

Age

Plasma•
y-GiuGin
J.lmolll

Urinary
y-GiuGin
HVE pH 3.0

Urinary
y-GiuGin
Cation-exchange
Chromatoaraphy

Urinaryb
Glutamine
J.lmOI/mmol
creatinine

CG

?NAGS

3d

43

Nl

Nl

ND

249

LP

CPS

6d

188

INT

INT

ND

3694

BL1

OCT

44h

94

ND

Nl

ND

5363

BL2

OCT

14h
33h

44
22

NA
Nl

NA
Nl

ND
NA

NA
NA

AD

OCT

3d

169

INT

Nl

ND

2968

JK

OCT

10y

21

ND

ND

NA

NA

ss

ASS

4d

111

ND

NA

ND

2641

JM

ASL

5d

59

ND

Nl

NA

NA

ABBREVIATIONS
I NT - interference
ND -not detected
NAGS- N-acelylglutamate synthetase deficiency
OCT- Ornithine carbamoyl transferase deficiency
ASL- Argininosuccinate lyase deficiency

NA - not analysed
Nl - not increased
CPS - Carbamoyl phosphate synthetase deficiency
ASS - Argininosuccinate synthetase deficiency

J.liTIOl/L (Hammond et a/1990)
Reference range - 52 - 205 J.lll1oVmmol creatinine (Parvy et a/1988)

a Reference range- <8
b

Urinary
y-GiuGin
HVE pH 1.9

Study in Patients with Hereditary Defects of the Urea Cycle

78

Table 3.2 shows a summary of the results obtained on all three separative systems.

gamma-Giutamylglutamine was not detected in any urine sample from this sub-set of
patients with primary hyperammonaemia regardless of the level in plasma.

Organic Acid Profile

Unfortunately the detection limit of 5-oxoproline by gas

chromatography and gas chromatography/mass spectrometry was up to 100-fold less
sensitive than the detection
chromatography.

of y-glutamyl

amino

acids

by

cation-exchange

The detection limit for our methods were between 230 and 180

J-l.mol/mmol creatinine respectively. However the mlz 156 ion that is characteristic of
5-oxoproline was observed at the appropriate retention time often in otherwise normal
urine samples run on routine screening of urinary organic acids in our laboratory. But
even the mlz 156 ion was not necessarily observed in the hyperammonaemic patients.

3.4.4

Discussion

The absence of y-glutamylglutamine from urine when the plasma y-glutamylglutamine
levels are moderately to grossly elevated is the strongest evidence so far that a highly
effective system of renal reabsorption of y-glutamyl compounds occurs via the
y-glutamyltransferase/y-glutamyl amino acid cyclotransferase system in humans.

In

fact the renal threshold for y-glutamylglutamine has not yet been established.

The interorgan transfer of y-glutamylglutamine from liver to kidney presumably occurs
in a similar fashion to that of GSH (Meister 1978). This y-glutamylglutamine may be a
source of glutamate for the synthesis of glutathione, as well as an effective normal
mechanism for the excretion of ammonium, for example, when post-prandial levels in
plasma rise above 8 J-t.moi/L. gamma-GT hydrolytic activity in the proximal tubule may
be important for this transfer. Mcintyre and Curthoys (1979) noted that the Km for the
hydrolysis of y-glutamylglutamine in rat kidney was 18 J-l.moi/L and higher than that of
GSH 5.7 J.Lmoi!L. The hydrolase reaction of y-GT would result in the
y·glutamyltransferase

y-Giutamylglutamine + H20

~

Glutamate+ Glutamine

translocation of glutamate and glutamine, that may participate in normal renal
ammonium synthesis and adaptive increase in ammonium synthesis during the onset
of acidosis.

gamma-Giutamylglutamine is also one of the best substrates for

y-glutamyl amino acid cyclotransferase (Orlowski et at 1969, Meister 1978).

This

interorgan transfer appears self-defeating in severe hyperammonaemia unless the
y-glutamylglutamine can be excreted.
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Ribes eta/ (1987) reported urinary 5-oxoproline levels of 140 and 152 J..lmollmmol
creatinine (reference range ::;; 44) in two patients, one with ASS and the other a
heterozygote for OCT, when their blood ammonium levels were 1220 and 1700 J..lmoi/L
respectively. Unfortunately the two stage organic acid screen used in this case was not
sufficiently sensitive to recognise levels below 230 J..LmOI/mmol creatinine and their
findings could not be confirmed. However results from this study show that the degree
of 5-oxoprolinuria found in hyperammonaemia and in patients with glutathione
synthetase deficiency, a disorder in which intracellular y-glutamylcysteine accumulates,
are clearly different.

Gross 5-oxoprolinuria, easily detected by routine organic acid

methods using GC/MS, is the biochemical marker of the latter disorder (Larsson 1988,
Meister & Larsson 1995).
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SUMMARY AND IMPLICATIONS OF FINDINGS

gamma-Giutamylglutamine was found to be:
•

present (<8 JJ.moi/L) in plasma from normal patients,

•

elevated in plasma from patients with primary hyperammonaemia due to an
inherited disorder of either cytosolic or mitochondrial enzymes of the urea cycle,

•

elevated in cerebrospinal fluid, and possibly even higher than plasma levels, from
patients with primary hyperammonaemia,

•

not excreted by any patient in the study even when markedly elevated in the
plasma and

•

not reflected in the excretion as 5-oxoproline (<230 f.Lmollmmol creatinine) in any
patient in the study.

The implications are that:
•

y-glutamylglutamine is removed from the human glomerular filtrate under the
normal and loaded conditions studied,

•

this reabsorption is likely to be the result of y-GT activity (combined with that of
y-glutamyl amino acid cyclotransferase),

•

y-glutamylglutamine in the human brain is likely to be synthesised independently of
that in liver and

•

in contrast to the case of intracellular y-glutamylcysteine overproduction,
reabsorption of y-glutamylglutamine by the kidney does not result in significant
5-oxoprolinuria.
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STUDY IN PATIENTS WITH PHENYLALANINE HYDROXYLASE DEFICIENCY

4.1

INTRODUCTION

In the previous chapter the results from studies on samples from hyperammonaemic
patients with urea cycle disorders were presented.

gamma-Giutamylglutamine was

identified in their plasma and was grossly elevated when their levels of plasma
glutamine were between

1210 and 7580 J.!moi/L.

The correlation

y-glutamylglutamine and glutamine in plasma was strong (P<O.OOOS).

between

None of the

patients excreted detectable y-glutamylglutamine, regardless of the level in plasma. It
is proposed that y-glutamyltransferase activity was responsible for the disappearance of
y-glutamylglutamine from the glomerular filtrate in these patients.

In contrast to the above findings for y-glutamylglutamine, reports by Peck & Pollitt
(1979) and Kamberling et

at (1980) indicated that y-glutamylphenylalanine was

excreted by patients with phenylalanine hydroxylase deficiency (McKusick 261600,
PKU) in whom the blood or serum phenylalanine levels were elevated. They found no
correlation between the level of y-glutamylphenylalanine in urine with blood or serum
phenylalanine levels. Neither group reported quantification of y-glutamylphenylalanine
in plasma, so it was not clear whether the presence of this y-glutamyl compound in
urine resulted

from

a renal threshold that

had

been

exceeded,

failure

of

y-glutamyltransferase hydrolysis or efflux from the kidney epithelium. In any case the
results of Peck & Pollitt (1979) and Kamberling et

at (1980) indicated that

y-glutamylphenylalanine may be handled differently from y-glutamylglutamine.

It was decided to check these findings by investigating fourteen untreated patients with
phenylalanine hydroxylase deficiency.

Their levels of plasma phenylalanine were

between 520 and 2040 J.!moi/L (reference range 32 - 79). Samples of random urine
and fasting plasma were collected from ten of the fourteen patients at the same
out-patient visit. The qualitative scores for urinary y-glutamylphenylalanine and urinary
phenylalanine obtained by HVE were recorded.

The fasting plasma phenylalanine

levels were analysed by another laboratory.

An attempt was also made to quantify the y-glutamylphenylalanine in non-fasting
plasma samples from four other patients with phenylalanine hydroxylase deficiency
using cation-exchange chromatography of physiological amino acids.
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Urine samples were obtained from ten untreated PKU patients.

These included

newborn infants in whom the disorder had been recently diagnosed and older patients
in whom compliance with dietary treatment was poor. These samples were stored at
-20°C prior to analysis.

Fasting plasma for routine phenylalanine monitoring was

collected from these patients during the same morning out-patient visit.

Non-fasting plasma from four other PKU patients was referred to our laboratory for
monitoring of their plasma amino acids and these were collected according to our
general instructions (Section 3.2.2).

4.2.2

HVE Analysis of Urine

Urine soaked blotters were prepared (Appendix A) and the urinary creatinine
estimated by the rate-reaction with alkaline picrate on a Beckman creatinine analyser
II. Urine samples were eluted onto the HVE sheets so that each track contained 80
nmol equivalents of creatinine.

An in-house reference urine (RU) containing

weighed-in phenylalanine to give 100 )..l.mol!mmol creatinine was run in tracks 1 and 2
of each HVE sheet.

The ninhydrin staining reaction of phenylalanine was scored

against this control.

gamma-Giutamylphenylalanine, obtained from Bachem, Bubendorf, Switzerland, was
prepared as an aqueous solution and applied as a fine streak of liquid superimposed on
the RU sample in track 2 to be equivalent to 312.5 J..l.mol y-glutamylphenylalanine/mmol
creatinine.

This

was

used

as

a

marker

to

confirm

the

location

of

y-glutamylphenylalanine on each sheet and provide a level for qualitative scoring.

HVE running conditions at pH 1.9 were those in Appendix A. The stained sheets were
viewed by transillumination
phenylalanine

scored

as

and the
trace,

+

results for y-glutamylphenylalanine
and

++

The

detection

y-glutamylphenylalanine in urine by HVE was 7 J-lmol/mmol creatinine.

limit

and
for

Trace of

y-glutamylphenylalanine corresponded approximately to 15 and + to 30 J.Lmol/mmol
creatinine. Phenylalanine scoring corresponded approximately + to <1 00, ++ to 100 200 and +++to >300 J.lmol/mmol creatinine.

TABLE 4.1

Detection of y-Giutamylphenylalanine in Urine from Patients with
Phenylalanine Hydroxylase Deficiency When Their Plasma
Phenylalanine Levels were Elevated

Patient

Age

Urinary
Phenylalanine
HVE pH 1.9

Urinary
y-GiuPhe
HVE pH 1.9

Plasma
Phenylalanine
l'molll

DR

7d

++

TR

1450

BM

14d

+++

TR

1340

KC

19d

++

TR

2040

NS

14y

+

Nl

520

NW

16y

+

Nl

550

JH

23y

+

Nl

550

MC

25y

+

TR

1840

NC

26y

+

Nl

1110

LB

34y

++

TR

1250

LM

47y

++

TR

1800

ABBREVIATIONS: TR- trace
NOTE: y-Giutamylphenylanine TR

Nl- not increased

=7 - 15 f!mol/mmol creatinine
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Analysis of Plasma

Routine monitoring of fasting plasma phenylalanine was carried out by another
laboratory using a reversed-phase HPLC system and the o-phthalaldehyde colour
reaction (Goldsmith et a/ 1987).

Non-fasting plasma samples for full physiological

amino acid analysis were prepared and run as described in Section 2.4.2.

A working standard containing 25.54 f.tmoi/L y-glutamylphenylalanine and 25.00 llmoi/L
AEC, was prepared by first diluting a 2.548 mmoi/L stock solution 1 in 10 with Beckman
Li-S sample diluting buffer and then taking equal volumes of this and 50.00 f.tmoi/L
AEC.

The y-glutamylphenylalanine was loaded onto the Beckman 6300 system

programmed to run the routine separation of physiological amino acids. It ran at the
front between A and D (Section 2.3.2). When the time for buffer A was extended
(Section 2.3.2), the peak of y-glutamylphenylalanine was resolved to baseline and
eluted at 34.6 min with citrulline running to 33.3 min and <X-aminobutyrate to 35.7 min.
The response ratio at 570 nm was 2.51 with respect to AEC, the internal standard, and
the detection limit was approximately 5 f.lmoi/L.

4.3

RESULTS

The qualitative scores obtained for urinary y-glutamylphenylalanine and phenylalanine
and the fasting plasma phenylalanine levels for each of the ten patients are shown in
Table 4.1. The y-glutamylphenylalanine was detected (> 7 f.tmol/mmol creatinine) in
urine samples when the fasting plasma phenylalanine was 1250 1-1moi/L or greater. The
results are listed according to the age of the patient at the time. No trend with age of
the patient was apparent and y-glutamylphenylalanine was approximately

10

f.tmol/mmol creatinine in one sample from a patient aged 47 years.

Urinary y-glutamylphenylalanine was not detectable until the plasma phenylalanine was
greater than 1250 ,..moi/L, whereas urinary phenylalanine was present in all samples
tested, that is when the plasma phenylalanine was greater than 520 f.lmoi/L. The level
of phenylalanine in fasting plasma samples did not appear to be closely related to
either the urinary y-glutamylphenylalanine or phenylalanine excretion in samples
collected at the same time.

Four plasma samples from non-fasting PKU patients aged 9 days, 10 days, 19 days
and 29 years were analysed by cation-exchange chromatography on the Beckman

TABLE 4.2
Urinary Phenylalanine and y-Giutamylphenylalanine in Patients
with Phenylalanine Hydroxylase Deficiency and Elevated Levels
of Fasting Serum Phenylalanine
Recalculated from Kamerling et a/ ( 1980)
Patient

Age

Urinary
Phenylalanine

Urinary
y-GiuPhe

Fasting Serum
Phenylalanine

~ol/mmol

J.1mol/mmo1

llmoi/L

creatinine

creatinine

AS

2y

451

10.8

1740

FK

5+y

311
372
593
356
317

3.8
6.0
8.6
5.8
8.2

1760
1940
1880
1960
1690

MP

7+y

39

1068
959

1.6
10.7
15.3
8.5

250
1790
2600
2700

7n

JvD

7+y

62
109
161
258
260
274

1.7
3.9
6.0
8.0
8.1
9.5

590
1050
1440
1970
2210
1890

CvdB

18y

198

2.7

2780

TABLE 4.3
Urinary Phenylalanine and y-Giutamylphenylalanine in Patients
with Phenylalanine Hydroxylase Deficiency and Elevated Levels of
Blood Phenylalanine
Recalculated from Peck and Pollitt (1979)
Patient

Age

Urinary
Phenylalanine

Urinary
y-GiuPhe

Blood
Phenylalanine

J..tmoVmmol

~mollmmol

~oi/L

creatinine

creatinine

1

4d

136

44.1

1000

2

5d
6d

351
79

10.2
7.9

4700

7d

385
181

11.3
33.9

3800

9d
Bd
Bd

283
1663

10.2
78.0

3100

5

Bd
9d

351
271

20.4
23.8

2000

6

9d

464

33.9

3200

7

9d

215

7.9

2400

a

11d

215

22.6

2700

3

4

-

-

-
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6300 system. The plasma phenylalanine levels in these samples were 1427, 839, 2040
and

1182

I.J..molll

respectively

(reference

range

32

79

I.J..moi/L)

but

y-glutamylphenylalanine was not detected (< 5 1-lmoi/L).

4.4

DISCUSSION

The excretion of y-glutamylphenylalanine has been reported in patients with
phenylalanine hydroxylase deficiency (Peck & Pollitt 1979, Kamerling et al 1980) but
not in patients with generalised aminoaciduria (Kamerling et a/1980).

These findings have been confirmed in the current study.

Personal experience

covering more than 65,000 urine samples from patients with possible amino acid
disorders

and

using

the

HVE

separation

at

pH

1.9,

showed

that

y-glutamylphenylalanine has not been detected (<7 I.J..mollmmol creatinine) in normal
urine or in non-specific aminoacidurias in which urinary phenylalanine was grossly
elevated due to non-specific liver disease or to overload via intravenous alimentation.

Screening of random urine samples from a group of PKU patients aged between 7
days and 47 years (N

= 1D)

showed that y-glutamylphenylalanine was detected (> 7

I.J..mol/mmol creatinine) whenever the corresponding fasting plasma phenylalanine was
greater than 1250 1-lmoi/L regardless of the age of the patient.

These results were similar to those of Kamerling eta/ (1980) who found that 24 hour
urine collections on PKU patients from 2 to 18 years contained from 1.6 to 15.3 I.J..mol
y-glutamylphenylalanine/mmol creatinine (Table 4.2).

They noted however that in

three patients aged between 2 weeks and three years and with serum phenylalanine
levels of 1470, 1380 and 1820 I.J..moi/L, the y-glutamylphenylalanine excretion was very
low. No overall correlation between the level of y-glutamylphenylalanine in urine with
blood or serum phenylalanine levels was obtained.

Peck and Pollitt (1979) (Table 4.3) reported that in their study the levels of urinary
y-glutamylphenylalanine appeared much higher in their newborn population (range of
7.9 - 78 J.lmollmmol creatinine) than in unpublished data from their older patients. In
considering this they suggested that it may be related to the normal ontogeny of the
transport processes related to the y-glutamyl cycle or a slow adaptation of these
systems to unusually high phenylalanine levels later in life.
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Comparison between the blood or serum levels of phenylalanine in these two previous
reports, suggests that factors other than patient age may also influence the excretion of
y-glutamylphenylalanine. The relatively high blood phenylalanine in the newborn group
ranged from 1000 to 4700 J..Lmoi/L (Peck & Pollitt 1979), whereas the 2 to 18 year olds
had generally lower levels of fasting serum phenylalanine from 250 to 2780 1-lmoi/L
(Kamerling et a/ 1980). A more comprehensive investigation would be required to
clarify whether age is a factor in the excretion of y-glutamylphenylalanine.

In the current study no peak of y-glutamylphenylalanine could be detected in plasma by
cation-exchange chromatography, even when the plasma phenylalanine was 2040
1-lmoi/L,

that

is

26

times

the

upper

limit

of

the

reference

range,

but

y-glutamylphenylalanine was detected in urine collected at the same time. Neither of
the two previous reports published levels for y-glutamylphenylalanine in plasma,
presumably because these were also below the detection limit of their method or were
indistinguishable from citrulline or a-amino-n-butyric acid which run in the same
general area and are much higher in plasma than in urine.

The metabolic source of the urinary y-glutamylphenylalanine present in PKU patients
has still not been resolved.

It may have been synthesised via: (a) intracellular

y-glutamylcysteine synthetase activity in the liver, (b) y-GT transpeptidation of
phenylalanine in the glomerular filtrate,

or (c)

intracellular y-glutamylcysteine

synthetase activity in the renal epithelium.

Phenylalanine hydroxylase activity is only expressed in the liver in humans and the
liver is the major site of an intracellular accumulation of phenylalanine when this
enzyme is deficient. It is therefore possible that synthesis of y-glutamylphenylalanine
in PKU patients occurs via the intracellular y-glutamylcysteine synthetase activity in the
liver. However evidence to support this is not available. On the contrary (a) no report
of y-glutamylcysteine synthetase activity with phenylalanine as a substrate in human
tissues could be located, (b) y-glutamylcysteine synthetase isolated from bovine lens
gave zero activity with

phenylalanine as substrate (Rathbun 1967) and

(c)

y-glutamylphenylalanine has not so far been detected in plasma. This would indicate
that interorgan transfer from the liver to the kidney took place. Not withstanding this, if
y-glutamylphenylalanine were present in the glomerular filtrate then it would be
available for hydrolysis or transpeptidation by y-GT. Tate and Meister (1974) found
that y-glutamylphenylalanine was an in vitro substrate for the rat kidney enzyme but
there is no data for humans. Excretion of y-glutamylphenylalanine in the case of PKU
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patients might suggest that the level of y-glutamylphenylalanine may exceed the
capacity of y-GT.

Another explanation for the presence of y-glutamylphenylalanine in urine from PKU
patients would be transpeptidation of phenylalanine in the glomerular filtrate. Although
theoretically possible, there are other circumstances where plasma phenylalanine is
grossly elevated in patients but y-glutamylphenylalanine is not excreted.

The third potential source of urinary y-glutamylphenylalanine might be de novo
synthesis from phenylalanine in the renal epithelium itself via y-glutamylcysteine
synthetase activity.

In this case the product, y-glutamylphenylalanine, may not be

converted to 5-oxoproline and phenylalanine, because y-glutamylphenylalanine is a
poor in vitro substrate for rat kidney y-glutamyl amino acid cyclotransferase (Taniguchi
& Meister 1978) and this may also be so in humans. gamma-Giutamylphenylalanine

may then be excreted intact.

gamma-Giutamylornithine is another y-glutamyl amino acid that has been isolated and
identified in urine (Lou 1975). Some of the findings with y-glutamylornithine parallel
those of y-glutamylphenylalanine, giving another clue to the possible source of both. In
this case y-glutamylornithine it was quantified in normal urine (Lou 1975, Roesel

et a/

1984) and elevated in urine from patients with HHH syndrome (hyperornithinaemia,
hyperammonaemia and homocitrullinuria; McKusick 238970) and with gyrate atrophy
associated with hyperornithinaemia (McKusick 258870)(Roesel

et a/1984). Neither of

these inherited defects is specific to the liver. The levels obtained in these disorders
were between 1.47 and 7.57

~mol!mmol

creatinine and did not correlate with ornithine

excretion. A 100 mg/Kg load of ornithine was given to one affected patient and the
excretion of y-glutamylornithine increased by a factor of three.
y-glutamylornithine in blood was not attempted.
y-glutamylphenylalanine,

is

an

unlikely

Analysis of

gamma-Giutamylornithine, as with

substrate

for y-glutamyl

amino

acid

cycl otransfe rase.

The renal handling of y-glutamylphenylalanine and y-glutamylornithine differs markedly
from that for y-glutamylglutamine described in Chapter 3.
y-glutamylglutamine ranging from 20 to 214

~moi!L

High levels of plasma

were found in newborn patients or

patients aged 7 months to 10 years with hyperammonaemia due to an inherited
disorder of the urea cycle and in whom the plasma glutamine ranged up from 1210
J.tmoi/L, that is only 300

~moi/L

above the upper limit of normal. There was a strong

positive correlation between the levels of plasma y-glutamylglutamine and plasma
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glutamine (p<O.OOOS) in these patients. There was no detectable y-glutamylglutamine
in their urine.

Possible explanations for differences between the handling of y-glutamylglutamine and
y-glutamylphenylalanine and y-glutamylornithine may be that: (a) the synthesis of
y-glutamylglutamine

proceeds

at

a

much

faster

rate

than

that

of

y-glutamylphenylalanine and y-glutamylornithine, so that the plasma level appears
much higher, (b) the activity of renal y-GT with y-glutamylglutamine may be greater
than that with y-glutamylphenylalanine and y-glutamylornithine, producing a high renal
threshold for y-glutamylglutamine or (c) the activity of y-glutamyl amino acid
cyclohydrolase may be greater with y-glutamylglutamine so that none escapes into the
urine.

The implications of these findings in relation to the physiological role of

y-glutamylglutamine will be discussed in Chapter 6.

Study in Patients with Phenylalanine Hydroxylase Deficiency
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SUMMARY AND IMPLICATIONS OF FINDINGS

gamma-Giutamylphenylalanine was found to be:
•

not excreted by a large population of symptomatic patients with an aminoaciduria
including grossly elevated phenylalanine that resulted from plasma overload or a
renal tubular defect;

•

excreted by 6 out of 10 patients with phenylalanine hydroxylase deficiency and
these 6 patients had higher plasma phenylalanine levels (>1250 J..lmoi/L) than the
four excreting <7 flmol/mmol creatinine;

•

not detected in plasma even when it was elevated in urine collected at the same
time; and

•

not detected in plasma even when the plasma phenylalanine was 26 times the
upper limit of the reference range.

The implication is that:
•

y-glutamylphenylalanine is handled differently from y-glutamylglutamine in the
human kidney.

PART II- ENZYME
STUDIES

CHAPTER FIVE

ENZYME STUDIES

5.1

INTRODUCTION

5.2

y-GLUTAMYLTRANSFERASE IN HUMAN TISSUES

5.3

y-GLUTAMYL AMINO ACID CYCLOTRANSFERASE IN RED CELLS

5.4

y-GLUTAMYL AMINO ACID CYCLOTRANSFERASE IN LENS

5.5

SUMMARY AND IMPLICATIONS OF FINDINGS
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ENZYME STUDIES

5.1

INTRODUCTION

The current study originated as a project to identify abnormal compounds excreted by
two Australian sisters. Seven y-glutamyl compounds were identified (Chapter 2) and
an investigation related to these y-glutamyl compounds commenced.

The enzymes involved in the degradation of y-glutamyl compounds,

namely

y-glutamyltransferase or y-glutamyltranspeptidase (EC 2.3.2.2, y-GT) and y-glutamyl
amino acid cyclotransferase (EC 2.3.2.4), were assayed in tissues from the two
patients and their parents.

Follow-up studies of y-glutamyl amino acid cyclotransferase were carried out on normal
and cataractous human lenses to measure the catabolic activity of this enzyme in an
avascular tissue containing high GSH levels.

5.2

y-GLUTAMYLTRANSFERASE IN HUMAN TISSUES

5.2.1

Objectives of the Study

Markedly reduced activity of the enzyme y-glutamyltransferase (EC 2.3.2.2, y-GT)
expressed in tissues from the two Australian patients and reduced activity in tissues
from their parents would confirm that y-GT deficiency (McKusick 231950) was a
recessively inherited defect. Urine and serum were obtained from all four and cultured
skin fibroblasts were obtained from the two siblings for study.

5.2.2

Analysis of y-Giutamyltransferase Activity in Serum, Urine and Cultured Skin
Fibroblasts

Samples for Study

Serum Blood was drawn from KW, BW, their parents and three controls. Serum was

obtained after allowing the sample to clot and centrifugation at 2000 X g for 10 min in a
Beckman JA21 centrifuge. Aliquots of each were made and stored at -80°C.
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Urine Urine was obtained as three hour collections from KW, BW, their parents and

two controls. Creatinine was estimated by a micro modification of the alkaline picrate
reaction using an end-point reaction.

The y-GT assay was carried out on:
•

the urine after gentle centrifugation at 1500 X g for 10 min at

sac to remove cellular

sediment,
•

the eluate of urine from a Sephadex G-25 medium, gel filtration column (Pharmacia
PD-10) and

•

concentrated protein from the eluate.

Gel filtration of urine had been reported to remove as yet unidentified, heat-stable,
dialysable inhibitors of y-GT activity (Szasz 1970, Maruhn 1979). Urine (2.5 ml) was
loaded onto a 9 ml Pharmacia PD1 0 gel filtration column previously washed with 25
ml 0.15 moi/L saline to remove the glycerol and sodium azide in the filter.
Immediately before loading the 2.5 ml of the urine supernatant, 4.0 ml of 0.15 moi/L
saline was applied and run to drain.

Proteins were eluted with 4.0 ml 0.15 moi/L

saline.

The

protein

in the

eluate was

concentrated

microconcentrator with 10,000 NMWL.

on

an

Am icon

Centricon™-1 0

Each filter was weighed before washing,

washed and then reweighed after inverted centrifugation. Eluate (1.6 ml) was added
to the units and centrifuged at 4200 X g for 50 min at 20°C. Retentate on the filter was
reconstituted with 200 J..LL of 0.15 moi/L saline.

The unit was then reweighed after

gentle shaking for solution. The retentate was recovered by inverting the reservoir and
centrifuging at 350 X g for 5 min into a preweighed cup that was then reweighed. The
reservoir was also reweighed to check for any residue.

Cultured Skin Fibroblasts Skin biopsies were taken from KW, BW and three controls

and cultured in Ham's F1 0 media prepared from Ham's F1 0 nutrient mixture (Gibco
BRL) with the following additives also obtained from Gibco; 10% (v/v) non-heat
inactivated foetal calf serum, 2 mmoi/L L-glutamine, 1% (v/v) penicillin-streptomycin,
1% (v/v) fungizone and 25 mmoi/L Hepes pH 7.3.

Cells at 90% confluence were harvested from 75 cm 2 tissue culture flasks using the
following procedure. After removal of the culture media, the cells were rinsed with
Dulbecco's phosphate buffered saline (PBS)(Commonwealth Serum Laboratories),
then trypsinised for 2 to 4 min at 37°C after pre-rinsing the flask with the trypsinising

TABLE 5.1
Reaction Conditions for the Assays of y-Giutamyltransferase Activity
Concentrations for the enzyme reaction are given as those in the final reaction mixture

Serum

Urine

Cultured Fibroblasts

Boehringer
Mannheim Kit

Boehringer
Mannheim Kit

Schulman ef a/1975

Rate Reaction

Rate Reaction

End-point Reaction

Temperature

30"C

30"C

37"C

pH

8.25

8.25

9.00

Glucana

Glucana

Glupna

Substrate Concentration

2.9mmoi/L

2.9 mmoi/L

1.0mmoi/L

Glycylglycine

100 mmoi/L

100mmoi/L

20mmoi/L

Tris

100 mmoi/L

100 mmoi/L

100 mmoi/L

nil

nil

10 mmoi/L

SamJ;lle l,lolume

100 flL

100J.tl

20,35 & 50 J.ll

Total 1/olume

1000 fLL

1000 J.ll

500 J.ll

Incubation Period

Up to 1h

Up to 1 h

4h

Beaction Condi!ions

Substrate

Magnesium chloride

ComJ;lletioo of Reactioo
Trichloracetic Acid

500 g/L, 50 fl.L

Acetic Acid

2 moi/L, 450 J.lL

Sgec!roghotQmetry
Absorbance
Read Against

406nm

406nm

406 & 410 nm

Air

Air

Air

ABBREVIATIONS: Glucana- -y-glutamyl-3-carboxy-4-nitroaniiide
Glupna - y-glutamyl-4-nitroanilide

TABLE 5.2
Volumes and Blanking System Used in the Rate Reaction

Test

y-GT Reagent

Tris/Giycylglycine

0.15 moi/L Saline

~L

~L

~L

1000

Sample Blank
Substrate Blank

L

100
1000

1000

Sample

100
100
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mixture that contained 0.1 o/o (w/v) trypsin in 0.54 mmoi/L ethylenediamine-tetra-acetate
(pH 8.0) (Commonwealth Serum Laboratories). Fibroblasts were collected as a pellet
by centrifugation at 350 X g for 10 min, washed twice with PBS and assayed either
immediately or after storage as liquid-free pellets at -80°C. Prior to analysis the cell
pellet was homogenised by four passes in a Pierce PTFE/glass homogeniser
containing 200 to 1200 J..LL of Milli-Q organics-free water depending on the cell
concentration.

Cells for enzyme assay were confirmed mycoplasma-free by staining with Hoechst
stain (ICN Biomedicals), viewing under fluorescent illumination and by comparison with
a positive and a negative control.

Assay of :y-Giutamyltransferase Activity in Serum and Urine

Equipment All spectra and absorbances were run on a Hewlett Packard diode array

8451A spectrophotometer (Hewlett Packard Company, Corvallis, OR) using Starna 6Q,
10 X 4 mm cuvettes with air as reference.

The spectrophotometer lamp was

equilibrated for at least 30 min prior to use and a stability check was run at the start of
each working day. The multiple cell transporter was heated to 30 ± O.SOC by calibrating
the temperature drop with two reference thermometers, one in a cuvette containing
equilibrated water and the other in an externally connected circulating water supply
held at 30.46°C by a Braun Thermomix water heater.

Reagents

The Boehringer-Mannheim :y-GT kit was purchased and prepared as

instructed at the commencement of each day of analysis. The :y-GT reagent contained
3.2 mmoi/L :y-glutamyl-3-carboxy-4-nitroanilide

(:y-Giucana)

as donor substrate,

glycylglycine (11 0 mmoi/L) as the acceptor and Tris pH 8.25 (11 0 mmoi/L) as the
buffer. A reagent containing the Tris and glycylglycine without donor substrate was
also prepared. The equation for the reaction is shown below.
r·glutamyltransferase

y-Giutamyl-3-carboxy-4-nitroanilide + Glycylglycine

B

y-Giutamylglycylglycine + 5-Amino-2-nitrobenzoate

Reaction Conditions The conditions and reagent concentrations in the final reaction

mixture used are shown in Table 5.1.

The volumes of additions and the blanking

system used are shown in Table 5.2.

The 1000 J..LL of :y-GT reagent or Tris/glycylglycine was pre-incubated in the cuvette at
30°C for 10 min.

The reaction was started by addition of 100 J..lL of either serum,
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cell-free urine, eluate of urine after gel filtration, concentrated eluate (X 8) of urine or
0.15 moi/L saline and mixed by rinsing the pipette (To Contain) into the cuvette.

Extinction Coefficient The product of the reaction, 5-amino-2-nitrobenzoate, was found

to have an optimum absorbance at 406 nm. The molar absorptivity of a highly purified
preparation of standard of 5-amino-2-nitrobenzoate (Boehringer-Mannheim) was
checked using the method recommended by Lehmann et a/ (1977).

The molar

extinction coefficient of 5-amino-2-nitrobenzoate was measured for the specific
reaction conditions of the assay. The results in nmol!min/mL were calculated using the
molar extinction coefficient of 9323. Activity was expressed nmol/min/mL at 30°C for
serum and nmollmin/mg creatinine at 30°C for urine.

Reliability The reagent blank was used to measure any non-enzymatic hydrolysis of

the enzyme during the incubation. The reaction was linear with amount of sample (1 0
to 100 f.lL) and linear with time in serum for at least 120 min and in urine for at least
180 min.

Aliquots of a large volume of serum were prepared and stored at -80°C. One aliquot
was run with each batch to monitor the between-run precision of the assay.
between-run precision was SD
SD

The

± 0.95 nmol/min/mL for the enzyme assays overall and

± 0.60 nmol/min/mL for serum alone.

The formation of turbidity from heparinised plasma during the enzyme reaction gave
activities approximately 0.3 nmol/min/mL "higher" than serum.

Assay of y-Giutamyltransferase Activity in Homogenates of Cultured Fibroblasts

Trials of the rate reaction assay based on the Boehringer Mannheim kit with cultured
fibroblasts indicated that the formation of turbidity would interfere with the detection of
low enzyme activity expected in the samples from KW and BW. Instead these cells
were tested using the end-point reaction with assay conditions based on those used by
Schulman et a/ (1975) and using y-glutamyl-4-nitroanilide (y-Giupna}, a less soluble
substrate than y-glutamyl-3-carboxy-4-nitroanilide.

Preparation of the Substrate Analytical grade magnesium chloride (MgCb.6H 2 0)(BDH)

12.5 mmoi/L and Tris as Trizma Base (Sigma) 125 mmoi/L were made up as a
combined solution in water and brought to pH 9.00 at 20°C with addition of 5 moi!L
hydrochloric acid. Glycylglycine (Tokyo Kasei) 200 mmoi/L was made up in water.

TABLE 5,3
Volumes and Blanking Sytem Used in the End-Point Reaction
Schulman et at 1975

Glupna!Tris

Glycylglycine

0.15 moi/L Saline

Cell
Homogenate

IlL

Ill

IlL

Ill

Test

400

50

50

Test Blank (Zero)

400

50

50

Sample Blank

400

50

Substrate Blank

400

100

Reagent Blank

400

ABBREVIATION:

50

Glupna - y-glutamyl-4-nitroanilide

50

50

Enzyme Studies

95

The y-Giupna with one water of hydration, was purchased from Boehringer. A 1.25
mmoi/L solution was prepared before each batch by weighing 7.16 mg into a glass vial
and adding 20 mL of the Tris/MgCI 2 , mixing and heating the vial to

sooc

until the

substrate dissolved (Szasz 1969). The pH of this reagent mixture was confirmed on an
Orion research pH meter.

Reaction Conditions The conditions and reagent concentrations in the final reaction
mixture used are shown in Table 5.1.

The volumes of additions and the blanking

system used are shown in Table 5.3.

The 400 J.LL of y-Giupna/Tris was pre-incubated for 5 min at

3rc.

To this was added

50 J.LL of glycylglycine acceptor (or 0.15 moi/L saline) followed by 50 J.LL of cell
preparation (or 0.15 moi/L saline) to start the reaction at

3rc.

Reactions were

terminated at zero or 240 min by addition of 50 J.LL of 50% (w/v) trichloroacetic acid at 0

oc

and then 450 J.LL 2 moi/L acetic acid after 5 min.

The acidified mixture was

centrifuged at 2000 X g for 10 min and the supernatants were read on the diode array
spectrophotometer at the absorption maxima of 410 nm against air.

The reagent blank was used as a check on non-enzymatic hydrolysis of the substrate
during the reaction
y-glutamyltransferase

y-Giutamyl-4-nitroanilide + Glycylglycine

B

y-Giutamylglycylglycine + p-Nitroanilide [1]

y-glutamyltransferase

y-Giutamyl-4-nitroanilide + H2 0

---t

Glutamate + p-Nitroanilide

[2]

The result for the transferase activity [reaction 1) was calculated by subtracting the
absorbance of the sample blank from the test activity. The sample blank gave the
hydrolase activity [reaction 2] of y-GT by substituting 0.15 moi/L saline for glycylglycine
acceptor in the reaction mixture. The reaction was linear with protein concentration
from 20 to 117 J.L9 in the reaction mixture and for at least 360 min.

Aliquots of a large volume of serum were prepared and stored at -80°C. One aliquot
was run with each batch to monitor the precision of the assay. The foetal calf serum
and complete Ham's media were checked for y-GT activity.

Tissue Protein Assay

Samples for Analysis

The precipitated protein from the terminated y-GT enzyme

incubations that did not contain glycylglycine were selected for protein assay. It had

TABLE5.4
y-Giutamyltransferase Activity in Serum, Urine and Cultured Fibroblasts

SERUM

URINE

nmollmin/ml at 30°C

nmollminlmg creatinine at 30°C

pH 8.25

pH8.25

CULTURED
FIBROBLASTS
nmol/h/mg protein at 37°C
_llH 9.0

KMJ

<0.3

<0.5

<0.8

BW

<0.3

<0.5

<0.8

Mother

5.7

9.5

Father

4.7

10.3

11.1, 13.4, 6.2

21.3, 20.6, 24.6, 28.8

PATIENT

Controls (F)
Published Range (F) a

5-25

Published Range (M) a

8-38

a

Szasz (personal communication) to Boehringer Mannheim

18.5, 8.1
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been found impossible to wash the glycylglycine off the precipitate with trichloroacetic
acid. The pellet of protein was digested with 1 moi/L sodium hydroxide overnight and
diluted to approximately 1 to 3 1-tg protein in the reaction mixture and 0.1 moi/L sodium
hydroxide concentration.

Standards and Controls A panel of six concentrations of bovine serum albumin (BSA)

standards were prepared in bulk from Boehringer Precimat protein and aliquots were
stored at -80°C in Minisorp™ tubes (Nunc) until use. The levels were chosen to give
0.82 to 4.13 1-lg protein in the final colour reaction mixture.
cerebrospinal fluid

The standards and a

protein control (Bio-Rad Lyphochek®) containing 0.82 mg

protein/ml were precipitated with 50% TCA (w/v), digested overnight with 1 moi!L
sodium hydroxide and diluted as for samples.

Colour Reaction

The ultramicro protein assay was a modification of the Pierce

bicinchoninic acid (BCA) protein assay using BCA reagent with sample volume reduced
to 50 f.LL and reagent mixture to 1000

~-tl.

The colour reaction was carried out at room

temperature for 16 h. The absorbance of the reagent blank, bovine serum albumin
standard curve and the digests of the precipitated fibroblast and CSF protein control
were read against air at 560 nm on a Hewlett Packard diode array spectrophotometer.
Colour reagent blanks contained 50 11L 0.1 moi/L sodium hydroxide instead of protein.

Analytical Reliability

The standard curve was linear to 5f.Lg in the colour reaction

mixture. The between-run precision for the 2.07 and 4.13 1-tg BSA standards were CV
±4.2 and ±3.8% respectively and CV ±3.0% for the spinal fluid control.

5.2.3

Results

gamma-Giutamyltransferase Activity in Serum and Urine

The results obtained on samples of serum and urine from KW, BW, their parents and
controls are shown in Table 5.4. The activity of y-GT in serum from the three female
controls (11.1, 13.4 and 6.2 nmol/min/ml) agreed with those stated in the Boehringer
Mannheim method kit.

These control ranges were 5 - 25 nmol/min/ml for normal

females and 8 - 38 nmol/min/ml for normal males at 30°C. The parents showed 5.1
nmol/min/ml for mother and 4.7 for father. Activities for KW and BW were below the
limit of detection for the method {<0.3 nmol/min/ml), that is <6% of the lower limit of
the normal range.
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The y-GT activity in cell-free urine from KW and BW was again below the limit of
detection, while results for the eluate after removal of possible y-GT inhibitors and an
eight-fold concentration of this eluate indicated that the y-GT activity was effectively
zero.

The assay of activities in urine from both parents showed results that were

approximately 50% of the controls.

gamma-Giutamyl Transferase and Hydrolase Activity in Cultured Fibroblasts

Initially activity for y-GT was obtained for the cell lines from KW and BW that had been
grown in a cytogenetic laboratory unaccustomed to the requirements of long-term
culture of fibroblasts.

This activity was high and not proportional to enzyme

concentration or time, as it had been in controls. It was supposed that the cultures
were contaminated with mycoplasma but none was identified in a limited investigation
by a reference laboratory at that time. No y-GT activity was found in later batches of
foetal calf serum and the media.

The cells were regrown from a remnant of the primary cultures and sent to another
tissue culture laboratory where routine checks for mycoplasma were carried out.
Subsequent long-term cultures to passage 8 of both cell lines have been found to be
uncontaminated.

The enzyme assays for y-GT activity were repeated and the cells from KW and BW
gave results that were essentially zero (Table 5.4).

The enzyme activity measured in two of control cell lines showed that 17% and 19% of
the total transferase activity resulted from the hydrolase. There was no evidence of
hydrolase activity in the cell lines from KW and BW.

5.2.4

Discussion

The enzyme results indicate that KW and BW are homozygous for the inherited defect
of y-GT deficiency (McKusick 231950), including both the transferase and hydrolase
activity measured in cultured skin fibroblasts. Urine samples from both parents gave
about half the normal activity and the serum results were at the lower limit of normal
and half the lower limit. The disorder is thus likely to be recessively inherited.
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The finding of y-GT activities that were effectively zero in cell-free urine from our
patients is particularly relevant to this study because the soluble enzyme in urine is
derived from the renal tubular lining (Szasz 1970).

The transferase activity obtained for cultured fibroblasts from the limited number of
controls compares well with that of States and Segal (1980) that ranged between 10
and 20 nmol/h/mg protein (N = 17) in a reaction mixture at pH 8.2 using 20 mmoi/L
glycylglycine as acceptor. Levels obtained by Schulman et al (1975) under the reaction
conditions used in the current study were 63 to 189 nmol/h/mg protein (N=6), whilst
those of Wright (1975) were 27 to 109 nmol/h/mg protein (N=9) run at pH 8.5. The
difference between these enzyme activities in control cell lines may result from
differences in blanking procedures, especially the blanking for hydrolase activity, as
well as pH differences between the assay conditions. Since no statement regarding
mycoplasma testing was reported, it is also possible that some of the cell lines in the
Schulman eta/ (1975) and Wright eta/ (1979) reports were not free of contamination.

Difficulties encountered with analysis of the enzyme in fibroblasts were not completely
resolved, because the organism that gave rise to the aberrant y-GT activity was not
isolated at that time.

Not withstanding this, it is unlikely that the increased activity

found in the early work was due to some other artefactual source such as an "aging"
fibroblast culture as reported by Takahashi & Zeydel (1982), because both of the y-GT
deficient cell lines were of relatively low passage number (3) when the y-GT was
measured initially.

The hydrolase activity in the two control cell lines was lower than that found by States
and Segal (1980). They obtained activities that 50% of the total y-GT activity (N=1 0)
when glycylglycine was used as the acceptor substrate.

Analysis of y-GT activity in serum has been used in clinical chemistry for over 25 years
to assess liver function (Szasz 1969).

The test is designed to detect gross liver

pathology and normal patients have relatively low activity, around 5 to 38 U/L. Both
patients, KW and BW, were tested by routine clinical chemistry departments on at least
three occasions.

Surprisingly the y-GT results for both patients, although below the

reference range, were not recognised or highlighted as unusual.

This may have

occurred because low results for y-GT activity, that is results <5 U/L, have not been
considered clinically significant until now.

In our experience this lack of awareness

amongst some clinical chemists has also occurred with the reporting of low serum
alkaline

phosphatase

activity,

a

marker

enzyme

for the

inherited

disorder
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hypophosphatasia (McKusick 241500) and low serum uric acid estimations, an indicator
of molybdenum cofactor deficiency (McKusick 252150).

It is also interesting that the results obtained by routine biochemistry testing for y-GT
activity in KW and BW were not 0 or 1 U/L, but 3 or 4. Retrospective checks showed
that heparinised plasma, not serum, was collected for testing.

The formation of

turbidity from heparinised plasma during the enzyme reaction (Wahlefeld & Bergmeyer
1983) may be sufficient to bring their very low activity up to the low normal. For this
reason detection of new patients with the disorder may be difficult in the future. It is
also unfortunate that new patients may not be detected on metabolic screening
systems that use HPLC for urine, rather than visualisation of HVE or TLC patterns.
The abnormal compounds that were isolated and identified (Chapter 2) could be
mistaken for drug artefacts on HPLC systems and be disregarded.

5.3

y-GLUTAMYL AMINO ACID CYCLOTRANSFERASE ACTIVITY IN RED CELLS

5.3.1

Introduction and Objectives of the Study

gamma-Giutamyl amino acid cyclotransferase (EC 2.3.2.4) is the intracellular enzyme
responsible for the scission of the peptide bonds of y-glutamyl amino acids and
y-glutamyl-y-glutamyl compounds (Orlowski

et at1969, Szewczuk & Connell 1975, York

1986). The enzyme is active with substrates containing a free cx,-carboxy group on the
amino acid linked to the y-glutamyl residue.

The products of the reaction are

5-oxoproline and the amino acid or y-glutamyl compound. The following reactions are
examples:
y-glutamyl amino acid cyclotransfera.se

y-Giutamylalanine

-+

5-0xoproline + Alanine

y-glutamyl amino acid cyclotransferase

y-Giutamyl-y-Giutamylalanine

-+

5-0xoproline + y-Giutamylalanine

Nuclear magnetic resonance (NMR) spectroscopy has been used to study enzyme
catalysed reactions in complex mixtures and intact cells and tissues (Kuchel 1981). In
particular it was used to monitor the cleavage of y-glutamylalanine by y-glutamyl amino
acid cyclotransferase in human erythrocytes (York
the assay have been described by York et at (1984).

et at 1984, York 1986). Details of
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In the current study the presence of the y-glutamyl amino acid, y-glutamylglutamine, as
well as the y-glutamyl peptides, in the urine of the Australian patients with y-GT
deficiency suggested the possibility that they might have a combined defect involving
both y-GT and y-glutamyl amino acid cyclotransferase. In order to test this, red cells
were obtained from both patients, their parents and a control and these were analysed
by Dr. Michael York for y-glutamyl amino acid cyclotransferase activity.

5.3.2

Measurement of y-Giutamyl Amino Acid Cyclotransferase Activity in Red Cells

Samples for Studv

Blood was drawn from KW, BW, their parents and a control and collected into tubes
containing ice-cold lithium heparin.

Erythrocytes were immediately prepared by

centrifugal washing twice in 3 volumes of ice-cold isotonic saline in water (1H 20). The
chilled cells were filtered through a cotton-wool column (2 X 6 em) to remove
leucocytes, washed once more in 1H2 0 then in 1 volume of gassed (0 2 :C0 2 , 19:1)
Krebs bicarbonate buffer constituted in 1H2 0 and centrifuged 1500 X g for 5 min. The
haematocrits of the suspensions were assumed to be 0.90.

NMR Measurements of y-Giutamyl Amino Acid Cyclotransferase Activity

The enzyme reaction was initiated by adding 25 Jl.L y-glutamylalanine solution (pH
adjusted to 7.2) to give a substrate concentration of 10 mmoi/L in the cell suspension
sample (500 Jl.L) that had been preheated to 37oc in the NMR tube. After thorough
mixing, the NMR tube was inserted and spectra were acquired. Zero-time was taken as
the time at which the substrate was added.

1H NMR spectra were taken over a time course at 37°C using a Bruker WM 400 NMR
spectrometer operating in the Fourier mode at 400 MHz.

For each enzyme assay,

10-50 consecutive spectra were run. The time assigned to each spectrum was the time
when half the number of transients for each spectrum had been acquired.

Alanine

concentrations were determined from the peak amplitude of the alanine H~ resonance.
The amplitude of an internal creatine methyl resonance was used to compare the
results of one time course with another. Calibration curves of alanine concentration
from 1.5 to 5 mmoi/L versus the amplitude of the alanine HP intensity were prepared by
addition of known amounts of alanine to red cell lysate samples. The concentrations of
reactants were corrected for sample volume (principally haemoglobin) not accessible to

TABLE5,5
y-Giutamyl Amino Acid Cyclotransferase Activity in Erythrocytes
PATIENT

ENZVME ACTIVITY

mmol y-GiuAia cleaved/h/L water at 37•C
Mean+SD

KW

124.9±5.7,

116.8±5.0

BW

124.9±9.7,

122.3±5.8

Mother

113.3±5.7,

119.7 ± 5.8

Father

117.6±4.8,

126.1 ±6.9

Control

112.3±6.7,

119.5 ±5.4

Abbreviation:

SD- standard deviation
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solute. Activity was expressed as mmol of y-glutamylalanine cleaved /h/L of cell water
at 37°C.

5.3.3

Results

The precision of the NMR method for determining the concentrations of the reaction
product, alanine, had been estimated previously by York (1986).

In that report, the

precision obtained by using peak amplitudes was better than that obtained by using
peak areas (intensities) and this was thought to be "due to difficulty in defining the
baseline limits of the resonances".

In a separate experiment, the coefficient of

variation of the mean of the peak amplitude of an internal reference, creatine methyl
resonance, in a given time course was less than ±5% (York 1986).

The results obtained on samples of erythrocytes from KW, BW, their parents and a
control are shown in Table 5.5. The activity of y-glutamyl amino acid cyclotransferase
in the patients and the control was estimated in two time courses and the rates over
each were calculated to give a mean ± SD. These agreed with those obtained by York
(1986) for a normal control at 105.2 ± 4.4 mmol y-glutamylalanine cleaved/h/L cell
water.

5.3.4

Discussion

The results show that the Australian patients, KW and BW, have normal activity for
y-glutamyl amino acid cyclotransferase in their erythrocytes.

Similar activities were

also found in red cells from both their parents. It is therefore unlikely that this family
has a combined defect of y-GT and y-glutamyl amino acid cyclotransferase.

Our Australian patients lack any behavioural or psychiatric disturbance (Hammond et a/
1995) such as that reported in two other patients with y-GT deficiency (Goodman et a/
1971, Wright et a/ 1979). Instead they appear to express a milder phenotype of the
y-glutamyltransferase defect.
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5.4

y-GLUTAMYL AMINO ACID CYCLOTRANSFERASE ACTIVITY IN LENS

5.4.1

Introduction and Objectives of the Study

The lens has an avascular structure that is arranged so that the dedifferentiated fibre
cell is not eliminated but compressed towards the centre of the tissue. The oldest fibre
cells are in the center of the lens and the youngest are on the periphery. Fibre cells
produced at all stages of life from foetal to old age are present (Rathbun 1989). The
lens depends entirely on the surrounding ocular fluids for the supply of ions and
metabolites such as glutamate, cysteine and glycine for GSH synthesis (Kinsey &
Reddy 1963). The layer of epithelial tissue on the anterior surface is the site of active
transport from the aqueous humor.

Normal human lens contains around 3.3 mmol GSH/Kg lens water (Dickinson

et

a/

1968, Harding 1970) and similar to the level in the human red blood cell, estimated at
between 1. 79 and 3. 79 mmol GSH/L cells (Hagenfeldt

et a/1978).

Lens also contains

another y-glutamyl peptide, y-glutamyl-a-aminobutyrylglycine (ophthalmic acid), that
was first isolated from calf lens (Waley 1956). The levels of ophthalmic acid in human
lens were shown to be one tenth those of GSH (Dickinson et a/ 1968, Tsuboi et a/
1984). Subsequent work has found that the level of GSH depended on the location
within the lens, the age of the patient and whether cataracts were present (Harding
1970, Rathbun 1989).

GSH and ophthalmic acid are not substrates for the intracellular enzyme y-glutamyl
amino acid cyclotransferase (Szewczuk & Connell 1975).

This raises an important

question related to glutathione metabolism that has not yet been fully answered. How
is GSH "lost" from human tissues and especially how is it "lost" from the human lens
prior to cataract formation (Harding 1970)? To that question might be added another.
What role, if any, has y-GT in this "loss" of GSH?

Lenses from

animal

studies appear to

exhibit

both

y-glutamyl

amino

acid

cyclotransferase (Cliffe & Waley 1961) and y-GT activity (Rathbun & Wicker 1973,
Reddy & Unakar 1973, Ross eta/ 1973), while human erythrocytes are without y-GT
(Board & Smith 1977) but contain the cyclotransferase (Board et a/ 1978, York et a/
1984). The intracellular location of the cyclotransferase in human lens has not been
recorded but y-GT is concentrated in the layer of lens epithelium (Reddy & Unakar
1973).

TABLE 5.6
Percentage Water Content in Normal and Cataractous Lenses
Lens

Patient Age
years

% of wet weight

Lens
Cataract Stage

Patient Age
years

% of wet weight

Normal

8

67.9

Yellow++

Unknown

66.9

Normal

54

67.2

Yellow+++

Unknown

64.3

Normal A
Normal B

53
53

70.6
69.5

Yellow+++

Unknown

64.2

Yellow+++

Unknown

64.1

Normal A
Normal B

65
65

71.2
70.8

Dark brown

Unknown

70.6

Normal A
NormaiB

83
83

67.8

Range

Water Content

Water Content

67.4

67.2. 71.2

Range

64.1 -70.6
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The use of NMR spectroscopy (Section 5.3.3) had made it possible to follow the
disappearance of the substrate and the appearance of the products of an enzyme
catalysed reaction within intact red cells.

It was thought that analysis of y-glutamyl

amino acid cyclotransferase activity in normal and cataractous human lenses using
NMR might also offer this advantage, however an exploratory experiment showed that
there was insufficient mass in a single lens (-200 mg), or even a lens pair, for an assay
on intact tissue.

Not with standing this, the activity of y-glutamyl amino acid

cyclotransferase in lens homogenate was demonstrated and an alternative set of
experiments on diluted homogenate was planned.

NMR was used to follow the enzyme reactions in lens homogenates from a variety of
patients and donors in relation to:
•

the location of cyclotransferase activity,

•

the variation of enzyme activity with the age of the donor,

•

the variation of enzyme activity between normal and cataractous lens and

•

the contribution of y-GT to breakdown of a y-glutamyl compound in human
lens.

5.4.2

Measurement of y-Giutamyl Amino Acid Cyclotransferase Activity in Human Lens

Samples for Study

Normal human lenses were supplied from donors to the Lions NSW Eye Bank, who had
suffered natural or accidental death. The lenses were obtained on the day of death and
were either used immediately or stored immediately in liquid nitrogen and later
transferred to -80°C until use. Cataractous human lenses were supplied by ophthalmic
surgeons at the Sydney Eye Hospital.

These lenses were obtained immediately

following surgery or after storage at 0°C.

Cataracts were graded according to

increasing nuclear colour.

Lens Water Content

The water content of lenses from five normal donors, including three pairs of lenses,
and five cataractous patients was measured.

Each lens was transferred to an

individual preweighed weighing boat of aluminium foil and weighed on a Mettler AT260
balance. The boat and contents were then transferred to a drying oven held at 1oooc
for 16 hours and dried to constant weight. The percentage water contents are shown in
Table 5.6. An average value for water content of 69% was used in the calculation of
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enzyme activity in lenses, except for the lenses from the 8 and 54 year old donors for
whom the water content in the paired lens was available.

Preparation of Normal Lenses for Enzyme Assay by NMR

Each lens was weighed and either dissected into nucleus and cortex by using a
stainless steel cork borer (internal diameter 5 mm) followed by slicing off the ends of
the core (Truscott & Augusteyn 1977) or the lens was used intact. The weighed tissue
was homogenised with three passes in a 2 mL PTFE/glass homogeniser (Pierce) with
either 500 or 1000

~-tL

PBS at pH 7 .3. The homogenate was transferred to a 1.5 mL

centrifuge tube. The homogeniser and pestle were then rinsed with a second volume
of PBS such that the ratio of tissue to total volume of buffer used for homogenisation
and rinsing was 100 mg of tissue to 1000 f!L of buffer. After adding this rinse to the
homogenate in the centrifuge tube, it was centrifuged at 12,000 rpm for 3 to 7 min at
+5°C and held at +5°C until use. Immediately prior to NMR analysis this supernatant
was diluted 1 in 4 with PBS and 500

~-tL

taken for the assay.

Preparation of Cataractous Lenses for Enzyme Assay by NMR

Lenses from cataractous patients were treated similarly to those of normal donors
except that the ratio of tissue to PBS in the homogenate for the nucleur preparation of
a lens contained 77 mg per 1000 J.LL.

NMR Spectra of the Enzyme Reaction

NMR measurements of y-glutamyl amino acid cyclotransferase activity were conducted
largely following the method of York eta/ (1984) described in Section 5.3.2.

The

instrument used was a Varian model XL-400 NMR, the buffer was PBS not Krebs
bicarbonate and single, not duplicate assays, were carried out.

Each NMR assay commenced with an initial spectrum for reference. This involved the
transfer of 500

~-tL

an

sealed

inner

of the clear, diluted homogenate to an outer NMR tube, placement of
tube

containing

an

external

reference

material

2,2-dimethyl-2-silapentane 5-sulphonate (DSS) into the homogenate, equilibration of
the temperature to 37"C and measurement of a spectrum.

The

enzyme reaction started with the addition

of 21

J.LL

of 245

mmoi/L

y-glutamylalanine at pH 7.4 into the same NMR tube. The homogenate and substrate
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were mixed by vortexing and the NMR tube was replaced in position for re-equilibration
to 37°C. The first spectrum could be taken between 4 to 6 minutes from the addition of
the substrate. The instrument was programmed to take a spectrum at intervals of 8.26
minutes thereafter over a total of 80 min.

The reaction rate was monitored and recorded by following the peak amplitude of the
alanine H~ resonance and of the DSS external standard using the computer linked to
the NMR.

The instrument was programmed to draw the relevant portion of the

spectrum at 8.26 min intervals onto A3 recorder traces. The data was also stored on
3.5 inch floppy discs for integration at a later stage.

Post-run analysis of the peaks involved both (a) automatic integration of peak areas
and peak amplitudes by the proprietary software supplied by Varian and (b) manual
measurements of the peak amplitudes made using the recorder traces and a magnified
micrometer scale.

NMR Spectra of Reference Compounds

Spectra were obtained at 37°C for the following compounds at pH 7.2 to 7.4 in
phosphate buffer (a) alanine 25 mmoi/L and 5-oxoproline 20 mmoi/L, (b) glycine at
12.28 mmoi!L and a-aminobutyrate at 2.72 mmoi/L (c) glycine at 31.62 mmoi/L and
a-aminobutyrate at 26.4 mmoi/L and (d) y-glutamyl-a-aminobutyrylglycine (ophthalmic
acid) at 10.08 mmoi/L.

A concentration curve of NMR response for alanine standard solutions of 9.7, 48.4,
96.7, 242.0, 484.0, 725.0, 967.0 and 2420

~moi/L

was also obtained

NMR Measurements of :y-Giutamyl Amino Acid Cyclotransferase Activity

Three groups of experiments were conducted over six 8-hour NMR sessions.

Experiments on Lens Nucleus

Activity of lenticular y-glutamyl amino acid

cyclotransferase activity was measured (a) on a lens nucleus obtained from a patient
with senile cataract and (b) on a lens nucleus from an 86 year old eye donor, using the
supernatant of nucleur homogenate.

Enzyme Studies

106

Experiments on Lens from a Cataractous Patient

An assay of lenticular y-glutamyl

amino acid cyclotransferase activity was carried out on the supernatant of homogenate
prepared from a lens from a patient with senile cataract.

Experiments on Lenses from Eye Donors Assays of lenticular y-glutamyl amino acid

cyclotransferase activity were conducted on lenses from six eye donors aged 8, 15, 52,
54, 62 and 86 years. The last 86 year old also donated the lens used for one of the
experiments on lens nucleus.

5-0xoproline, the common product of all y-glutamyl amino acid cyclotransferase
reactions, was not observed after the relatively short time courses conducted over 80
minutes, because detection of the 5-oxoproline triplet resonance in a NMR spectra is
relatively insensitive when compared with the sharper doublet peak obtained for the
alanine H~ resonance.

We calculated the detection limit for 5-oxoproline from the

reference spectrum of the standard solution. Using that level we then calculated the
length of assay required to confirm 5-oxoproline as a product of the cyclotransferase
reaction by NMR. Three of the assays on normal lens were taken beyond the routine
time of 80 minutes to from 10 to 11.75 hours

NMR Measurement of r:-Giutamyltransferase and Aminopeptidase M Activity

Since ophthalmic acid is not a substrate for the y-gtutamyl amino acid cyclotransferase
but is a substrate for y-GT, it was employed to test for y-GT activity in a paired lens
from the 54 year old eye donor (above). Combined activities of the y-GT hydrolase
and aminopeptidase M on y-glutamyl-a-aminobutyrylglycine would result in production
of glutamate, a-aminobutyrate and glycine.
y-glutamyltransferase

y-Giutamyl-cx-aminobutyrylglycine + H20

~

Glutamate + a-Aminobutyrylglycine

Aminopeptidase M

cx-Aminobutyrylglycine

~

cx-Aminobutyrate + Glycine

Supernatant of homogenate was prepared from the second lens from this patient and
500

f.lL

of

this

was

incubated

with

21

f.lL

of

245

mmoi/L

y-glutamyl-a-aminobutyrylglycine at 37•c for an extended incubation of 18.75 hours.

5.4.3

Results

The concentration curve of NMR amplitude response for alanine standards from 9.7 to
2420 f..l.moi!L showed that noise in the NMR system was greater than the response for

FIGURE 5.1
Calibration Curve for Alanine Standard at 37°C and pH 7.4
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the two lowest concentrations.

The alanine standard of 9.7 ).Lmoi!L was below the

detection limit of the system, while the 48.4 11moi/L standard gave a peak amplitude of
0.5 mm on the limit of detection with the y intercept of the linear regression at 0.6 mm
and the standard error of yon x (SEy,x)at 0.78 mm.

The precision obtained by using peak amplitude measured manually was better than
that obtained by using peak amplitude or peak areas (intensities) generated by the
proprietary software with the Varian model XL-400 NMR. This may be explained by the
observation that the eye, with the aid of a magnifier, could assess small but significant
variations in the baseline and adjust for these, whereas the computer-generated
measurement was taken at a fixed point either side of the peak and because the
alanine H~ resonance was a doublet. The precision of peak height measurements was
also more precise in the case of the NMR investigation of erythrocytes with a Bruker
WM 400 NMR spectrometer (Section 5.3.3).

Figure 5.1 shows a plot of the concentration curve for alanine standards from 48.4 to
2420 11moi/L obtained using peak amplitude measured in mm with a magnified
micrometer scale. The error bars in Figure 5.1 represent the SEy,x of 0.78. The linear
concentration curve obtained was y ::: 0.01447x + 0.66 and the slope was used to
calculate the rates of alanine production for each enzyme reaction.

The series of incubations that had been deliberately extended in order to confirm the
presence of both products, alanine and 5-oxoproline, did demonstrate the triplet of
5-oxoproline as predicted.

The hydrolysis of y-glutamyl-a.-aminobutyrylglycine by lens y-GT was tested at 3rC
and pH 7.4 in another experiment that was conducted over 18.75 hours. At the end of
the extended incubation neither a.-aminobutyrate nor glycine product could be
detected. No apparent hydrolysis had occurred under these conditions.

Figure 5.2 shows the linear regression lines for the y-glutamyl amino acid
cyclotransferase activity obtained in the nine experiments conducted on lenses and on
lens nucleus.

Table 5.7 shows the cyclotransferase activities in lens and in lens

nucleus expressed as nmol alanine/min/mg dry lens weight.

Whole lens and lens

nucleus prepared from the same 86 year old donor showed that cyclotransferase
activity in the nucleus was 29% of that in the whole lens.

FIGURE 5.2
y-Glutamyl Amino Acid Cyclohydrolase Activity in Human Lens at 37°C, pH 7.4
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TABLE5.7
y-Giutamyl Amino Acid Cyclotransferase Activity in Human Lenses
SUBJECT

CONDITION

Age in years

LENS
nmol/h/mg dry weight at

37°C

8

Normal Donor

3.93

15

Normal Donor

1.94

52

Normal Donor

1.02

54

Normal Donor

1.02

62

Normal Donor

1.27

86

Normal Donor

1.22

Unknown

Senile Cataract

0.82

LENS NUCLEUS
nmol/h/mg dry weight at

37°C

86

Normal Donor

0.35

Unknown

Senile Cataract

0.12
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Discussion

This is the first report of y-glutamyl amino acid cyclotransferase activity in the human
lens and the first to compare the cyclotransferase activity in whole lenses with that in
lens nucleus.

Previous data had been obtained on calf and rabbit lens.

Calf lens

showed activity at pH 6.4 was higher for y-L-glutamyi-L-a-aminobutyrate (182 units)
than for y-L-glutamylglycine (30 units) (Cliffe & Waley 1958).

Ross et at (1973)

measured cyclotransferase activity in rabbit lens at pH 8.0 and found 159 nmol/h/mg
dry weight with y-glutamyi-L-methionine as substrate and 96 nmol/h/mg dry weight with
y-glutamyi-L-a-aminobutyrate. This latter data indicates a possible 50-fold difference
between y-glutamyl amino acid cyclotransferase activities for human lens in the current
study compared with that reported for rabbit lens. Assay conditions, including the pH of
7.4 versus 8.0 and the substrate used, may have contributed to this difference.

The current finding of lower y-glutamyl amino acid cyclotransferase activity in the
nucleus, compared with that in the whole lens, implies that its activity may be higher in
the outer, metabolically active region. Lenticular y-GT activity occurs predominantly in
the outermost layer of lens epithelium (Reddy & Unakar 1973, Ross et at 1973). If
these two enzymes form a functional y-GT/y-glutamyl amino acid cyclotransferase
system, then it might be expected that they occur on either side of the single plasma
membrane in the lens.

Two other enzymes related to glutathione metabolism, namely y-glutamylcysteine
synthetase and glutathione synthetase, had undetectable and low (1.4% of total
activity) activity respectively in human lens nucleus when compared with the lens
epithelial and cortical region (Sethna 1982). The distribution of total glutathione levels
in human lens shows a twenty-fold difference between that in the nucleus and that in
the outer metabolically active epithelial layer (Reddy et a/1980).

The most significant finding in the current study on lenses was the evidence that
lenticular y-glutamyl amino acid cyclohydrolase activity was highest in the 8 year old
donor (3.93 nmol/h/mg dry weight), half as high in the 15 year old donor (1.94
nmol/h/mg dry weight) and half as much again in the mature and elderly adults (1.02 1.27 nmol/h/mg dry weight).

This trend

has also

been demonstrated for

y-glutamylcysteine synthetase activity in human lens (Sethna

et a/ 1983).

The

synthetase appears to suffer a 16-fold reduction over an 83-year time span, with 85%
of the decrease occurring before 10 years of age.

Glutathione synthetase also

decreases with age in lenses of both the human and rhesus monkey (Sethna et a/
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1983). York (1986) showed that the y-glutamyl amino acid cyclohydrolase activity of
human erythrocytes was 17% lower in older, (that is the more dense population of red
cells equivalent to 12% of the population), when compared with the younger, less
dense group (6% of the population).

Free glutathione levels in normal human lens steadily decrease with age dropping from
a plateau from -3.5 mmoi/Kg lens water at 20 years to half that at 65 years of age. In
human cataract there was a further decrease regardless of age (Harding 1970).

In contrast to these findings the activity of y-GT in "aging" cultured fibroblasts, that is
cells of high passage number, had 8-fold higher activity in very old compared with very
young cells (Bannai 1983). Glutathione content of the old cells was however depleted.
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SUMMARY AND IMPLICATIONS OF FINDINGS

gamma-Giutamyltransferase activity was found to be:
•

1% of the normal range for urine, less than 10% of the lower limit of the normal
range in the serum and approximately 1% of the control activity in cultured
fibroblasts in samples from the two Australian patients who excreted y-glutamyl
compounds,

•

at a level between normal controls and the homozygous affected patients for the
urine of both parents and at the lower limit or below the normal range in their
serum and

•

active as a hydrolase.

17% and 19% of the total y-GT activity in cultured

fibroblasts from 2 controls was due to hydrolase activity and this was absent from
fibroblasts from both the patients deficient in y-GT transferase activity.

gamma-Giutamyl amino acid cyclotransferase activity was found to be:
•

normal in red cells from the two Australian patients who excreted y-glutamyl
compounds and in both of their parents.

gamma-Giutamyl amino acid cyclotransferase activity was also found to be:
•

higher in whole lens compared with lens nucleus;

•

lower in a single lens from a patient with senile cataract compared with that of
donors of a similar age; and

•

decreased in whole lens with maturity of the patient, the activity in an 8 year old
being twice that of a 15 year old and four times that of a group of mature and
elderly adults.

The implications are that:
•

the two Australian patients are homozygous for y-glutamyltransferase deficiency
(McKusick 231950) and their parents are heterozygous for the disorder;

•

the

two

Australian

patients

do

not

have

a

combined

defect

of

y-glutamyltransferase/y-glutamyl amino acid cyclotransferase; and
•

the decrease in human lenticular y-glutamyl amino acid cyclotransferase activity
with maturity, along with reports of a similar decrease in y-glutamylcysteine
synthetase and glutathione synthetase, may be a pattern that is reflected in other
tissues such as the kidney.
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6.1

PHYSIOLOGICAL SUBSTRATES OF THE y-GLUTAMYLTRANSFERASE/
y-GLUTAMYL AMINO ACID CYCLOTRANSFERASE SYSTEM

Part I of this study presented observations on the levels of y-glutamyl compounds and

amino acids, including cystine and cysteine, in human urine and plasma.

The

physiological substrates of renal y-GT and y-glutamyl amino acid cyclotransferase were
inferred from these results.

Chapter 2 focussed on patients with y-GT deficiency. The current findings have been

compared with those of:
•

the American

patient who was

glutathione:cysteine

and

reported

to

excrete

y-glutamylcysteine:cysteine

reduced

(Goodman

glutathione,

et a/ 1971,

Schulman et a/ 1975, Pellefigue et a/ 1976, Goodman personal communication
1984) and
•

the English patient studied by Wright et a/ (1979) and later by Griffith and Meister
(1980) who found moieties of reduced glutathione, y-glutamylcysteine and cysteine
but not free GSH, free y-glutamylcysteine or free cysteine in her urine. They also
obtained

indirect

evidence

for

the

presence

of

GSSG

and

glutathione:y-glutamylcysteine.

The current study showed that urine from the two Australian patients and patient C, the
English

patient who was

again

investigated,

contained

abnormal

levels

of

y-glutamylglutamine and y-glutamyl-a-aminobutyrylglycine (ophthalmic acid), the
disulphides of glutathione and y-glutamylcysteine and the mixed disulphides of
glutathione, y-glutamylcysteine and cysteine, but not of cystine. Freshly passed urine
from

the

Australian

patient

BW

contained

y-glutamylglutamine,

GSH,

y-glutamylcysteine and cysteine as well as the disulphides and mixed disulphides but
not increased amounts of cystine.

From this it has been surmised that GSH,

y-glutamylcysteine and cysteine are likely physiological substrates of y-GT and that the
disulphides of GSH and y-glutamylcysteine and the mixed disulphides of GSH,
y-glutamylcysteine and cysteine are probably artefacts generated by thiol-thiol oxidation
and possibly thiol-disulphide exchange (Jocelyn 1972, Munday 1989).

Chapter 3 presented results from a study on hyperammonaemic patients with inherited

defects of the urea cycle. gamma-Giutamylglutamine was found to accumulate in their

TABLE 6.1
Summary of Findings in Fresh Urine and Plasma from Patient BW with y-Giutamyltransferase Deficiency
Physiological Substrates

Freshly Passed Urine

Normal Levels

Fresh Urine Incubated 4h

Fresh Plasma

Normal Levels

Jlf'TlOI/mmot creatinine

lllTlOI/mmot creatinine

11mol/mmot creatinine

~moi/L

~moVL

Plasma
Interpretation

Free r-Giutamylcysteinylglycine

72

0.3 ± 0.1·

30

<5

1 to 10.7°

Nat increased

r-Giutamyl-a-aminobutyrylglycine

NA

Not reported

NA

NA

NA

Detected

Not reported

NA

<5

0.02- 5.6c

Not increased

y-Giutamylglutamine

51

Not reported

51

3.5

<8d

Low-normal

Free Cysteine

37

Not reported

14

<2.5

1.9 to 16.7•

Not increased

16

3 -17b

23

56

25-70°

Normal

bis(y-Giutamylcysteinylglycine)

29

Not reported

35

BDL

0.1 -1.89c

Glutathione:y-glutamylcysteine

23

Not reported

30

BDL

Not reported

Glutathione:cysteine

52

Not reported

58

Between 3-10

Not reported

1

Not reported

NA

BDL

Not reported

53

Not reported

50

7.3

3.1 & 4.0"

Normal

Various b

No change

Cit, Val, Leu, lie,
Phe & Tyr

Table 2.10

Free r-Giutamylcysteine

Unconfirmed Physiological Substrate
Cystine

Uncertain or Unlikely Physiological Substrates

bis(y-Giutamylcysteine)
y-Giutamylcysteine:cysteine

Amino acids other than cysteine and cystine

Not increased
Possibly increased
?derived from GSH & Cys
Post-prandial sample

-

Abbreviations:

BDL - below detection limit
• Aebi et a/1991
b Parvy et a/1988

NA - not analysed
c references Section 1.2.2

d

Section 3.3.3

• results and references Section 2.4.3
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plasma but the level of y-glutamylglutamine in their urine, if present, was below the
detection limit of the methods used (<5 1!mol/mmol creatinine). The opposite situation
was found in patients with another inherited defect of phenylalanine hydroxylase
deficiency (Chapter 4). They excreted y-glutamylphenylalanine but no increase was
found in plasma.

Table 6.1 contains a summary of the data from Section 2.4.3 obtained on a freshly

passed urine sample, aliquots of that urine incubated at
plasma sample from patient BW with y-GT deficiency.

3rc

for four hours and a

These observations are

important. They provide the best information so far available about thiols excreted in
this disorder and form the basis for the inferences drawn in this study.

6.1.1

Physiological Substrates of y-GT in Urine

It is likely that some previous results on patients with y-GT deficiency have led to
conflicting findings because the metabolites of particular interest are unstable. In this
section the evidence for particular compounds in urine being physiological substrates of
renal y-GT is summarised.

Glutathione

GSH was the major abnormal compound excreted by one of the Australian patients
with y-GT deficiency (71 f.tmol/mmol creatinine) and the American patient, for whom
comparative quantitative data is not available (Goodman et a/ 1971).

GSH is

considered to be the most important physiological substrate of renal y-GT in humans.
Experimental results of Schulman et a/ (1975) showed that [35 s]glutathione was an
excellent in vitro substrate in cultured human fibroblasts and that their American patient
was deficient in y-GT activity using [35S]glutathione as the substrate.

Cysteine

As far as can be ascertained this study contains the first in vivo evidence that cysteine
is a physiological substrate of human renal y-GT and the first report of an inherited
disorder causing cysteinuria in humans. Urinary cysteine, of at least 37 J.Lmol/mmol
creatinine, was found in freshly excreted urine from BW (Section 2.4.3).

When

conditions in the bladder were "reproduced and extended" experimentally, this urine
sample contained 60% less GSH and cysteine and more cystine and disulphides,
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The cysteine level did not

increase from reduction of cystine by GSH.

Griffith and Meister (1980) found cysteine conjugated to other species, but not free
cysteine, in the urine samples from patient C. They regarded the increased excretion
of cysteine moiety in human y-GT deficiency as indicating the physiological function of
y-GT but they did not discuss the prospect of cysteine itself being a physiological
substrate for human y-GT, even though indirect evidence obtained from in vitro studies
on the enzyme purified from rat indicated that this was possible (Thompson & Meister

1975, Thompson & Meister 1976).

The involvement of y-GT in transpeptidation of extracellular cysteine may have been
overlooked when Meister (1988) discussed unpublished data on mouse kidney in which
y-glutamylcysteine synthetase was virtually completely inhibited.

Extracellular

[35S]cyst(e)ine, but not [1 4C]glutamate, was reported to be incorporated into kidney
GSH. Meister did not suggest that y-glutamylcysteine might be formed directly by y-GT
transpeptidation of cysteine.

Cystine

No evidence was found in the current study to support the proposal that cystine is an
important in vivo substrate of y-GT.

However cystine is undoubtedly an in vitro substrate for human y-GT. Schulman et a/

(1975) found that cystine was an acceptor in their in vitro assay of y-GT activity with
normal human cultured skin fibroblasts. The cells from the American patient with y-GT
deficiency gave no detectable activity with cystine as the acceptor. Activity with the
enzyme isolated from human kidney was 79% as active with cystine as the most active
acceptor substrate glycylglycine (Shaw et a/1978).

Meister (1988) considered cystine an important physiological substrate of the enzyme
and showed the transpeptidation of cystine with GSH specifically in illustrations of the
"y-glutamyl" cycle (Figure 1.2 facing page 17). The knowledge that cystine was an
excellent in vitro substrate for y-GT (Thompson & Meister 1975, Thompson & Meister

1976, Thompson & Meister 1977) and that cysteine was a low-level intracellular
metabolite (Bannai 1983), may have influenced him and this opinion has persisted until
the present (Meister & Larsson 1995).
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Not withstanding this, significant elevations of urinary cystine, that is elevations
comparable with those of the other disulphides excreted, were not found in the three
patients with y-GT deficiency in the current study, nor in other reports of this disorder
(Schulman et a/1975, Wright et a/1979, Griffith & Meister 1980). In fact, only slightly
elevated cystine levels were obtained in stored urine from both Australian patients
(Section 2.3.3), while a normal level was found in a freshly excreted sample from BW
(Section 2.4.3). These results would be consistent with normal cystine excretion plus
some thiol-thiol oxidation of cysteine. Either cystine is not an important physiological
substrate of renal y-GT or some other factor or factors have influenced its excretion.

One factor that may have led to the absence of "cystinuria" in y-GT deficiency is the
highly effective transport system for cystine normally present in the human proximal
tubule.

Reabsorption of cystine from the glomerular filtrate is known to be sodium

dependent and linked with transport of lysine, ornithine and arginine (Segal & Thier
1995). Classical cystinuria is an inherited renal transport defect in humans resulting in
excretion of cystine, lysine, ornithine and arginine and affecting 1 in 16,000 of the
Australian population (Wilcken et a/1980). Levels of cystine excretion in homozygous
affected patients range from between 110 - 530
data, N

= 120).

~-tmol/mmol

creatinine (unpublished

These levels are up to 50 times those found in patients with y-GT

deficiency. It is quite possible that this transport system dominates in the renal tubule
and effectively reabsorbs all of the cystine present in the glomerular filtrate in patients
with y-GT deficiency, thus masking the loss of enzyme activity.

qamma-Giutamylcysteine

gamma-Giutamylcysteine was detected in freshly excreted urine from BW and the total
y-glutamylcysteine level was elevated in both KW and BW.

This indicates that

y-glutamylcysteine may be a physiological substrate of renal y-GT in humans, although
it could have been formed from carboxypeptidase activity on GSH.
Carboxypeptidase

y-Giutamylcysteinylglycine

4

y-Giutamylcysteine + Glycine

Tate and Meister (1974) found that y-glutamylcysteine was an in vitro substrate for y-GT
purified from rat kidney, giving 77% of the activity expressed with the most active
substrate y-glutamyl donor, y-glutamylglutamine.

Griffith and Meister (1980) had shown that y-glutamylcysteine conjugated to other
species, but not free y-glutamylcysteine, was present in urine from the English patient
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They suggested "that the physiological function of y-GT is

associated with the metabolism or transport (or both)" of the y-glutamylcysteine moiety,
but were unclear as to whether the reduced and/or oxidised form might be the actual
physiological substrate.
Glutathione:y-qlutamylcysteine. y-Giutamylcysteine:cysteine and
bis(y-Giutamylcysteine)
On the basis of findings in the current study glutathione:y-glutamylcysteine and
bis(y-glutamylcysteine) do not appear to be important physiological substrates of y-GT.
Rather their presence in the urine of all three patients studied with y-GT deficiency,
probably reflects in vitro changes due to thiol-thiol oxidation. The evidence related to
y-glutamylcysteine:cysteine is less clear and this will be discussed separately in
Section 6.1.2.

Ophthalmic acid

In the current study, the positive identification of y-glutamyl-a-aminobutyrylglycine
(ophthalmic acid), a non-thiol analogue of glutathione, in the urine of the two Australian
patients with y-GT deficiency was a surprising new finding.

This compound had not

been identified in human tissues other than lens.

On the basis of the current results ophthalmic acid may be considered a physiological
substrate of y-GT in the human kidney. Evidence from a report by Tate and Meister
(1974) showed that y-glutamyl-a-aminobutyrylglycine and GSH had similar in vitro
activities as y-glutamyl donors for the rat kidney y-GT.

qamma-Giutamylqlutamine

All three patients with y-GT deficiency excreted y-glutamylglutamine, whereas a sub-set
of the hyperammonaemic patients with elevated levels of plasma y-glutamylglutamine,
but with documented or presumed normal y-GT activity, had urinary levels below the
detection limit of the method (<5 J.Lmol/mmol creatinine). These findings indicate that
y-glutamylglutamine is a newly identified, physiological non-thiol substrate of y-GT.

It is interesting to note that despite the high levels of y-glutamylglutamine in plasma, no
5-oxoprolinuria was detected in any hyperammonaemic patient studied. It may be that
the 5-oxoprolinuria was present but below the high analytical detection limit (230
J.Lmol/mmol creatinine) or the load of y-glutamylglutamine in the renal tubule was fully
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hydrolysed by y-GT to glutamate and glutamine or that y-glutamylglutamine participated
in a y-GT transferase reaction such that the capacity of the y-glutamyl amino acid
cyclotransferase and 5-oxoprolinase were not exceeded.

The importance of y-glutamylglutamine in renal ammonium metabolism is yet to be
established.

qamma-Giutamylphenylalanine

In the present study untreated patients with phenylalanine hydroxylase deficiency and
presumed normal renal y-GT activity, excreted y-glutamylphenylalanine when their
plasma phenylalanine levels were >1250 J..lmoi/L. The level of y-glutamylphenylalanine
in plasma was below the detection limit of the method, that is <5 J..lmoi/L.

These

findings agreed with those of two previous studies (Peck & Pollitt 1979, Kamerling eta/
1980).

The y-glutamylphenylalanine excretion cannot yet be attributed to a failure of y-GT
hydrolysis or transpeptidation activity in this or previous reports, because its presence
has not yet been confirmed in plasma.

Further investigation would be required to

determine whether y-glutamylphenylalanine is a physiological substrate of y-GT.

gamma-Giutamylornithine

gamma-Giutamylornithine has been identified and quantified in normal urine (Lou
1975, Roesel et a/1984) with levels up to 0. 79 ,...mol/mmol creatinine in children. It was
also isolated from urine from patients with HHH syndrome and patients with gyrate
atrophy associated with hyperornithinaemia (Roesel et a/ 1984). The levels obtained
were between 1.47 and 7.57 J..Lmol/mmol creatinine, that is 10-15 times normal, and did
not correlate with ornithine excretion. When a 100 mg/Kg load of ornithine was given
to one affected patient, the excretion of y-glutamylornithine increased by a factor of
three.

gamma-Giutamylornithine excretion, like the case of y-glutamylphenylalanine, cannot
yet be attributed to a failure of y-GT hydrolysis or transpeptidation activity because its
presence has not yet been confirmed in plasma. Further investigation is required to
determine this.
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General Amino Acids

In the present study on the English and two Australian patients with y-GT deficiency, no
evidence for a generalised defect of amino acid transport was obtained. This agrees
with three previous reports on patients with y-GT deficiency (Goodman et a/ 1971,
Schulman et a/1975, Wright et a/1979) that focussed particularly on this aspect. Thus
the proposal by Orlowski & Meister (1970) that y-GT might be involved as part of a
system for general amino acid transport, at least in the kidney, has not been fulfilled.

It is quite possible that, as may be the case with cystine, the renal transport systems for
the other amino acids also dominate in the tubule and effectively mask the effect of
reduced y-GT activity in all four reported patients with the enzyme deficiency.

6.1.2

Physiological Substrates of y-GT in Plasma

Part I of the current study also presented findings of y-glutamyl compounds in plasma
from one of the Australian patients with y-GT deficiency, patients with inherited defects
of the urea cycle and another group with phenylalanine hydroxylase deficiency.

Results from a plasma sample obtained from one of the two patients with y-GT
deficiency (Section 2.4.3) showed that there was no apparent elevation of free GSH.
Nor were the free cysteine, free y-glutamylcysteine, y-glutamylglutamine or cystine
increased. gamma-Giutamylcysteine:cysteine, a newly-recorded metabolite in plasma,
was marginally higher in BW than in two normal adults.

Glutathione:cysteine was

detected but not necessarily increased. The quantification of y-glutamylglutamine in
this plasma sample is more reliable than that of the thiols because y-glutamylglutamine
is a stable compound.

It does not require any of the special precautions in sample

handling recommended for thiols (Section 1.2.2) and it runs as a discrete peak
(Section 2.3.2).

The low-normal result for y-glutamylglutamine (3.5 J..Lmoi/L, reference range <8 J..Lmoi/L)
indicates that this physiological substrate of renal y-GT in humans behaves according
to a common pattern of renal reabsorption. It has a high renal threshold (Chapter 3),
and is not elevated in plasma when the renal threshold is lowered, as it is in renal y-GT
deficiency.
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The contrasting findings of:
•

elevated levels y-glutamylglutamine in plasma but undetectable y-glutamylglutamine
in urine (<5 11mol/mmol creatinine) from patients with urea cycle defects (Chapter

3) along with
•

the very low levels of y-glutamylphenylalanine and y-glutamylornithine in plasma but
slight to moderate excretion of both in urine (Chapter 4, Kamerling et a/1980, Peck
& Pollitt 1979, Lou 1975, Roesel et a/1984)

reveal the complex nature of the y-GT/y-glutamyl amino acid cyclotransferase system.
In this section the evidence for particular compounds in plasma being physiological
substrates of renal y-GT is summarised.

Glutathionaemia

Glutathionaemia in r-GT deficiency Glutathionaemia has been claimed as a hallmark

of y-GT deficiency in the two patients reported previously (Meister & Larsson 1995) and
in animal experiments in which in vivo inhibition of the enzyme was induced (Griffith &
Meister 1979b, Griffith & Meister 1980). However it is difficult to assess the metabolic
basis for these increases in plasma total glutathione. Schulman eta/ (1975) suggested
that it may be caused by GSH leakage from cells.

It appeared important to reconsider the previous findings on two counts.

Firstly the

stable non-thiol substrate of y-GT, y-glutamylglutamine, was not elevated in the plasma
from BW. Secondly the glutathionaemia reported in the American and English patients
was relatively modest when compared with the elevated levels of plasma amino acids
seen in other generalised enzyme defects and glutathionaemia in the presence of
constant gross renal loss of glutathione would normally infer some renal overload effect
(Bremer et a/1981).

Extensive literature relating to the sensitivity of plasma thiols to pre-analytical variables
(Section 1.2.2) indicates that attention to detail is probably the most critical factor in

their quantification. Differences between the apparent level in the patients and their
respective control population may be artefactual.

Plasma total glutathione levels, analysed by the glutathione reductase (EC 1.6.4.2)
recycling method of Tietze (1969), were reported for:
•

one plasma with a level of 7.9 11moi/L and on one serum sample with a level of 4.6
11moi/L from the American patient (control plasma range 1.1 - 1. 7 llmoi!L,
N=4)(Goodman

et a/1971, Schulman et a/1975) and
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one plasma with a level of 20.8 f..Lmoi/L from the English patient (control range 9.1 16.9 f..Lmoi/L, N=9)(Wright et a/1979).

The levels of total glutathione (4.6 and 7.9 f..Lmoi/L) obtained for the American patient
with y-GT deficiency do not appear high when compared with a reference range (0.128.88 f..Lmoi/L, N=30) obtained by Chawla et a/ (1984) using the same analytical method
and with the reference ranges reported by other analysts using separative techniques

et a/ 1978, Martensson 1987, Aebi et a/
1991, Mansoor et a/ 1992a, de Quay et a/ 1992, Witschi et a/ 1992, Andersson et a/

for analysing plasma total GSH (Hagenfeldt

1993).

However the levels reported for the control population for the level on the

American patient are comparatively low (1.1 - 1.7 f..Lmoi/L, N=4).

Schulman

eta/ (1975) describe that "serum samples were promptly deproteinized with

sulphosalicyclic acid (65 mg/ml) and all samples were stored at -20°C". Although rapid
acidification of the sample may protect thiols to some extent, the serum cystine was
reported as "not detected", indicating that artefactual loss had occurred prior to
acidification. Delay in handling the samples from the control population may therefore
have caused the low range of results for the controls (Griffith 1985).

The result for plasma total glutathione on the English patient (20.8 f..Lmoi/L) and the
control range (9.1 - 16.9 J.tmoi/L) are significantly higher than any other reported
reference range for total glutathione with the highest being up to 10.7 J.tmoi/L (de Quay

et a/1992). The reason for this difference is not apparent. No special sample handling
procedures were described.

Even so, the level for patient C was slightly increased over and above the high range
of the controls.

This may have been due to haemolysis of the patient's sample.

Wendel & Cikryt (1980) noted that the analysis of plasma GSH was particularly
susceptible to contamination from haemolysis of erythrocytes. Haemolysis of just 2 f..LL
erythrocytes, containing GSH at -2.8 mmoi/L (Hagenfeldt et a/ 1978), in 1 mL of
plasma could increase the plasma GSH by 5 J.tmoi/L. This level of haemolysis is not
readily detectable by eye and may not be uncommon in a traumatic venipuncture from
an uncooperative patient.

Glutathionaemia in Normal Adults

Glutathionaemia has been artificially induced in

pharmacokinetic studies on 10 normal adults (Aebi

et a/1991). An intravenous bolus of

2 g/m2 of GSH was given and the half-life of GSH in the circulation was -15 minutes.
The plasma total GSH increased to 823 ± 326 f..Lmoi/L (mean ± SD). The urinary total
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GSH increased -300-fold but this represented only 0.8% of the administered dose
indicating the significant capacity of human renal y-GT for GSH hydrolysis and/or
transpeptidation.

Glutathionaemia in In Vivo Animal Experiments

Glutathionaemia was reported in the in vivo animal experiments conducted by Griffith
et at (1978), Griffith and Meister (1979b) and Griffith and Meister (1980), when the

inhibition of y-GT was induced.

Two points are particularly relevant to the current

discussion of glutathionaemia in humans with y-GT deficiency.

Firstly there are species differences in the handling of GSH between humans, mice and
rats.

This is indicated, for example, by the baseline levels of total glutathione in

plasma from mice being 30- 35

~-tmoi/L,

8 to 12 times that in humans (Griffith 1985),

and the difference between the preference of y-GT from human kidney for glutamine as
a y-glutamyl acceptor relative to other amino acids as compared with the rat kidney
enzyme (Tate & Ross 1977).

Secondly reports by Anderson and Meister (1980), Anderson et at (1980) and Anderson
and Meister (1986) inferred that the analysis of total glutathione may be subject to
sporadic variables such as haemolysis of the sample, abdominal pressure causing an
artificial increase and secondary effects from use of a potent inhibitor.

Haemolysis The findings on rat and mouse plasma may have been influenced by

haemolysis, because Griffith and Meister (1979a) comment on "applying a correction"
for plasma total glutathione when haemolysis in their samples reached 0.02 - 0.04%,
whereas later work by Anderson and Meister (1980) and Anderson et at (1980) reported
that they limited their data more stringently to samples containing <0.02% haemolysis.

Effect of Abdominal Pressure on Mice Anderson and Meister (1986) suggested that

moderate abdominal pressure was sufficient to increase plasma total glutathione in
mice. In order to avoid this, they conducted experiments on different sets of animals
when both plasma total glutathione analysis and urine collections were required.
Presumably some of the data predating this publication and involving simultaneous
plasma and urine collections may include spurious results.

Effect of y-GT Inhibitors Anderson and Meister (1986) comment of the toxic affect L-

and 0-y-glutamyl-(o-carboxy)phenylhydrazide, two effective inhibitors of y-GT used in
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much of the early work (Griffith & Meister 1979a, Griffith et a/ 1979b).

These

y-glutamyl compounds would be hydrolysed by y-GT in the initial stages of inhibition
experiments to form o-carboxyphenylhydrazine, a compound fatal to mice at high
doses and presumably having a milder but significant effect on the liver at lower doses.

The toxicity of y-GT inhibitors themselves suggests that the metabolic consequences of
experimentally induced y-GT deficiency are likely to be complex and not confined to
the inhibition of a single enzyme. Leakage of intracellular metabolites, as well as GSH,
into plasma may have occurred. If so, then generalised membrane failure may have
been responsible for glutathionaemia and glutathionuria in these reports.

gamma-Giutamylcysteine

The level of y-glutamylcysteine in plasma from BW was below the detection limit of the
method used in the current study {<5 J.l.moi/L) and probably not elevated when
compared with levels in normal patients. Reported ranges for normal controls vary
from 2.4 - 5.6 J.tmoi!L (Hagenfeldt et a/1978) and 1.3 - 2.1 (Martensson 1987) to 0.02 0.1 J.l.moi/L (Andersson 1993).

gamma-Giutamylcysteine:cysteine

Evidence for the identity of y-glutamylcysteine:cysteine in plasma is strong and
includes two recovery experiments (Sections 2.4.2 and 3). The mixed disulphide of
y-glutamylcysteine and cysteine was detected in BW (7.3 J.l.moi/L) and was slightly
increased over that found in two normal plasma samples, one capillary (3.1 J.tmoi!L)
and one venous (4.0 J.l.moi/L).

gamma-Giutamylcysteine:cysteine may have been disregarded previously because it
eluted at the buffer change from A to C on the routine Beckman 6300 program. In the
sample from BW, an unusual increase in the height of the buffer front was noted during
post-run analysis.

This observation was followed up by an investigation using the

extended program for buffer A.

Plasma y-glutamylcysteine:cysteine may arise from thiol-thiol oxidation of free GSH
and free cysteine [reaction 1], followed by carboxypeptidase activity [reaction 2]. This
being so, then the in vivo levels of GSH and cysteine would have been at least 7.3
J.l.moi/L and be considered normal levels for GSH (Table 1.2 facing page 4) and for
cysteine (Aebi et a/1991, Mansoor et a/1992a, Mansoor et a/1992b).
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[1]

Glutathione: cysteine

y-Giutamylcysteinylglycine + Cysteine
Carboxypeptidase

Glutathione: cysteine

---+

[2]

y-Giutamylcysteine:cysteine + Glycine

y-Giutamylcysteine + Cysteine

---+

[3]

y-Giutamylcysteine: cysteine

Plasma y-glutamylcysteine:cysteine may also be the product of thiol-thiol oxidation of
free y-glutamylcysteine and free cysteine [reaction 3]. In this case the original in vivo
level of 7.3 J.l.moi/L it would be higher than any previously reported range for
y-glutamylcysteine (Hagenfeldt

et

a/1978, Martensson 1987, Andersson 1993) but it

could have been enhanced by carboxypeptidase activity on free GSH {Griffith &
Meister 1980). Further investigation would be required to resolve this.

gamma-Giutamylglutamine

gamma-Giutamylglutamine was found to be grossly elevated in plasma from patients
with hyperammonaemia due to a urea cycle defects (Hammond
to

the

findings

on

patients

with

y-GT

deficiency,

the

et al1990). In contrast
renal

threshold

for

y-glutamylglutamine by y-GT in patients with normal activity was not exceeded by
levels up to 188 J.l.moi!L in plasma.

The level of plasma y-glutamylglutamine in normal patients is <8 J.l.moi/L and therefore
the renal load appearing after filtration at the glomerulus may be similar to that of GSH.
Levels of both plasma y-glutamylglutamine and GSH may vary and depend on whether
the patient is fasting or post-prandial.

6.2

THE PHYSIOLOGICAL ROLE OF THE y-GLUTAMYLTRANSFERASE/y-GLUTAMYL
AMINO ACID CYCLOTRANSFERASE SYSTEM IN THE HUMAN KIDNEY

The current study has shown that the physiological substrates of human renal y-GT now
include three that had not been previously apparent, namely y-glutamylglutamine,
y-glutamyl-a-aminobutyrylglycine (ophthalmic acid) and cysteine.

The physiological

role of the y-GT/y-glutamyl amino acid cyclotransferase enzyme system may be
reassessed in the light of this.

Much of the previous work on y-GT and y-glutamyl amino acid cyclotransferase,
published in the 1970's and early 80's, did not succeed in fully defining the
physiological role of this enzyme system. The model that predominated was that of the
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"y-glutamyl cycle", as described by Meister in 1988 (Figure 1.2 facing page 17). This
model has been extraordinarily successful in conveying aspects of GSH synthesis and
degradation. Not with standing this there are inconsistencies in some aspects of the
model as shown below:
(i) y-GT is involved in transport of amino
acids

(i) y-glutamyl amino acids without a free
a-carboxyl group on the second amino
acid residue are not substrates for the
intracellular y-glutamyl amino acid
cyclotransferase (Szewczuk & Connell
1975 and
amino acids may not generally be
transported across plasma membranes
via y-GT activity (Pellefigue

(ii) y-glutamylcysteine:cysteine is a

et a/1976)

(ii) y-glutamylcysteine:cysteine is not a

proposed major product of y-GT

particularly active substrate for

metabolism

glutathione reductase (Griffith 1985).

The model may have placed undue emphasis on the transferase reaction of y-GT with
GSH as the donor and amino acids, including cystine, as the acceptor substrates
(Anderson & Meister 1983, Meister 1988, Meister & Larsson 1995).

Other workers considered this dominance of the transferase reaction in the literature of
the "y-glutamyl cycle" to be inappropriate. Instead they thought that the main function
of y-GT, in the kidney in particular, was the hydrolysis of compounds containing a
y-glutamyl group, including GSH and S-conjugates of GSH (a step in the mercapturic
acid pathway), and the transport of the products into renal cells (Orlowski & Wilk 1975,
Orlowski & Wilk 1976, Elce & Broxmeyer 1976, Mcintyre & Curthoys 1979).

Their

reports emphasised that the extracellular environment of the renal tubule has a pH
around 7, the optimum for in vitro y-GT hydrolytic activity. In contrast the pH optimum
of the transferase reaction in vitro was between pH 8 and 9.

Resolution of this debate seems important, because the transferase reaction of y-GT
supplies products to the cell that are potential substrates for y-glutamyl amino acid
cyclotransferase and for glutathione synthetase.

The hydrolase reaction provides

potential substrates for y-glutamylcysteine synthetase.

During the current study the

findings in urine and plasma led to a re-evaluation of the role of y-GT and y-glutamyl
amino acid cyclotransferase metabolism in the metabolism of GSH and cystine. This
revised perspective will be considered in the following sections.

FIGURE 6.1
Reactions of y-Giutamyltransferase and y-Giutamyl Amino Acid Cyclotransferase with
the Probable Physiological Substrates y-Giutamyi:X, y-Giutamyl-y-glutamyi:X and
Cysteine in Humans

Hydrolase Reaction of :y-GT

y-glutamyltransferase

y-Giutamyi:X + H2 0

Glutamate+ X

Transferase Reaction of :y-GT

y-glutamyltransferase

y-Giutamyi:X + Cysteine

B

y-Giutamylcysteine + X

Autotransferase Reaction of :y-GT

y-glutamyltransferase

2 y-Giutamyi:X

---+

y-Giutamyl-y-glutamyi:X + X

Reactions of :y-Giutamyl Amino Acid Cyclotransferase

y-glutamyl amino acid cyclotransferase

y-Giutamyi:X

5-0xoproline + X

---+

y-glutamyf amino acid cyc1otransferase

y-Giutamylcysteine

5-0xoproline + Cysteine

---+

"[-glutamyl amino acid cyclotransferase

y-Giutamyl-y-Giutamyi:X

---+

5-0xoproline + y-Giutamyi:X
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6.2.1

The Interrelationship Between y-Giutamyltransferase and y-Giutamyl Amino Acid
Cyclotransferase

The present findings suggest that y-GT has a significant role in the salvage of
y-glutamyl

compounds,

including

GSH,

y-glutamyl-a-aminobutyrylglycine,

y-glutamylglutamine and possibly y-glutamylcysteine as well as cysteine from the
glomerular filtrate and it is likely that the y-glutamyl amino acid cyclotransferase acts on
the y-glutamyl products of the transferase reaction of y-GT. The role of this enzyme
system in transport and recycling of thiols must now be extended beyond the
degradation of GSH alone as portrayed by Meister (1988) and illustrated in Figure 1.2
(facing page 17).

Current findings suggest that, for the time being, human renal y-GT may be regarded
as:
•

not being involved in the transport of general amino acids;

•

hydrolysing y-glutamyl amino acids, y-glutamyl peptides and other y-glutamyl
compounds such as glutathione S-conjugates,

•

using cysteine, not cystine, as acceptor and employing y-glutamyl compounds
as donors for its transpeptidation and

•

having some role in renal ammonium metabolism via y-glutamylglutamine.

Figure 6.1 summarises the equations incorporating the proposed physiological

substrates in the hydrolase, transferase and auto-transferase reactions and the
reactions of y-glutamyl amino acid cyclotransferase on the products.

The present findings support (and extend) the proposal of Orlowski, that y-glutamyl
compounds are important physiological substrates of renal y-GT (Orlowski & Wilk 1975,
Orlowski & Wilk 1976). Their data from in vivo experiments on mice showed that the
kidney was highly active in the uptake of y-glutamyl derivatives of amino acids, such as
L-y-[14C]glutamyi-L-2-aminobutyrate, with rapid incorporation of the label into renal
glutamate, glutamine and aspartate indicating hydrolysis by y-GT. They proposed that
"both the hydrolytic and y-glutamyl transfer reactions catalysed by y-GT are active in
the renal handling of y-glutamyl compounds".

The authors went on to show that a

synthetic y-glutamyl derivative of dihydroxyphenylalanine could be used as a carrier, or
pro-drug, of dopamine and that this y-glutamyl compound would specifically target the
kidney

(Orlowski

&

Wilk

1978,

Wilk

et

a/

1978).

Trials

of

Possible Metabolic Consequences of Incorporating Cysteine into the
y-Giutamyltransferase Pathway in the Human Kidney
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L-y-glutamyi-L-3,4-dihydroxyphenylalanine have since been successfully conducted on
humans (Worth et a/1985, MacDonald et a/1989, Cummings et a/1990).

The hydrolytic reaction of renal y-GT has also been the basis for the design of peptides
for

improved

intravenous

feeding

mixtures.

gamma-Giutamyltyrosine

and

y-glutamylglutamine, two heat-stable and soluble y-glutamyl compounds, have been
incorporated into intravenous solutions to overcome the disadvantages of the relatively
insoluble amino acid tyrosine and the unstable amino acid glutamine (Hilton et a/1991,
Futuka & Hara 1990).

6.2.2

The Role of Cysteine in the Renal y-Giutamyltransferase/y-Giutamyl Amino Acid
Cyclotransferase System

Figure 6.2 illustrates the consequences of incorporating cysteine into the pathway as a
physiological acceptor for y-GT.

Extracellular cysteine and GSH or y-glutamyi:X, where X may be any y-glutamyl amino
acid, y-glutamyl peptide, glutathione S-conjugate or a synthetic compound such as
y-glutamyi-L-3,4-dihydroxyphenylalanine, are presumably provided from the glomerular
filtrate.

Hydrolysis of GSH,

y-glutamyl-~-aminobutyrylglycine,

y-glutamylglutamine,

y-glutamylcysteine or y-glutamyi:X may occur or these may act as y-glutamyl donor for
the transferase.

Newly-formed y-glutamylcysteine is potentially a major y-glutamyl product with cysteine
as the acceptor and it may be translocated into the renal epithelium to participate
directly in the second and final step of GSH synthesis [reaction 1]. The Km for GSH is
lower than that for y-glutamyl amino acid cyclotransferase [reaction 2] (Smith et a/
1980) so that only excess y-g/utamylcysteine would be degraded.
Glutathione synthetase

y-Giutamylcysteine + glycine

~

-Giutamylcysteinylglycine

[1]

or
y-glutamyl amino acid cyclotransferase

y-Giutamylcysteine

The conventional

~

5-0xoproline + Cysteine

pathway for the

metabolism

(2]

and transport

of GSH

and

y-glutamylcysteine:cysteine in the kidney is shown in Figure 6.3, that has been taken
from Anderson & Meister (1983) and based largely on in vivo experiments on animals.
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FIGURE 6.3
Metabolism and Transport of Glutathione and y-Giutamylcystine by the Kidney
Anderson and Meister 1983
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1,
Synthesis of y-glutamylcysteine from glutamate and cysteine by y-glutamylcysteine
synthetase; 2, synthesis of GSH from y-glutamylcysteine and glycine by GSH synthetase; 3,
reduction of GSSG by GSSG reductase; 4,
reduction of y-glutamylcystine by
transhydrogenation with GSH; 5, feedback inhibition of y-glutamylcysteine synthetase by
intracellular GSH; 6, transport of GSH out of the cell; 7, transport of y-glutamylcystine into cell;
8, formation of y-glutamylcystine from GSH and cystine by y-glutamyltranspeptidase; 9,
inhibition of transport of y-glutamylcystine by high levels of extracellular GSH.
y-Giutamylcyst(e)ine is also a substrate of y-glutamylcyclotransferase that would convert it to
cyst(e)ine and 5-oxoproline.

Figure 6.3 shows GSH efflux from the renal cell, a mechanism that may or may not

occur in humans. On the outside of the membrane, y-GT [enzyme 8) catalyses the
reaction of GSH with cystine to form y-glutamylcysteine:cysteine, that is then
translocated into the cell.

The mixed disulphide is shown as being reduced by

thiol-disulphide exchange with GSH intracellularly (the current study showed that this
reaction may have occurred extracellularly in the follow-up study on fresh urine from
BW in Section 2.4.3).
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lnterorgan turnover of cysteine itself as well as the interorgan turnover of glutathione,
particularly from the liver to kidney via the blood in humans, may be important
mechanisms to conseNe systemic cysteine and may have nutritional significance.
Figure 6.4, taken from the review by Tateishi and Sakamoto (1983), illustrates the

interrelationships between methionine, cysteine and GSH in the liver. Methionine is an
essential amino acid for growth and is the metabolic source of cysteine in humans.
The nutritional requirement for methionine would be lowered (Tateishi & Sakamoto
1983, Deneke & Fanburg 1989) if cysteine and GSH are both recycled by the renal
y-GT.

Depleted GSH stores in the liver may be the trigger for replenishment of

cysteine via methionine degradation.
FIGURE 6.4
Interrelationship of Methionine, Cysteine and Glutathione in Liver
Taken from Tateishi and Sakamoto 1983
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6.2.3

The Role of the y-Giutamyltransferase/y-Giutamyl Amino Acid Cyclotransferase
System in Glutamine Metabolism

The role of y-GT and y-glutamyl amino acid cyclotransferase in the renal metabolism of
glutamate and glutamine warrants further investigation. It is not clear from the current
findings why plasma y-glutamylglutamine is elevated

in

patients with

gross

hyperammonaemia due to a urea cycle defect but with otherwise normal liver function
(Section

4.2.3)

and

yet

not

necessarily

elevated

hyperammonaemia due to a secondary cause (Hammond

in

other

patients

with

et a/1990).

At least three factors may influence the level of y-glutamylglutamine in plasma:
• y-glutamylcysteine synthetase activity in the liver,
• acid-base homeostasis and
• glutaminase activity by y-GT.

There was a strong correlation between the levels of y-glutamylglutamine and
glutamine in plasma from the patients with hyperammonaemia due to urea cycle
defects (Chapter 4).

If y-glutamylglutamine in plasma originates from liver

y-glutamylcysteine synthetase activity, then the level in plasma may reflect that aspect
of liver function.

Elevated y-glutamylglutamine and elevated plasma glutamine, as

seen in the group of patients with primary hyperammonaemia but otherwise normal
liver function, may indicate appropriate y-glutamylcysteine synthetase activity in the
liver. Lack of an increase in plasma y-glutamylglutamine, but with elevated plasma
glutamine, in patients with secondary hyperammonaemia may reflect diminished or
under developed capacity of liver y-glutamylcysteine synthetase and possibly reduced
liver function particularly in perivenous hepatocytes, where glutamine synthetase is
expressed (Souba 1992).

Metabolic acidosis may or may not be present in patients with hyperammonaemia. It
may be one factor influencing the level of plasma y-glutamylglutamine in patients with
secondary hyperammonaemia. lnterorgan transfer of glutamine from the liver to the
kidney is important. Glutamine nitrogens account for two-thirds of the ammonium ion
excreted by the kidneys and therefore glutamine has a central role in acid-base
homeostasis (Souba 1992). This role becomes critical in metabolic acidosis, where the
greater the acidosis, the greater the rate of glutamine production in response.
Glutamate may be diverted from synthesis of y-glutamylcysteine and GSH in the liver
to supply hepatic glutamine synthetase activity.
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The strong correlation between the levels of y-glutamylglutamine and glutamine in the
group of patients with primary hyperammonaemia could result from a combination of
the glutaminase activity and transpeptidase activity of y-GT in the circulation (Dass
1983, Dass & Wu 1985).
shown in the

reaction

Dass proposed that the y-glutamyl-enzyme intermediate,
below,

could react with

plasma glutamine to form

y-glutamylglutamine.
r-glutamyltransferase

2 Glutamine

----+

y.g\utamyltransferase

y-Giutamyl-enzyme + glutamine
+ NH+4

----+

y-Giutamylglutamine

However this is an unlikely source of the plasma y-glutamylglutamine found in our
patient

with

y-GT

deficiency

y-glutamylglutamine level.

although

it

could

explain

the

low

plasma

It must be supposed then that there are two synthetic

pathways leading to production of the y-glutamylglutamine in the circulation. Further
study will be required to tell if this is so.

lnterorgan transfer of y-glutamylglutamine from the liver to the kidney for excretion as
ammonium ion may be a normal process that becomes important in metabolic acidosis.
However renal salvage of y-glutamylglutamine by y-GT appears self-defeating in
severe primary hyperammonaemia.

6.2.4

Possible Joint Roles for the y-GT Hydrolase and Transferase Reactions

Resolution of the debate as to whether the hydrolase reaction or the transferase
reaction of y-GT dominates in the glomerular tubule has not been achieved in this
study. However the newly-recorded involvement of cysteine and y-glutamylglutamine
in renal y-GT metabolism does indicate that both reactions probably occur.

It would be informative to conduct pharmacokinetic studies on the patients with y-GT
deficiency and a normal control population by loading them intravenously with 2 g/m2
of y-glutamyl-a-aminobutyrate, a non-thiol substrate for y-GT but not y-glutamyl amino
acid cyclotransferase. Hydrolytic activity of y-GT in the control group might result in
increased plasma and urine levels of a-aminobutyrate similar to the increased GSH
and cysteine found in a previous loading study with GSH (Aebi et a/1991). The y-GT
deficient patients might be expected to excrete the y-glutamyl-ex--aminobutyrate
unchanged. Ethical considerations for our patients make this option unavailable.
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SPECULATION

In

the

current

study

it

is

proposed

that

renal

salvage

of

GSH,

y-glutamyl-a-aminobutyrylglycine, y-glutamylcysteine, y-glutamylglutamine and cysteine
for GSH synthesis is a major physiological role of y-GT in humans. The scheme shown
in Figure 6.2 (facing page 127) is based on the assumption that the substrates for y-GT
are normal metabolites present in the glomerular filtrate and indicates that
newly-formed y-gfutamyfcysteine is a major product of y-GT activity.

Plasma as the Source of Urinary Metabolites in y-Giutamyltransferase Deficiency

Plasma is the most likely continuous source of the physiological substrates of y-GT that
reach the glomerular filtrate.

Human plasma contains from 1 to 10.7 f.Lmoi/L GSH

(Table 1.1 facing page 4), from 1 to 6 f.Lmoi!L y-glutamylcysteine (Hagenfeldt et af
1978, Martensson 1987), from 2 to 8 f.Lmoi/L y-glutamylglutamine {Section 3.3.3) and
from 2 to 17 f.Lmoi/L cysteine (Aebi et a/ 1991, Porta et a/ 1991, Witschi et a/ 1992,
Mansoor et a/1992a and 1992b, Andersson et af 1992).

It seems likely that plasma is a major source of the urinary compounds in this disorder.
The proportions of total GSH, total y-glutamylcysteine, y-glutamylglutamine and total
cysteine present in normal plasma, approximately 8:4:5:10, are similar to those found
in urine from the two Australian patients with y-GT deficiency, namely 11:5:4:10 for KW
and 13:6:4:13 for BW. Supportive evidence for this hypothesis comes from calculation
of the approximate renal clearance of GSH in our patient BW, based on a theoretical
plasma GSH level of -5 f.Lmoi/L, that might result in excretion of 90 f.Lmol GSH in 3
hours. Her actual excretion of total GSH over one 3 hour period was 79 f.Lmol (Section
2.4.3).

If the glomerular filtrate is the sole source of the physiological substrates of y-GT, as it
may be in humans, then patients with y-GT deficiency, who excrete approximately 1
mmol GSH and 1 mmol cysteine per mmol creatinine in 24 hours, could become
systemically depleted. The levels obtained in patients with y-GT deficiency may be in
keeping with other reports of short-term or chronic reduction of hepatic GSH reserves.
Loss of glutathione, as a consequence of paracetamol overdose or abuse, results in
lowered plasma GSH (Lauterburg et a/ 1984, Trenti et a/ 1992).

Systemic GSH

deficiency has been documented in symptom-free HIV-seropositive individuals (Buhl et
af 1989), alcoholics (Lauterburg & Velez 1988) and in patients with hepatic cirrhosis
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(Chawla et a/1984, Burgunder & Lauterburg 1987), although the causes have not been
shown.

The Role of y-Giutamyltransferase in the Synthesis of Glutathione

Urinary total GSH and total cysteine were very similar, although the levels were
different, in each of the two Australian patients with y-GT deficiency (Table 2.7). This
indicates that, under normal circumstances, GSH is the major y-glutamyl donor,
cysteine the major acceptor and newly-formed y-glutamy/cysteine the major product of
normal human renal y-GT activity.

The translocation of y-g/utamylcysteine into the

renal epithelium may then bypass the first reaction in intracellular GSH synthesis,
namely the y-glutamylcysteine synthetase reaction, and in doing so conserve ATP.

Evidence for the direct involvement y-GT in GSH synthesis was suggested by results
presented by Anderson and Meister (1983), however their interpretation differed from
that of the present study.

They pretreated mice with an intraperitoneal injected of

buthionine sulphoximine to inhibit intracellular y-glutamylcysteine synthetase and then
administered y-glutamylcysteine (2 mmoi/Kg) subcutaneously.
substantial (3-fold) increases in kidney GSH.

This resulted in

At the time they thought that

y-glutamylcysteine was transported across the lumenal membrane intact.

The proposal from the current study would suggest that any y-glutamylcysteine
reaching the glomerulus would have reacted with cysteine in the glomerular filtrate via
y-GT transpeptidation, forming y-g/utamy/cysteine and be translocated into renal
epithelial cells where it may be converted to renal GSH by the glutathione synthetase.

Further to this, Meister (1988) emphasised findings from another set of experiments on
mice published in conference proceedings. Once again y-glutamylcysteine synthetase
was virtually completely inhibited and there was incorporation of [35S]cyst(e)ine, but not
[14C]glutamate, into GSH.

It was thought that this was consistent with a pathway

involving formation of y-glutamylcysteine:cysteine by y-GT.

Meister suggested that

tumours with high y-GT activity might use this "alternative pathway", that bypassed
y-glutamylcysteine synthetase, for GSH synthesis.

The human kidney, like tumours, has high y-GT activity that has been estimated to be
three times that of the rat kidney (Shaw et a/1978). It is possible that synthesis of GSH
in

human

kidney proceeds via y-GT transpeptidation

activity under normal

circumstances and via the conventional pathway when renal GSH stores have become

The Genetics of y-Giutamyltransferase

lsoenzymes of y-glutamyltransferase isolated from human liver, kidney, pancreas and duodenum
have been demonstrated (Shaw et al 1980).

The authors concluded that the polypeptide

portions of the isoenzyme molecules were similar but that the carbohydrate moieties differ
significantly in structure and topography.

The isoenzyme pattern for normal serum on

electrophoresis (Huseby 1981) showed a band corresponding to y-glutamyltransferase from
liver. It was already known that the enzyme in urine was derived from the kidney (Szasz 1970).

The kinetic properties of the isoenzymes of y-glutamyltransferase were investigated by Shaw et
a! (1980). They found that kidney y-GT was most strongly inhibited by glycylglycine followed by

pancreas, with liver and duodenal isoenzymes only slightly inhibited. Differences between the
other kinetic constants of these isoenzymes were much smaller.

The genetics of y-g\utamyltransferase have recently contributed to our understanding of the
these isoenzymes and the differences between the enzyme activity in the rat and human.
Figlewicz eta! ( 1993) found that, while y-glutamyltransferase in the rat genome is represented by
a single gene, at least four y-glutamyltransferase genomic sequences were identified in humans
and that two of these were localised to two distinct regions of chromosome 22. Following on
from this Courtay eta/ (1994) were able to lciok at segments of seven different potential human
y-glutamyltransferase genes. Five of the seven genes were expressed and four of the five were
expressed in a tissue specific manner, suggesting that their corresponding gene products may
exhibit distinct functions in these specific tissues.

While placental, kidney, pancreatic and

hepatoma messenger RNA are all transcripts of a single gene, that from kidney appears to be
distinct (Pawlak eta! 1989).

With this in mind it is possible that the genomic defect inherited by I<NV and BW is distinct from
that in the English and American patients with y-GT deficiency. The genetics may also account
for the different clinical phenotypes with the Australian siblings appearing to have a milder form
of the disorder.
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acutely depleted.

It is probable that the conventional pathway for GSH synthesis

involving y-glutamylcysteine synthetase may normally apply to tissue with low y-GT
activity such as liver and it is interesting to note that the erythrocyte has no y-GT
activity (Srivastava 1977, Board & Smith 1977) depending exclusively on the
y-glutamylcysteine synthetase/glutathione synthetase pathway for GSH production.

Synthesis of r-glutamylcysteine via y-GT transpeptidation of cysteine does riot conflict
with the proposal of Smith et a/ (1 980) that kinetic partitioning could explain the
presence of two intracellular enzymes, glutathione synthetase and y-glutamyl amino
acid cyclotransferase, each active with the same substrate y-glutamylcysteine (Figure
1.1). They suggested that under normal circumstances the intracellular concentration

of y-glutamylcysteine was low (around 30 f.Lmoi/L in the case of erythrocytes) and
around the Km of glutathione synthetase. This would be the case when systemic GSH
and cysteine levels were high or normal. Transpeptidation of cysteine may provide
sufficient y-glutamy/cysteine for normal renal GSH turnover. When GSH became
depleted, the feedback control on y-glutamylcysteine synthetase would no longer take
affect and activity of y-glutamylcysteine synthetase, using intracellular cysteine, would
be activated. Once the level of y-glutamylcysteine met the requirements of glutathione
synthetase, the excess y-glutamylcysteine would be converted to cysteine and
5-oxoproline via the y-glutamyl amino acid cyclotransferase.
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HIGH VOLTAGE ELECTROPHORESIS AND THIN LAYER CHROMATOGRAPHY OF
y-GLUTAMYL COMPOUNDS

A.1

Background and Objectives of the Study

High voltage electrophoresis was employed in many previous studies involving
y-glutamyl compounds (Kakimoto et a/ 1964, Kanazawa et a/ 1965a, Kanazawa et a/
1965b, Sano et a/1966, Kanazawa & Sana 1967, Reichelt 1970, Lou 1975, Lou & St
Onge 1978, Tanaka & Nakajima 1987, Peck & Pollitt 1979, Roesel

et a/1984).

High

voltage electrophoresis at pH 1.9 had also been the routine system used for screening
urine samples for abnormalities of amino acid excretion in our laboratory.

Some

65,000 samples had been tested. Amongst these were the urine from KW and BW, the
Australian patients with y-glutamyltransferase deficiency (Chapter 2).

High voltage

electrophoresis was also useful for the provisional identification of the abnormal
compounds isolated from urine (Chapter 2), plasma (Chapter 3) and cerebrospinal
fluid (Appendix C).

The separation of y-glutamyl compounds on cellulose thin layer chromatography (TLC),
employing butanol/acetic acid/water solvent system, was used in the current study
whenever a check on the integrity of an isolated y-glutamyl compound was required
(Chapter 2 and Chapter 3).

This section gives details of the high voltage electrophoresis and thin layer
chromatography methods used.

The relative migration of a panel of reference

compounds run by high voltage electrophoresis at pH 1.9 and by thin layer
chromatography are presented.

A.2

Reference Compounds

GSH,

GSSG

and

cysteine

were

purchased

from

Merck.

Glutathione:y-glutamylcysteine, glutathione:cysteine, y-glutamylcysteine:cysteine and
bis(y-glutamylcysteine) were synthesised (Section 2.2.2), while y-glutamylcysteine was
prepared by reduction using sodium borohydride (Section 2.3.2).

Other y-glutamyl

amino acids and y-glutamyl peptides were purchased from Sachem, Bubendorf,
Switzerland. Aqueous standard solutions of each compound were prepared using a
Perkin Elmer electronic ultramicro balance and a calibrated 5 mL standard flask. The
levels were 2.5 mmoi/L. Aliquots of 200 f..LL were stored at -80

ac until use.
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A.3

High Voltage Electrophoresis Systems for Separation of y-Giutamyl Compounds

Equipment

The HVE equipment was supplied by Camag, Muttenz, Switzerland. High quality HVE
paper was obtained from Camag C/N S&S 20438 40 X 20 em or from Macherey-Nagel,
Duren, Germany C/N MN214 40 X 20 em and batch-tested prior to use.

HVE Buffers

Five different buffers and running conditions were used during identification procedures
and the following mixtures were prepared:
•

the pH 1.9 buffer contained 26 ml of 26 moi/L formic acid, 120 mL 18 moi/L acetic
acid and 1000 ml of water,

• the pH 2.8 0.025 moi/L buffer contained 2.7 ml pyridine, 60 mL 18 moi!L acetic
acid made up to a litre with water,
•

the pH 4.0 buffer contained 2.4 ml pyridine, 4.5 ml 18 moi/L acetic acid made up
to 1000 ml,

• the pH 5.15 0.05 moi/L buffer contained 4.2 ml pyridine and 1.6 mL 18 moi/L acetic
acid made up to 1000 ml with water and
• the pH 7.4 0.025 moi/L buffer was a mixture of 40.5 ml of 0.2 moi/L sodium
hydrogen phosphate with 9.5 ml of 0.2 molll sodium dihydrogen phosphate and
diluted to 400 ml.

Reagents

General reagents were purchased from Merck, Darmstadt, Germany or BDH
Chemicals, Poole, UK and were of reagent grade or better. Milli-Q (Millipore, Bedford,
MA, USA) organics-free water was used throughout.

Pierce (Rockford, IL, USA)

supplied the ninhydrin for localisation, while chloroplatinic acid (Sigma C/N P5775) was
used for the sulphur staining.

Application of Aqueous Standards

The origin was marked on the 40 X 20 em HVE paper with lead pencil at either of two
locations. When the pH 1.9 buffer was used, the origin was 10 em in from the end
nearest the positive electrode. The origin was set centrally, at 20 em from either end,
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when all other buffer systems were used. The line was drawn 1.5 em in from each
edge and with 1.5 em gaps each 0.5 em. Nine samples could be applied to each sheet
along the 1.5 em lengths.

The reference compounds and reconstituted or concentrated aliquots of fractions from
preparative procedures were applied in aqueous solution (1 0 J..i.L) with a 10 J..i.L SGE
syringe fitted with a needle that was coated with PTFE and had a straight cut bevel
(SGE P/L, Melbourne, C/N 1OA-RN). This resulted in fine bands 1.5 em across. The
samples were set 0.5 em apart, so that nine could be run on each sheet. The bands
were dried with a continuous stream of warm air.

Application of Urine Samples

Urinary creatinine was estimated using the alkaline picrate reagent.

The method

employed was either (a) a modification of the end-point reaction or (b) a rate reaction
using a Beckman creatinine analyser II (Beckman Instruments, Palo Alto, CA).

Urine-soaked blotters were prepared by pouring urine evenly over strips of Whatman
3MM paper that had been guillotined to 150 X 30 mm, draining and touching any
excess droplet off onto lint-free absorbent paper. The strips were suspended vertically
and dried at room temperature or in an oven for 5 min at 95°C.

A template, prepared to indicate standardised areas of blotter that correspond to the
area wetted by a volume of urine, for example 10, 20, 50 or 100 J..i.L, was used to guide
the cutting of a strip of urine-soaked blotter. The area for cutting was equivalent to that
volume of urine that would contain 80 nmol equivalents of creatinine and shaped as a
chevron. The amino acids and peptides in urine were drawn to the tip of the chevron
by placing the area between, and extending beyond, two microscope slides containing
an inner 3MM paper wick that was partially immersed in a shallow tray of Milli-Q water
for 10 min. Excess water at the lower end of the slides was absorbed with lint-free
paper and the tip of the chevron gently drawn across 1.5 em on the origin of the HVE
paper to elute the urine components as a fine band. This process was repeated twice
for each chevron and then the origin was dried with a gentle current of warm air.

Liquid urine (-40 nmol creatinine) was applied as a fine band of liquid as for aqueous
standards.

TABLEA.1
Running Conditions for the High Voltage Electrophoresis Systems

System

Voltage

Time
minutes

Current
mA

pH 1.9

4000

17-18

85-110

pH2.8

4000

30

55

pH4.0

4000

17

45

pH 5.15

4000

17

40

pH 7.4

4000

17

95

FIGUREA.1
Composite Diagram Showing the Separation of y-Giutamyl Compounds by High Voltage
Electrophoresis at pH 1.9, 4000 V
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The reference compounds were applied on two separate HVE sheets as fine 1.5 em bands at
the origin. The results form a composite diagram with the track on the far left containing the
reference urine from a heterozygote cystinuria patient with added compounds 1. paracetamol,
2. phosphoethanolamine and 3. cysteic acid. The remaining tracks show the positions of 4.
y-glutamyl-y-glutamylglutamate,
5.
y-glutamyltyrosine,
6.
y-glutamylglutamine,
7.
y-glutamylglutamate, 8. y-glutamyl-c:x-aminobutyrlyglycine, 9. y-glutamylphenylalanine, 10.
y-glutamylmethionine, 11. y-glutamylthreonine, 12. GSH, 13. GSSG, 14. GS:y-GiuCys, 15.
(y-GiuCys)2, 16. GS:Cys, 17. y-glutamylalanine, 18. y-GiuCys:Cys, 19. y-glutamylglycine, 20.
aspartate and 21. cysteine. The bands containing thiols or disulphides have been shaded in.
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HVE Running Conditions

The HVE paper was wetted with the appropriate HVE buffer so that two buffer "fronts",
one from either direction, met exactly at the origin. This was a critical step, because it
resulted in tight bands when the current was applied. The running conditions for each
of the five HVE systems are listed in Table A.1.

Post-run Staining and Overstaininq

After each run the HVE paper was dried at 95°C, stained with ninhydrin/collidine/copper
sulphate solution (Niederwieser & Curtius 1969) containing 0.5 g ninhydrin, 90 mL
acetone, 5 mL collidine and 5 mL of a copper sulphate/methanol solution prepared with
saturated copper sulphate, water and methanol (2:5:200, v/v). The stained sheet was
heated at 95°C to visualise the amino acids and peptides and was either photographed
using transillumination or photocopied.

When iodoplatinate overstaining of the sheets was required, 0.2 g ninhydrin in 100 mL
acetone was used instead of the ninhydrin/collidine/copper sulphate mixture.

The

ninhydrin-positive areas were marked with lead pencil and the sheets were dipped
through a mixture of 10 mL chloroplatinic acid of 1 g/500 mL water, 1 mL of 167 g/L
potassium iodide, 2 mL of 6 moi/L hydrochloric acid and 85 mL acetone (Niederwieser

et a/1973).

The ninhydrin colour reaction was decolourised by the acid present in the

reagent mixture and the sulphur-containing amino acids and peptides appeared as
white or cream coloured bands against an even peach coloured background.

Location of Reference Compounds Using HVE

Figure A.1 shows a composite diagram of the separation of amino acids and

y-glutamyl compounds run on two HVE sheets at pH 1.9 and 4000 V and combined.
The bands containing thiols or disulphides have been shaded in.

All y-glutamyl

compounds tested ran in the acidic area of the separation and quite clear of the amino
acids present in normal urine or plasma. In the case of y-glutamylglutamine, this factor
was used to great advantage in the isolation of this compound from plasma amino
acids (Chapter 3) and amino acids in cerebrospinal fluid (Appendix C).
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A.4

A Thin Layer Chromatography System for Separation of y-Giutamyl Compounds

Equipment

Desaga supplied the glass TLC tanks and precoated cellulose acetate TLC sheets were
obtained from Merck, Darmstadt, Germany C/N 5730.

Reagents

General reagents were purchased from Merck or BDH Chemicals, Poole, UK and were
of reagent grade or better. Milli-Q (Millipore, Bedford, MA, USA) organics-free water
was used throughout.

Pierce (Rockford, IL, USA) supplied the ninhydrin for

localisation.

TLC Solvent

The solvent system used contained butanol/18 moi/L acetic acid/water (2:1 :1, vlv).
This mixture was prepared one hour prior to each run and poured over Whatman 3MM
paper that lined the walls of the TLC tank creating an atmosphere that saturated the
tank with solvent.

Sample Application and Running Conditions

The origin was marked with pencil as a faint line at 1.5 em from the lower edge of each
TLC plate and 1.0 em in from either side.
sample tracks of 1.0 em.

Intervals of 0.5 em were kept between

The samples in this study were applied as -0.8 J..tL of

aqueous solution containing -2.5 nmoi!J.lL with a 5 J.lL SGE syringe and then dried with
a warm flow of air.

The cellulose plates were run as either single or double development separations, each
taking approximately 1 hour. At the end of each separation, the plates were left to
stand vertically in a fumehood for at least 60 minutes to remove the excess solvent.
Double development plates were rerun after the drying was completed.
prepared solvent mixtures and tanks were used.

Freshly

TABLE A.2
Retention Data for y-Giutamyl Compounds Applied on Cellulose Thin Layer Plates and
Separated as Single or Double Developments
Rf

Rf

Rf

Rf

Compound

Single
Development
Plate I

Single
Development
Plate II

Double
Development
Plate I

Double
Development
Plate II

GS:Cys
y-GiuCys:Cys
GSSG
GS:y-GiuCys
(y-GiuCys)z

12.1
12.7
13.3
14.5
15.7

15.4
16.1
16.1
17.3
18.5

24.2
24.2
25.8
27.3
28.0

21.0
23.4
21.0
23.4
25.0

y-GiuGin
Aspartate
y-GiuGiy
y-Giuy-GiuGiu
y-GiuGiu
y-GiuAia
y-GiuAbuGiy
y-GiuTyr
r-GiuMet
r-GiuPhe
y-GiuLeu

28.3
30.1
31.3
33.7
33.7
40.4
44.6
48.2
55.4
61.5
67.5

29.0
30.9
35.2
33.3
39.5
45.7
45.1
51.2
56.8
64.8
68.5

41.0
45.1
47.7
47.5
53.1
60.2
60.5
65.9
72.2
79.7
84.9

42.5
47.0
47.7

48.5
52.3
59.4
61.4
68.8
76.2
83.6
88.5
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Post-run Staining

Once all traces of the solvent had evaporated, the plates were sprayed with a fine mist
of the ninhydrin stain prepared with 0.2 g ninhydrin in acetone. The TLC plates were
then placed in an oven at 105

oc

for 2 minutes to develop the colour reaction.

A

photographic record was made of each.

Location of Reference Compounds Using TLC

Table A.2 shows the Rf values obtained for the reference standards of '}'-glutamyl

compounds and aspartate separated on two different occasions (Plate I and Plate II)
and using single and double development systems.

When the single development system was run all of the y-glutamyl amino acids tested
ran in an order similar to that of the corresponding amino acids present in urine or
plasma, that is y-glutamylleucine ran with an Rf similar to that of leucine,
y-glutamylphenylalanine ran with an Rf similar to that of phenylalanine and so on. The
y-glutamyl peptides containing disulphides were low-running with Rf values similar to
cystine. Ophthalmic acid (y-glutamyl-a.-aminobutyrylglycine) ran slightly faster (Rf 45)
than y-glutamylglycine (Rf 35), but 'Y-glutamyl-y-glutamylglutamate ran to Rf 33 - 35
which was similar to that of y-glutamylglutamate.

When the double development system was run, as in the case of the single
development system, all of the y-glutamyl amino acids tested ran in an order similar to
that of the corresponding amino acids present in urine or plasma, that is
y-glutamylleucine ran with an Rf similar to that of leucine, y-glutamylphenylalanine ran
with an Rf similar to that of phenylalanine and so on.

This TLC system gave better discrimination between the y-glutamyl compounds tested
than that obtained using the HVE system at pH 1.9. It proved particularly useful when
the fractions obtained in Section 2.2.2 were being tested for contamination by amino
acids.
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DEVELOPMENT OF AN HPLC METHOD FOR THE QUANTIFICATION OF REDUCED
GLUTATHIONE, y-GLUTAMYLCYSTEINE AND CYSTEINE IN URINE

8.1

Introduction and Objectives of the Study

Quantification of the intact disulphides and mixed disulphides in the urine of patients
with y-GT deficiency had not previously been reported and Griffith and Meister (1980)
only alluded to the proportions of GSH and cysteine moieties present in urine from the
English patient. The reason for this lack of quantitative data was very possibly the
difficulty of the task using cation-exchange chromatography (Section 2.3.2) and this
difficulty was probably compounded when both the peptides and ordinary amino acids
were present in urine (Figure 2.7). However, once our quantitative results came to
hand and the ramifications of the levels of cysteine-containing disulphides became
clear, confirmatory analysis by some other separative technique seemed essential.

In an earlier collaborative study, a method for the separation and quantification of
cystine

and

reversed-phase

penicillamine-cysteine
HPLC

with

disulphide

post-column

had

reduction

been
of

developed

the

disulphides

using
and

electrochemical detection (EC) (Sampson et a/1986). Selection of this technique for
confirmatory analysis of the intact disulphides and mixed disulphides in the urine of the
patients with y-GT deficiency had two advantages.

Firstly, cation-exchange

chromatography and reversed-phase HPLC are two different separative techniques and
therefore excellent for obtaining confirmatory data and secondly, the specificity of an
EC oxidation potential at + 0.1 V meant that EC detection would not suffer interference
from the other amino acids present.

The HPLC method for cystine could not be adapted directly.

We recognised from

earlier work that post-column reduction of the disulphide of penicillamine was difficult,
probably because of steric hindrance.
glutathione-related compounds.

Steric hindrance was also likely with the

Pre-column reduction was therefore necessary.

Griffith and Meister (1980) had used dithiothreitol to reduce the glutathione-related
compounds in urine from the English patient, prior to cation-exchange chromatography.
However dithiothreitol would interfere with EC detection and even though residual
reagent could be removed by ethyl acetate extraction of the thiols before injection
(Jocelyn 1987), this would lead to losses.

It was decided instead that pre-column

reduction of the urinary disulphides with sodium borohydride (Wiley et a/1988) followed
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by acidification to decompose the reagent, might result in better recoveries of GSH,
y-glutamylcysteine and cysteine.

This developmental project was carried out in three stages.

First the reaction

conditions for borohydride reduction of the disulphide standards were investigated.
Then the components of the mobile phase were optimised to separate GSH,
y-glutamylcysteine, cysteine and homocysteine, a possible internal standard.

The

method was also tested on normal urine, to which standards had been added. Finally
the same urine samples from the two Australian patients with y-GT deficiency that had
been quantified by cation-exchange chromatography were analysed.

B.2

Development of the Method

Reagents

Sulphosalicyclic acid, chloroacetic acid and Titrasol sodium hydroxide were supplied by
Merck, Darmstadt, Germany. Disodium ethylenediaminetetraacetic acid (EDTA) was
purchased from Tokyo-Kasei, Tokyo, Japan.

Mallinkrodt ChromAR HPLC grade

acetonitrile and methanol were supplied by Mallinkrodt Speciality Chemicals,
Meadowbank, Australia. A Milli-Q organics-free water system, Millipore HA 0.45 1-lm
filters and Millex-GS 0.22 f!m filters were obtained from Millipore Corporation, Bedford,
MA.

Sodium octyl sulphate HPLC grade was purchased from KODAK Laboratory

Chemicals, Rochester, NY.

Sodium borohydride LR grade was supplied by BDH

Chemicals, Poole, UK.

Standard Compounds

GSSG and cystine were obtained from Merck.

bis(y-Giutamylcysteine) was

synthesised as described in Section 2.2.2. Aldrich Chemical Company Inc., Castle
Hill, Australia supplied the DL-homocysteine (Hey). GSH and cysteine hydrochloride
were supplied by Sigma Chemical Company, St. Louis, MO, USA.

Equipment

Waters 510 and 590 HPLC pumps and a WISP autoinjector were obtained from Waters
Assoc., Milford, MA, USA.

Two BAS LC-48 amperometric detectors (Bioanalytical

Systems Inc., West Lafayette, IN, USA) with a dual mercury gold amalgam working
electrode were used.

Triple distilled mercury (BAS) was used to resurface the

Clrection of
mobile phose flow

electrode material

Au!Hg

Au/Hg

electrode potential

-I.OV

+0.15

electrode function

post-COlumn reactor
for disulfide
reduction

thiol meoSlJ'"ement

al'(llysis ofdisulfides RSSR
analysis of thiols

2RSH

+ 2H++2e-

-

v

Hg
2RSH ~ Hg (SR) 2+2H+ + 2eHg
2RSH ~
Hg (SR)2+2H++ 2e,

FIGURE R1
Analysis of Disulphides and Thiols using Dual Me.rcury/ Gold Electrodes in Series
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electrode before each working session. Figure 8.1 shows the configuration of the dual
electrode system for analysis of thiols and disulphides used in the previous study
(Sampson et al 1986).

Only the downstream electrode was required in the current

method for monitoring separations. The working electrode (downstream) was held at a
potential of + 0.1 V relative to a Ag/AgCI reference electrode. Detector response was
taken from the downstream electrode and the sensitivity adjusted to 50, 100, 200 or
500 nA full scale deflection. The Spherisorb S1 0 ODS2 column (25 em X 4.6 mm) was
kindly supplied by ICI Instruments, Dingley, Australia.

Samples for Study

Normal random urine collections were obtained freshly from healthy control subjects.

Borohydride Reduction

Reagent blanks containing water instead of sample, standard mixtures of GSSG and
cystine, or urine, 100 i!L, were reduced with 50 i!L of freshly prepared sodium
borohydride (120 mg made up in 1.2 mL 0.1 moi/L sodium hydroxide) at 37°C under a
stream of research grade nitrogen for times varying from 30, 60, 90 and 120 min. After
cooling, the reagent blank, reduced urine or reduced standard mixtures were diluted
with 250 i!L of sulphosalicyclic acid reagent (0.2 g/mL), 50 i!L of a solution containing
disodium EDTA (1 mg/mL) and 500 or 2000 i!L of water (Sampson et a/1986). The pH
of this acidified post-reduction sample was between 1.5 and 2.5. Analysis showed no
evidence of auto-oxidation when completed within 3 hours of reductive pretreatment.

Preparation of Mobile Phase

Proportions of methanol, chloroacetic acid and sodium octyl sulphate were varied to
determine the optimum conditions for separation of the thiols. All mobile phases were
prepared using Milli-Q organics-free water and the pH adjusted with 10 moi/L sodium
hydroxide using a Beckman pH meter. Each final mixture was filtered and degassed
under reduced pressure through a 0.45 i!m filter. Sixteen hours prior to analysis the
mobile phase was transferred to a sealed reflux system and sparged with helium at
room temperature. During use the mobile phase was warmed in a heating mantle to
enhance the sensitivity of the electrode.

FIGURE 8.2 Retention Times Obtained at pH 2.41 to pH 3.40 for Sodium Octyl Sulphate Concentrations from 1 to 8 mmoi/L
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HPLC Method

The chromatographic behaviour of the thiols was investigated using a flow rate of 0.8
mUmin. Five to 30 J.LL aliquots containing from 10 to 1100 pmole of thiol were injected
on column. Detector was adjusted to give a 50 nA or 100 nA full scale deflection and
the response was measured as peak height on a chart recorder.

8.3

Results

Borohydride Reduction

The efficiency of reduction was judged by peak height of reduction products derived
from standard mixtures containing cystine, GSSG and bis(y-glutamylcysteine) up to

1100 pmole.

The

levels of reduction

product, that

y-glutamylcysteine, reached a plateau after 60 min at 37°C.

is cysteine,

GSH

or

Extension of the time

served no advantage.

Chromatography

The behaviour of the thiols was investigated by varying the pH, the concentration of ion
pair and the concentration of methanol in the mobile phase, while retaining the
concentration of chloroacetic acid at 0.1 moi!L. Figure 8.2 shows the retention times
for cysteine, GSH, y-glutamylcysteine and homocysteine, the internal standard,
obtained when the pH of the mobile phase was varied between pH 2.41 and pH 3.40
for sodium octyl sulphate concentrations of 1, 2, 4, 6 or 8 mmoi/L. At acidic pH values
all four thiols are retained, but they elute earlier as the pH increases. These findings
agree with those of Allison et a/ (1983) and suggest that since the ionisable functional
groups in these molecules include carboxylic acids (PKa -2), amines (PKa -8-9) and
thiols (PKa -9), there is increasing retention on column as the pH decreases with the
carboxylic acid group becoming increasingly protonated. The pKa of cysteine has been
reported as 8.5 and that of glutathione as 9.2 (Munday 1989).

Figure 8.3 shows the same data plotted to show the effect of sodium octyl sulphate

concentration.

Comparison between retention of these compounds at 1 mmoi/L ion

pair and 2 and 4 mmoi/L indicates the increase in retention that can be obtained.

Results for similar experiments in which the concentration of methanol was varied from
2, 4 and 6% (v/v) showed that addition of methanol speeded up elution of

FIGURE 8.3 Retention Times Obtained for 1 to 8 mmoi/L Sodium Octyl Sulphate from PH 2.41 to pH 3.40
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longer-retained compounds.

These findings also agree with those of Allison et a/

(1983).

Based on these studies and advice from Bioanalytical Systems Inc. regarding possible
deterioration of the column at pH below 2.80, the following chromatographic conditions
were adopted: a mobile phase containing 0.1 moi/L chloroacetic acid, 4% methanol
(v/v), 4 mmoi/L sodium octyl sulphate with the pH adjusted to between 2.75- 2.80.

Linearity. Stability and Recoveries

Figure B.4 shows the standard curves obtained for cysteine and y-glutamylcysteine
from 213 to 1067 pmole and for GSH from 203 to 1013 pmole.
equations appear alongside the appropriate curve.

The regression

The EC electrode response for

cysteine was almost double that of GSH and y-glutamylcysteine.

The detector

response was measured as peak height and was linear for cysteine, GSH and
y-glutamylcysteine (r = 0.999, 0.998 and 0.999 respectively) from at least 10 to 800
pmole at 50 nA and at least 200 to 11 00 pmole at 100 nA.

The stability of the thiols was judged by noting any variation in peak height over a
working day, that is for the same mercury gold electrode coating.

There was no

evidence of deterioration of the thiols within three hours of reductive pretreatment.
Standard mixtures of reduction products were stable over 4 months at -80°C.
Recoveries obtained by the addition of GSSG, cystine and bis(y-glutamylcysteine) to
normal urine were between 92 and 95%.

8.4

Discussion

The chromatographic results from the current investigation were similar to those
obtained by Allison et a/ (1983).

However the scope of their study included the

disulphides GSSG, cystine and penicillamine disulphide as well as the corresponding
thiols and for this complex mixture the optimal concentration of ion pair, at 1 mmoi/L,
was lower and their pH higher, at pH 3.00, than those of the current study.

One restriction of this HPLC-EC method was the difficulty encountered in recoating the
mercury gold amalgam, when compared with the ease of use of the more robust glassy
carbon electrodes used with routine catecholamine assays.

The freshly surfaced

mercury gold electrode required particular care: (a) during installation so that shorting
out did not occur, (b) during priming when 250 pmole injections of thiol were required

FIGURE 8.4
Standard Curves for GSH, y-Glutamylcysteine and Cysteine with the HPLC-EC Set on 100 nA Range
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until a constant peak height was obtained and (c) with deoxygenation of the mobile
phase to prevent formation of mercuric oxide on the electrode surface.

Helium

sparging overnight and during analysis was thought to be the most effective way of
achieving deoxygenation. Not withstanding these difficulties reliable quantification of
urinary total cysteine, total GSH and total y-glutamylcysteine was obtained (Chapter 2).
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ISOLATION

AND

IDENTIFICATION

OF

GAMMA-GLUTAMYLGLUTAMINE

FROM

CEREBROSPINAL FLUID

C.1

Objectives of the Study

During the investigations leading to the identification of y-glutamylglutamine in plasma
of patients with hyperammonaemia due to a urea cycle defect, it was noted that an
unknown compound with RT similar to the one present in plasma also occurred in
cerebrospinal fluid (CSF) referred from one of these patients. A study to determine the
identity of the unknown in CSF was therefore conducted in parallel with that reported in
Section 3.2.2.

First the abnormal compound was isolated from CSF using preparative HVE.

The

compound in a desalted eluate from HVE paper was provisionally identified by acid
hydrolysis,

retention

relative

to

reference

standards

on

cation-exchange

chromatography, reversed-phase HPLC using the pre-column o-phthalaldehyde (OPA)
reaction and TLC and by migration relative to reference standards on HVE at pH 3.0.
The compound was positively identified by fast atom bombardment mass spectrometry
(FAB-MS).

C.2

Isolation and Identification of the Abnormal Compound

Samples and Reference Compounds

Samples for Study Two mL of CSF was used for identification of the unknown and was
referred from a patient SS with a defect of argininosuccinate synthetase activity
(McKusick 215700). A sample for quantification was also referred from patient BL 1
with ornithine carbamoyl transferase deficiency (EC 2.1.3.3, OCT).
instructions for collection included freezing at

-sooc within 30 min.

Our routine

CSF was stored at

-80°C in the laboratory with minimal time at room temperature. Both samples were
clear and colourless.

Reference Compounds

Serva, Feinbiochemica, Heidelberg, FRG and Sachem

Bubendorf, Switzerland supplied the y-glutamylglutamine and L-y-glutamylglutamic acid
(y-GiuGiu).
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Cation-Exchange Chromatography and Quantification

Details of ultrafiltration of protein, sample preparation and the Beckman 6300 amino
acid analyser system are outlined in Sections 2.3.2 and 2.4.2 and these also apply to
the analysis of CSF except that CSF is diluted only 1 in 2 with 50 f.tmoi/L AEC before
injection.

Preparative HVE of CSF

Details of the HVE systems run at pH 1.9 and 3.0 are outlined in Appendix A. An
ultrafiltrate of CSF (75 f.tL) from SS was applied to an HVE sheet along with that of a
CSF control and the y-glutamylglutamine reference standard.

This separation was

carried out at pH 1.9, 4500 V, 1DO rnA for 17 min to check the likelihood that the
unknown compound could be isolated using preparative HVE.

Four 500 f.tL aliquots of CSF were deproteinised with an equal volume of analytical
grade ethanol (BDH), left stand at room temperature for 10 min and then centrifuged at
11 ,000 X g for 3 min. Two millilitres of supernatant was applied across the origin of
each of 2 HVE sheets of paper and dried with a continuous stream of warm air. The
sheets were then run by HVE at pH 1.9 for 17 min.

Following electrophoresis, strips were cut down the length of both sides of the paper
and stained with ninhydrin to locate the position of the unknown and the amino acids.
Each sheet was then reconstructed and the area of unstained paper containing the
unknown was located and removed.

The unknown was eluted from the macerated

areas of these paper strips by standing overnight in Milli-Q organics-free water. An
equivalent blank area of unstained paper was located, removed and treated similarly.

Identification Procedures

The identity of the compound isolated using HVE at pH 1.9 was established along with
reference standards in four separative systems: cation-exchange chromatography
under standardised conditions, reversed-phase HPLC using o-phthalaldehyde colour
reagent (Goldsmith et a/ 1987), TLC cellulose acetate plates (Merck C/N 5730) with
butanol/ 18 moi/L acetic acid/water (2:1 :1, v/v) and HVE at pH 3.0.

The isolated compound, reference standards and water blank were each hydrolysed for
16 h using Pierce constant boiling point hydrochloric acid Sequanal Grade (C/N 24309)
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sealed under nitrogen at 112°C.

The products of hydrolysis were analysed on the

Beckman 6300 system.

The isolated compound (30 J.lg) was dissolved in methanol/water (1 :1, v/v), 1 J.LL was
mixed with 1 J.LL of thioglycol, applied and dried on the target of a VG 12-12 mass
spectrometer. A fast atom beam of xenon was generated at 8 kV and 2 mA. Spectra
were collected from 10-500 amu at 2 s/scan.

C.3

Results

Preparative Recovery of the Unknown A yield of 54% was shown by running portion of

the isolated compound on cation-exchange chromatography.

This separation also

indicated that minimal contamination with CSF amino acids had occurred with 2.3% for
tyrosine (the amino acid running closest to the unknown on HVE at pH 1.9), 0.1% for
citrulline and 0.09% for glutamine.

Identification Procedures Initially CSF from patient SS was run on HVE at pH 1.9 to

test suspicions that the unknown might be y-glutamylglutamine. The result indicated
that preparative HVE at pH 1.9, which had been used to isolate y-glutamyl compounds
from fractions collected from urine of the two patients with y-GT deficiency (Section

2.2.2) would again be useful.

Provisional identification of the abnormal compound as y-glutamylglutamine was
obtained by the following results. The isolated compound appeared a single peak on
the Beckman 6300 system with a retention time agreeing with the y-glutamylglutamine
standard. Peak response ratios at 570 nm/ 440 nm were 12.0 and 11.9 for the isolated
compound and

tor

y-glutamylglutamine reference standard.

The isolated compound

ran to 11.1 min on the reversed-phase HPLC system which used o-phthalaldehyde
colour reagent (Goldsmith et at 1987) and corresponded exactly to the retention time of
the

y-glutamylglutamine

reference

standard.

On

TLC

a

single

band

co-chromatographed with the y-glutamylglutamine standard (Rf 0.28) and not with
y-GiuGiu (Rf 0.34). gamma-Giutamylglutamine and the unknown gave single bands
which also migrated to the same position on HVE at pH 3.0.

The products of acid hydrolysis for the unknown and the y-glutamylglutamine standard
were two moles of glutamic acid to one of ammonia, while y-glutamylglutamic acid
gave two moles of glutamic acid only.

TABLE C.1
Concentrations (J.Lmoi/L) of y-Giutamylglutamine, Glutamine, Citrulline and
Ammonium in Individual Samples of Cerebrospinal Fluid and Plasma from
Two Patients with Hyperammonaemia due to a Urea Cycle Defect
Patient

Diagnosis

Age

BL1

OCT

44h
64h
71h

ss

ASS

4d
4d
7d

Glutamine

Citrulline

94
92
313

3730
4590
7700

<1
<1
5

2070
1860
1850

111
128
201

7580
7480
6610

2780
2990
1560

400
470
370

y-GiuGin

ABBREVIATIONS:
OCT- Ornithine carbamoyl transferase deficiency
Italics show results obtained on plasma

Ammonium

ASS - Argininosuccinate synthetase deficiency
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The FAB mass spectra were obtained for the isolated compound and for
y-glutamylglutamine standard taken through the final elution step. The fragments at
mlz 217, 221, 237, 239, 261, 276 and 298 ions were common to both, while the ion m/z

181 was derived from the thioglycol matrix.

Quantification Levels of y-glutamylglutamine, glutamine and ammonium were obtained

in the CSF from two patients with defects of the urea cycle and in plasma samples
collected from the same patients. These are shown in Table C.1.

C.4

Discussion

gamma-Giutamylglutamine was first identified as an acidic dipeptide in bovine brain
(Kakimoto et a/ 1964) and later located in many areas of human brain (Kanazawa &
Sana 1967).

gamma-Giutamylglutamine has not been recorded in cerebrospinal fluid until this study
(Hammond et a/1990). The presence of high levels of y-glutamylglutamine in CSF in
both of the hyperammonaemic patients in the current study was sufficient to allow
isolation from a few millilitres of sample and positive identification. Evidence for the
presence of other y-glutamyl amino acids, and in particular y-glutamylglutamic acid,
was not obtained.

Two previous reports had illustrated or described an abnormal peak in CSF. Jaeken
(1985) had found an unusual double peak in the acidic area of cation-exchange
chromatographs of CSF from hyperammonaemic patients and showed that the peak
disappeared following acid hydrolysis of the sample. Goldsmith

et a/ (1987)

illustrated,

but did not comment on, an unidentified compound that ran in the acidic region of the
chromatogram of all CSF samples analysed by their reversed-phase chromatography
and pre-column OPA reaction.

The

liver has

been

proposed

as

a possible

major source

of

circulating

y-glutamylglutamine in hyperammonaemic patients (Section 3.3.4). The identification
of

y-glutamylglutamine

as

a

major

component

of

human

CSF

during

hyperammonaemia is significant, especially since the levels may exceed those in
plasma (patient BL 1 Table C.1). This suggests that y-glutamylglutamine is synthetised
independently in the brain. Indeed, one of the patients with hyperammonaemia due to
secondary causes (Hammond

et a/1990), patient FR, was found to

have a normal level

of y-glutamylglutamine in plasma (<8 1-Lmoi/L) even though his plasma glutamine was
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10,000

~-tmoi/L

(reference range

405 - 907

~-tmoi/L),

y-glutamylglutamine was significantly elevated at 97
~-tmoi/L)

with a CSF glutamine of 5820

whereas in CSF his level of

~-tmoi/L

(reference range 1.6 - 8.8

~-tmoi/L.

One explanation for this finding in the patient FR might be that his plasma
y-glutamylglutamine was hydrolysed by y-GT during sample collection and handling.
Activity of plasma y-GT (glutaminase reaction [4] Section 1.3.2)(da Fonseca-Wolheim

1990) has been proposed to explain the increase of plasma ammonia after blood
collection.

However the serum y-GT at 21 U/L for FR however was not elevated

(reference range 8- 43 U/L).

The interpretation of the plasma results on patient FR are further complicated by his
clinical condition of chronic renal failure and the fact that a urine sample was not
available for study.

It is therefore not clear whether this patient was unable to

synthesise y-glutamylglutamine in the liver (or peripheral tissue) due to reduced ATP
levels, or some other factor, during his severe hyperammonaemia or whether y-GT
and/or y-glutamyl amino acid cyclotransferase activity resulted in the removal of
y-glutamylglutamine from his circulation. Further investigations will be carried out to
assess whether the level of y-glutamylglutamine in plasma is a sensitive indicator of
reduced y-glutamylcysteine activity and perhaps of reduced liver function.

Recently Jaeken (1994) reported the detection of y-glutamylglutamine in CSF from
patients with transient neonatal hyperammonaemia syndrome. The report implied that
y-glutamylglutamine is an abnormal finding in CSF. However Hammond eta/ (1991)
showed that y-glutamylglutamine was a normal component of CSF. Reference ranges
for y-glutamylglutamine in CSF were obtained using reversed-phase chromatography
and

pre-column

OPA

chromatography (1.6 - 8.8

reaction
~-tmoi/L,

(2

- 9

~-tmoi/L)

and

using

cation-exchange

N =20) showing very close agreement.

Jaeken (1994) noted that so far evidence for whether y-glutamylglutamine contributes
to the symptomatology and brain damage of hyperammonaemia remain to be
determined. The current study found that y-glutamylglutamine is a stable compound. It
may be more useful than unstable glutamine as a gauge of hyperammonaemia in
post-mortem CSF samples and this will also be the subject of further study.
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ADDENDUM

Page 32, Line 14

preparative column (780 mL, approx length 80 em and diameter 12 em) of
Dowex 50X8, hydrogen form, 200-400 mesh

Page 33, Line 8

delete "acetate"

Page 50, Line 24

y-glutamylglutamine in fresh urine and plasma from KW and BW, with
sample collection and handling planned to be completed in the minimum
possible time.

KW did not attend, however a fresh urine and a single

capillary blood sample were collected from BW.
Page 60, Line 33

levels could not be obtained to confirm this. Control experiments to show
the formation of the 6 disulphides when the three thiols were added to
normal urine were considered but not attempted because the time
required to integrate the resulting complex mixtures of compounds was
prohibitive and the results were not fundamental to the discussion.

Page 67, Line 21

delete "acetate"

Page 69, Line 4

delete "acetate"

Page 134, Line 20

An Insert has been included after the final paragraph

Page 140, Line 2

delete "acetate"

Page 149, Line 27

TLC cellulose-coated glass plates (Merck C/N 5730)

ADDITIONAL REFERENCES

Courtay C, Heisterkamp N, Siest G, Groffen J. Expression of multiple y-glutamyltransferase

genes in man. Biochem J 1994;297:503-508
Figlewicz DA, Delattre 0, Guellaen G, Krizus A, Thomas G, Zucman J, Rouleau GA.

Mapping of human y-glutamyl transpeptidase genes on chromosome 22 and other human
autosomes. Genomics 1993; 17:299-305
Huseby NE. Separation and characterisation of human y-glutamyltransferase. Clin Chim Acta

1981;111:39-45
Pawlak A, Wu SJ, Bulle F, Suzuki A, Chikhi N, Ferry N, Baik JH, Siegrist S, Guellaen G.

Different gamma-glutamylpeptidase mRNAs are expressed in human liver and kidney. Biochem
Biophys Res Commun 1989;164:912-918

Shaw LM, Petersen-Archer L, London JW, Marsh E. Electrophoretic, kinetic and

immunoinhibition properties of y-glutamyltransferase from various tissues compared. Clin Chem
1980;26: 1523-1527

Allbook Bindery
9i Ryedale Road
West Ryde 2114
Phone: 807 6026

